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Introduction
Introduction
General introduction
Epidemiology
Atrial fibrillation is the most common cardiac arrhythmia increasing
exponentially with age (Kannel 1982, Wolf 1987, Feinberg 1995). The estimated
prevalence roughly doubles with each decade of advancing age, from 0.5% at
age 50-59 years to almost 9% at age 80-89 years. Moreover, the prevalence
seems to have increased in the past two decades, particularly in men (Kannel
1998). It should be noted that these epidemiological trends occur despite a
decline of rheumatic heart disease in the Western world, a condition historically
associated with the arrhythmia. Advancing age, hypertension, diabetes, heart
failure, valvular heart disease, and male gender are other conditions
independently associated with atrial fibrillation (Kannel 1982, Benjamin 1994,
Psaty 1997, Kannel 1998). When the above mentioned numbers of the
Framingham study (in out-patients) are translated to the Netherlands, as many
as 121.800 people aged 50 to 89 years would suffer from atrial fibrillation in
the year 2000 (based on 15.8 million inhabitants, 13.6% above 65 years of age
(CBS 1998)). The yearly incidence of atrial fibrillation in this cohort would be
about 21.200 cases. The Netherlands Heart Foundation has calculated a
comparable prevalence of 127.308 patients for the year 1996 (Konings-Dalstra
1999), based on a model combining data from domestic and foreign studies
(Lake 1989, Phillips 1990, Wolf 1991, Furberg 1994, Langenberg 1996, Ott
1997). Remarkably, no specific data on atrial fibrillation are available for the
Netherlands at the Central Bureau for Statistics. However, with the expected
“ageing” and increase of the Dutch population (16.6 million in the year 2010,
14.8% above 65 years of age (CBS 1998)), more people will be suffering from
atrial fibrillation, putting an increasing demand on public health care. This
scenario is supported by already more than a doubling of the number of hospital
admissions for atrial fibrillation between the years 1980 and 1997
(Konings-Dalstra 1999).10
Classification
The arrhythmia is not uniform in its presentation. Different temporal patterns,
each requiring specific therapy, can be distinguished. Classically, atrial
fibrillation has been divided in paroxysmal (in attacks) and chronic (continuous)
atrial fibrillation. More recently, however, it has become clear that both types
are to be considered as “chronic” since the first attack (or episode) will not be
the last (Suttorp 1993, Van Gelder 1996). Still, the following patterns can be
distinguished according to Gallagher and Camm: (a) atrial fibrillation occurring
in episodes, predominantly lasting less than 24 hours and often self-terminating,
(b) atrial fibrillation continuously present while sinus rhythm can be restored
with cardioversion, and (c) permanent atrial fibrillation in which restoration
of sinus rhythm is either not possible anymore or deemed unnecessary (Table
1).
Etiology
Atrial fibrillation is also not uniform with respect to concomitant disease.
Although an associated disease which might trigger and sustain the arrhythmia
is often present, an obvious etiology may be absent (“lone” atrial fibrillation).
In persistent atrial fibrillation structural heart disease is present in ±85% of
the patients. By contrast, in paroxysmal atrial fibrillation only 40-50% of the
patients have structural heart disease (Murgatroyd 1993). Table 2 shows the
distribution of underlying heart disease and other predisposing factors as
Table 1. Classification of atrial fibrillation by temporal pattern
Paroxysmal Episodes of atrial fibrillation typically <24-48 hours (up to 7 days)
Intermittent sinus rhythm
Terminating spontaneously or with an antiarrhythmic drug
Persistent Continuous presence of atrial fibrillation >24-48 hours duration
Not spontaneously terminating
(Electrically) cardiovertible
Permanent Continuous presence of atrial fibrillation >24-48 hours duration
Not spontaneously terminating
Not cardiovertible (anymore)11
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Table 2. Distribution of common etiologies and predisposing factors in  atrial
fibrillation
Paroxysmal AF* Persistent AF* Permanent AF* Persistent AF†
(“Recent onset”) (“Chronic”) (“Cardiovertible”)
Underlying heart disease (%)
Coronary artery disease 12 19 18 21
Hypertensive heart disease 17 25 22 34
Rheumatic valvular disease 10 12 20 2
Dilated cardiomyopathy 2 9 13 5
Hypertrophic cardiomyopathy 3 9 4 0
Non-rheumatic valvular disease 5 3 3 25
Sinus node dysfunction 2 1 1 0
Miscellaneous 6 3 3 18
Idiopathic or “lone” 46 28 23 15
Other predisposing or associated factors (%)
Hyperthyroidism 4 5 2 2
Hypertension 35 46 38 -
Bronchopulmonary disease 10 10 13 6
Diabetes 7 9 13 7
Congestive heart failure 14 18 43 36
* = adapted from Levy 1999. † = in 509 patients from our institute who entered serial electrical cardioversion
therapy between 1995-1999. AF = atrial fibrillation.
recently found in a French study (Levy 1999), together with data from our own
cardioversion population. When compared to nearly a decade ago (1986-1991),
the distributions of hypertensive and rheumatic heart disease seem to have
changed positions while coronary artery disease has remained unchanged (Van
Gelder 1991b).
Consequences of atrial fibrillation
Although not immediately lethal once it occurs, the arrhythmia is not benign.
Atrial fibrillation carries the risks of considerable morbidity and increased
mortality.
Symptoms
With respect to symptomatology, the presentation of the arrhythmia is
inconsistent. Although most patients have symptoms secondary to atrial12
fibrillation, about 10% (or even more) have none (Levy 1999). The most
frequently reported symptoms include palpitations, chest pain, dyspnea (on
exertion), syncope, dizziness, and fatigue. Typical for the paroxysmal form is
polyuria during or immediately after an attack, and fatigue, sometimes
persisting for days after the attack. Up till now, the clinical significance of
asymptomatic atrial fibrillation is not always clear. Essentially patients with
tachycardiomyopathy lack symptoms of atrial fibrillation but have significant
heart failure symptoms. Likewise, asymptomatic patients may suffer from
cerebral thromboembolism and are identified as having atrial fibrillation in
the neurology department. In line with these uncertainties, data on the impact
of the arrhythmia (and subsequent treatment) on feelings of well-being and
social functioning are sparse. However, measuring quality of life in patients
with atrial fibrillation is important as it may guide us in the assessment of
therapeutic choices.
Thromboembolism
A most serious complication is thromboembolism from the left atrium (usually
from its appendage) to the cerebral vasculature, resulting in a “stroke”. In
particular rheumatic atrial fibrillation is associated with a high risk for stroke
(Wolf 1987). It is estimated that the yearly risk for stroke in non-rheumatic
atrial fibrillation is 5-7%, and that the cumulative risk approaches 35%
(Chesebro 1995). Stroke secondary to atrial fibrillation has a high lethality
rate and survivors often suffer from persisting neurological impairment (Lin
1996). Importantly, cerebral damage while in atrial fibrillation may occur quite
insidiously. In the absence of clinical stroke, a clear association with dementia
and impaired cognitive function was observed (Ott 1997), possibly related to
silent stroke (Petersen 1987). In the presence of structural heart disease or
other risk factors, the probability for embolism rises (twofold or even higher)
considerably (Wolf 1991, SPAF Investigators 1992a, SPAF Investigators 1992b).
These factors comprise previous stroke or a transient ischemic attack, higher
age, hypertension, clinical heart failure, diabetes mellitus, overt coronary artery
disease, left atrial enlargement, and left ventricular dysfunctioning.
Large clinical trials have investigated the prevention of thromboembolism
and demonstrated the efficacy of long-term oral anticoagulation, especially in
older patients (>75 years) and in the presence of risk factors (AFASAK 1989,13
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BAATAF 1990, SPINAF 1990, CAFA 1991, SPAF I 1991, SPAF II 1994, SPAF
III 1996). If aspirin is considered, its use should be limited to younger patients
(<65 years) without risk factors (SPAF II 1994). The studies, however, indicate
that thromboembolism still occurs in 1-3% of the patients per year despite
anticoagulative therapy. Moreover, depending on anticoagulation intensity,
bleedings are introduced (up to 2.5% per patient/year) with sometimes serious
consequences. Nevertheless, anticoagulation should be instituted in any patient
with risk factors and/or age >65 years independent of the type of atrial
fibrillation, since all previously mentioned studies included both patients with
persistent and paroxysmal atrial fibrillation. It is as yet unsettled whether
patients with lone atrial fibrillation are at increased risk for thromboembolic
events.
Heart failure
Another clinical complication of atrial fibrillation is the occurrence of heart
failure. Several underlying mechanisms have been identified or postulated.
Firstly, ventricular rate usually becomes high once atrial fibrillation occurs.
As a consequence, diastolic filling time becomes relatively short, thus decreasing
stroke volume. Secondly, the loss of atrial contraction lowers cardiac
performance by ±15% (Naito 1983). Thirdly, the irregularity of ventricular rate
per se, irrespective of rate, contributes to deterioration of ventricular function
(Daoud 1996, Clark 1997). Finally, a sustained, high ventricular rate may
produce tachycardia-induced cardiomyopathy (or tachycardiomyopathy).
Lowering of ventricular rate (either by rate or rhythm control) improves or
normalizes ventricular function (Van den Berg 1993, Van Gelder 1993, Brignole
1994), which is an essential feature of tachycardia-induced cardiomyopathy. It
should be noted, however, that reversibility is lost once structural changes
such as atrophy and interstitial fibrosis develop. Alternative concepts of heart
failure in atrial fibrillation include progressive impairment of cardiac function
due to an underlying disease or progressive atrial natriuretic peptide depletion
(Van den Berg 1998). The mechanisms, however, behind the coexistence of
heart failure in atrial fibrillation have not yet been fully elucidated.
Mortality
It is a subject of ongoing debate whether atrial fibrillation is associated with14
increased mortality (Middlekauff 1991, Carson 1993, Krahn 1995, Stevenson
1995, Benjamin 1998, Dries 1998, Crijns 2000). The risk of dying is estimated
to be doubled in the presence of atrial fibrillation, although stroke, underlying
cardiac disease, and the presence of heart failure in particular are held
responsible for this outcome. Still, recent data from the Framingham study
suggest that after adjusting for underlying cardiovascular conditions, mortality
remains (about 1,5 fold) excessive (Kannel 1998). Moreover, after long-term
follow-up of patients with lone atrial fibrillation, total mortality appears to be
(about twofold) increased (Jouven 1999). Consequently, reassuring a patient
with atrial fibrillation (and few symptoms) is not justified on the basis of these
data. Importantly, it is as yet unclear whether (permanent) restoration of sinus
rhythm will normalize mortality rates.
Study rationale
The above mentioned considerations would be irrelevant if atrial fibrillation
in general could be (easily) terminated and prevented. However, until now,
this is not the case. Patients with the paroxysmal form often progress to the
persistent form, which is to be regarded as progression of the disease (Petersen
1986). In turn, persistent atrial fibrillation tends to become permanent, in
spite of intensive serial cardioversion and antiarrhythmic drug therapy (Crijns
1991, Van Gelder 1996). It was observed that underlying heart disease has a
negative impact on arrhythmia outcome. In addition, a long history or duration
of the arrhythmia carries a poor prognosis, which indicates that changes occur
as a consequence of the arrhythmia itself (Van Gelder 1996, Duytschaever
1998).
In the past decade, experimental studies were initiated to gain more insight in
the pathophysiology of atrial fibrillation. It was a landmark finding that atrial
fibrillation, as a result of atrial fibrillation per se, contributes to its own
perpetuation by means of “electrical remodeling” (characterized by shortening
of the atrial refractory period and flattening, or even inversion, of physiological
rate adaptation). In animal experiments, atrial electrical remodeling seems to
be completed within several days (Morillo 1995, Wijffels 1995), and reversibility
after restoration of sinus rhythm occurs within the same time-frame (Wijffels
1995, Garratt 1999). A comparable course of electrical remodeling and recovery15
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from electrical remodeling appears to occur in humans (Franz 1997, Pandozi
1998, Yu 1999). The clinical representation of the latter may be the high
incidence of subacute arrhythmia recurrences (within the first week after
cardioversion) due to a persisting arrhythmogenic substrate in conjunction
with frequent premature atrial beats, serving as triggers (Tieleman 1998).
Although electrical remodeling is important, it is not the only determinant of
atrial remodeling. Particularly animal studies show that other changes occur
after electrical remodeling. These changes include contractile (Manning 1994),
(neuro)hormonal (Roy 1987, Jayachandran 2000), and in particular
(ultra)structural cellular adaptive processes (Ausma 1997, Gaspo 1997, Van
Wagoner 1997, Yue 1997, Brundel 1999, Van Gelder 1999, Van Wagoner 1999,
Brundel 2000). Comparable to electrical remodeling, it may be surmised that
these processes are dysfunctional, eventually facilitating arrhythmia
persistence.
At present, it is insufficiently understood what factors determine atrial
remodeling and (subsequent) arrhythmia intractability in the clinical setting.
First, human atrial fibrillation apparently occurs spontaneously. Thus, triggers,
substrate, and modulating factors (for instance abnormal autonomic influences)
presumably coincide. Second, different mechanisms may be active in different
patients. Frequently occurring premature atrial complexes or atrial tachycardia
(triggers) are important for paroxysmal atrial fibrillation; despite absence of
structural heart disease (substrate) atrial fibrillation is repeatedly induced.
Eventually, as a result of remodeling, a vulnerable substrate may develop,
facilitating permanent atrial fibrillation. Another mode of induction occurs in
the patient with structural heart disease (vulnerable electrical environment
or substrate) in whom a single premature atrial complex may suffice. In this
case, the substrate is relatively important for arrhythmia persistence.
Conversely, many patients with structural heart disease never develop atrial
fibrillation, either due to absence of triggers or unfavourable modulating factors,
or due to yet unknown “protective” mechanisms. These possible scenarios
illustrate that different chains (or pathophysiological processes) are possible.
Figure 1 illustrates the interaction between the aforementioned factors, using
the concept of the triangle of arrhythmia. Elements of atrial remodeling are
initially considered to be modulating factors and are shown accordingly.16
Eventually, however, these elements can acquire the status of substrate, which
exemplifies the intractability of the arrhythmia. Yet, the determinants involved
in the pathophysiology of atrial fibrillation should first be identified before an
actual integrated concept can be made. Both fundamental research on the level
of the atria (with electrophysiological, molecular biological, and histological
techniques) and the critical evaluation of the outcome of current arrhythmia
management (disclosing clinical factors of failure) are mandatory to reveal the
determinants of arrhythmia intractability and to improve our understanding
of the arrhythmia.
Aims of the thesis
The first aim was to investigate electrophysiological, neurohormonal, and
autonomic nervous changes associated with human atrial fibrillation (Parts A
& B). Appendices 1 and 2 deal with such consequences of the arrhythmia on
the level of the atria, or more specifically, atrial remodeling. On a systemic
level, appendices 3 and 4 illustrate neurohumoral and autonomic nervous
system responses. The second aim was to illustrate these pathophysiological
processes with respect to arrhythmia management in the setting of heart failure
and atrial arrhythmia surgery (Part C). Appendices 5, 6, and 7 focus on the
common intersection of atrial fibrillation and heart failure. Clinical course is
studied in patients with both atrial fibrillation and heart failure. Finally, in
appendices 8 and 9, the feasibility of surgery for atrial fibrillation after failure
of conventional treatment is described.
Trigger
Substrate Modulating factors
Atrial fibrillation
intractability
• Atrial premature beat (EAD)
• Focal atrial tachycardia
• Atrial flutter, AVNRT, or WPW-CMT
• Depressed conduction velocity
• Non-uniform conduction
• Action potential shortening
• Dispersion of refractoriness
• Autonomic nervous system
• Neurohormonal status
  - catecholamines
  - angiotensin II
  - natriuretic peptides
• Electrolyte disturbances
• Ischemia
• Surgery
• Thyroid metabolism
• Antiarrhythmic drugs
• Atrial remodeling
  - electrical
  - autonomic / neurohormonal
  - structural / ultrastructural
Figure 1. The triangle of arrhythmia in reference to atrial fibrillation and its intractability.17
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Basic and clinical aspects of atrial fibrillation
Atrial electrophysiological aspects
Atrial fibrillation implies absence of normal regular sinus rhythm and a random,
chaotic electrical activation of the atria with a high frequency (350-600/min).
The normal P-wave is absent on the surface electrocardiogram and the baseline
consists of an irregular wave pattern, or “f-waves” (fibrillation waves). In the
absence of total AV-block, the resulting ventricular response is totally irregular.
The mechanism underlying the perpetuation of atrial fibrillation is multiple
wavelet reentry. This concept was hypothesized by Moe in 1959, and
subsequently supported by atrial “mapping” studies (Allessie 1985, Cox 1991,
Konings 1994). The reentry circuit in atrial fibrillation is of the “leading circle”
type, implying a functionally determined circuit, in contrast to e.g. common
atrial flutter where it is anatomically determined. The center of such a
functionally determined circuit is invaded by multiple centripetal wavelets,
that collide and extinguish, resulting in an area of non-excitability
(refractoriness). The circulating impulse travels across the myocardium along
the shortest possible route, reexciting tissue as soon as it recovers from
refractoriness. The distance travelled by a wavelet is determined by the
refractory period and the conduction velocity: the wavelength equals conduction
velocity times refractory period. This implies that, for atrial fibrillation to
continue, the wavelength should “fit” in the atria. In dogs, the critical length is
estimated to be about eight centimeters (Rensma 1988). In addition, a critical
number of wavelets is necessary for atrial fibrillation to continue. In man, at
least three coexistent wavelets seem required. To further illustrate the
complexity of the electrophysiology of atrial fibrillation, as many as three types
of temporal-spatial patterns of atrial fibrillation were identified in high-density
atrial mapping studies in humans (Konings 1994). Inherent to the above
considerations, certain conditions promote the induction and perpetuation of
atrial fibrillation; a short refractory period, dispersion of refractoriness,
depressed conduction velocity, or non-uniformity in conduction all promote atrial
fibrillation. These electrophysiological conditions are frequently found in
diseased or enlarged atria.
Recently, it was discovered that focal and rapidly firing premature atrial
impulses (often originating from one of the pulmonary veins) trigger atrial18
fibrillation. Once atrial fibrillation is induced, electrical remodeling will
reinforce the perpetuation of the arrhythmia and facilitate reinduction. Removal
of these foci with radio frequency (RF) ablation appears to be curative in the
sense that it prevents induction of atrial fibrillation by removal of a triggering
mechanism. (Haissaguerre 1998, Haissaguerre 2000). It illustrates that
induction and perpetuation of the arrhythmia may be mediated through
different mechanisms.
Apart from atrial fibrillation due to preexisting arrhythmogenic conditions,
the arrhythmia itself produces atrial electrophysiological changes, thereby
domesticating itself; “atrial fibrillation begets atrial fibrillation”. In experiments
conducted in goats, it was found that atrial refractoriness shortens within 24-
48 hours of atrial fibrillation, without affecting conduction velocity (Wijffels
1995). Furthermore, the normal progressive shortening of atrial refractoriness
at fast heart rates became absent or was even inverted. This process was named
atrial electrical remodeling. Later experiments have suggested that electrical
remodeling occurs in humans as well (Franz 1997, Pandozi 1998, Yu 1998). In
the experiments by Allessie’s group, complete recovery from electrical
remodeling was observed (within 1 week), suggesting reversibility of the process.
Other animal studies show comparable results (Garratt 1999). The time course
of reversal in “naturally” occurring atrial fibrillation in man appears to be
within the same magnitude (within 1 week), but it is unclear whether the
recovery is complete (Tanabe 1999, Yu 1999, Hobbs 2000). Heterogeneity in
refractoriness (or nonuniform electrical remodeling) as a consequence of atrial
tachycardia further enhances vulnerability to atrial fibrillation in a dog model
(Fareh 1998). This would be another important factor enhancing intractability
of atrial fibrillation. The clinical importance of electrical remodeling on top of
chronic, structural heart disease remains to be determined.
The ionic or cellular mechanisms underlying the above mentioned electrical
changes of the atria have gained widespread interest. In a study by Wijffels et
al. it was concluded that autonomic modulation, ischemia, hemodynamic loading
of the atria, and atrial natriuretic peptide administration do not mediate
electrical remodeling (Wijffels 1997). Evidence points in a different direction,
namely abnormal calcium handling by the atrial myocyte (De Pauw 1996, Van
Wagoner 1997a, Yue 1997, Brundel 1999a, Van Gelder 1999a, Ausma 2000a).19
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Consequently, it was argued that a calcium-entry blocking agent might
attenuate electrical remodeling, and improve the restoration and subsequent
maintenance of sinus rhythm. Indeed, the use of verapamil seems to slow down
or attenuate early electrical remodeling (Daoud 1997, Tieleman 1997, Lee 2000),
while digoxin delays the recovery from electrical remodeling (Tieleman 1999).
Retrospective data from our institute point to an improved arrhythmia outcome
when intracellular calcium lowering drugs (initiated during atrial fibrillation)
are continued after cardioversion (Tieleman 1998). Adding to this concept, it
was recently shown in a prospective randomized study that verapamil added
to a class Ic antiarrhythmic drug reduced both acute and subacute (within
first week) arrhythmia recurrences (De Simone 1999). Whether calcium-entry
blocking agents are truly useful in this respect will have to be confirmed by
other randomized trials such as the “VERDICT-NHS” protocol, sponsored by
the Netherlands Heart Foundation. In this Dutch study, patients with persistent
atrial fibrillation will start with either verapamil or digoxin as rate control
drug, and continue to use it during serial cardioversion therapy. The primary
end-point of the study is subsequent maintenance of sinus rhythm. It is
hypothesized that verapamil will improve arrhythmia outcome compared to
digoxin.
Atrial structural and functional aspects
Paroxysmal atrial fibrillation in relatively young patients is frequently
unassociated with cardiovascular disease. By contrast, persistent atrial
fibrillation usually does not come alone; heart disease preceding persistent
atrial fibrillation is the rule. An inherent dilemma in this respect is to
distinguish which functional and structural atrial changes are “primary” and
which are “secondary” to atrial fibrillation (Gallagher 1997b).
On the one hand, structural heart disease has definite influence on atrial
structure and function. Rheumatic heart disease is associated with atrial fibrosis
causing conduction delay. Valvular heart disease, congenital heart disease, and
left ventricular dysfunction produce hemodynamic effects thereby loading and
stretching the atria. This in turn affects electrophysiology (conduction,
refractoriness). Indeed, deterioration in echocardiographically assessed diastolic
parameters (indicative of progressive loss of atrial function) predicted the onset20
of atrial fibrillation in patients with chronic heart failure (Pozzoli 1998). Heart
failure may also promote atrial fibrillation by producing interstitial atrial
fibrosis which affects conduction and refractoriness (Li 1999). Systemic
hypertension itself does not impose a load on the left atrium, but once
ventricular hypertrophy has developed diastolic dysfunction is likely, loading
the left atrium. Ischemic heart disease is presumably associated with atrial
fibrillation in the same fashion; diastolic ventricular dysfunction resulting from
impaired relaxation secondary to ischemia loads the left atrium.
Hyperthyroidism is also known to promote atrial fibrillation; in this instance
by affecting cellular metabolism, thus probably changing electrophysiology.
Other etiologies include pulmonary embolism, infections, cardiac surgery, or
alcohol intoxication, but these will not be addressed in detail. Table 2
summarizes the most common cardiac and non-cardiac etiologies (or
predisposing conditions) of atrial fibrillation.
On the other hand, atrial fibrillation produces functional and structural atrial
responses. Although the chaotic atrial contraction pattern during atrial
fibrillation depresses atrial function, it is not the only determinant. Atrial
contractility also becomes impaired due to metabolic derangement (atrial
stunning, or more correctly, hibernation (Van Gelder 1999b)), which becomes
clear after cardioversion of persistent atrial arrhythmia (Jordaens 1993,
Manning 1994). The longer the arrhythmia has lasted, the more prolonged
and incomplete the recovery of atrial contractile function (as assessed by
Doppler-echocardiography of transmitral flow). Eventually, after very long
standing atrial fibrillation, atrial contractile function is lost permanently (even
after cardioversion), accompanied by electrical and endocrinological “silence”
(Seino 1991). At the same time, progressive atrial enlargement occurs during
ongoing atrial fibrillation (Sanfilippo 1990). These findings suggest disrupted
myocyte integrity. On a cellular level, it was found that persisting atrial
fibrillation leads to cellular dedifferentiation and ultrastructural changes
(Ausma 1997a, Ausma 1997b, Ausma 2000a). These adaptations resemble those
found in chronic hibernating (“sleeping”) ventricular myocardium and are linked
to a disturbed cellular calcium metabolism (Leistad 1996, Sun 1998). Although
atrial size decreases again after cardioversion (Van Gelder 1991a, Gosselink
1993), it is unknown whether the (ultrastructural) cellular changes are21
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completely reversible. However, recent observations in a goat model of atrial
fibrillation suggest partial reversibility (Ausma 2000b). Furthermore,
irreversible damage such as atrophy (whether by apoptosis or necrosis) and
interstitial fibrosis will also determine the extent of recovery from atrial
remodeling (Li 1999). Recently, the occurrence of apoptotic death of atrial
myocytes during atrial fibrillation was shown (Aime-Sempe 1999). Although
the time course until “irreversibility” is unclear, four time domains in response
to atrial fibrillation are proposed by Allessie (Allessie 1998). They comprise
short-term (metabolic) changes, moderate-term changes (electrical remodeling),
long-term changes (contractile remodeling), and very-long-term changes
(anatomical remodeling). Of note, notwithstanding these distinctions, all
changes presumably occur concomitantly as they are linked to a disturbed
cellular calcium metabolism after the onset of the arrhythmia. Another
important consideration is that initially “protective” atrial responses or
adaptations may eventually have detrimental effects.
Apart from effects on the atrial level, the ventricle may also become depressed
by the arrhythmia. In animal models, ventricular systolic and diastolic
remodeling secondary to atrial tachycardia have been described (Spinale 1990).
In man, after cardioversion of persistent atrial fibrillation, left ventricular
ejection fraction slowly improves in the month thereafter (Van Gelder 1993).
An increase in left ventricular function has also been observed after His bundle
or AV-node ablation (Heinz 1992, Brignole 1994). These data indicate that atrial
fibrillation causes some degree of left ventricular dysfunction or
“tachycardiomyopathy” which is at least partial reversible. Although this effect
may be secondary to high rate there is evidence that the irregularity of heart
rate per se also depresses ventricular function (Daoud 1996, Clark 1997). In
other words, tachycardiomyopathy may be inherent to atrial fibrillation.
Nevertheless, lowering of high ventricular rate per se is important as it may
improve ventricular function (Van den Berg 1993). On a structural level, studies
on ventricular abnormalities secondary to atrial fibrillation were conducted in
animal models with rapid atrial pacing, showing cellular dedifferentiation and
alterations in collagen tissue structure (Spinale 1991a, Spinale 1991b).22
Atrial ultrastructural cellular aspects
The genetic basis of atrial fibrillation is an unexplored area. Although the
arrhythmia seems to occur in families, its expression is variable and the overlap
with naturally occurring, age-related atrial fibrillation makes it difficult to
identify familial cases. One typical example is a Spanish family with a genetic
defect underlying atrial fibrillation (Brugada 1997). Nevertheless, the discovery
of atrial tachycardia-induced electrical remodeling has led to numerous studies
on ion channel activity (or current density), protein expression, and mRNA
expression. Additionally, contractile remodeling of the atria in response to atrial
tachycardia or fibrillation has put a focus on changes in cellular calcium
handling.
Ultrastructural cellular changes as a consequence of atrial fibrillation
Rapid atrial tachycardia in dogs reduced I
CaL (depolarizing current during the
plateau phase) and I
to (outward K
+-current) densities without concomitant
changes in kinetics and voltage dependence (Yue 1997). In subsequent
experiments, the observed changes seemed to correspond with a reduced
number of functional L-type Ca
2+-channels (transcriptional down-regulation)
rather than an alteration in ion channel properties (Yue 1999). So far, no changes
in density of I
K1 (inward rectifier), I
KR and I
KS (rapid and slow delayed rectifier),
I
to2 (calcium dependent Cl
--current), or T-type Ca
2+-channel were observed in
this model. Besides changes in refractoriness, slowing of conduction velocity
in atrial tachycardia occurs as well, albeit with delay (Gaspo 1997a). These
alterations are paralleled by a progressive reduction of I
Na due to attenuated
gene expression (Yue 1999).
Investigating (ultrastructural) cellular mechanisms of electrical remodeling
in man is difficult because of uncontrolled variables such as age, underlying
cardiac disease, and concomitant medication. Nevertheless, I
CaL density proved
to be lower in patients undergoing cardiac surgery with atrial fibrillation as
compared to sinus rhythm (Van Wagoner 1999). Furthermore, I
to and I
Ksus
densities were depressed, accompanied by a lower mRNA expression of Kv1.5
which is encoding for the ultra rapid component of the delayed rectifier (Van
Wagoner 1997b). In line with these data, we demonstrated a lower mRNA
expression of the L-type Ca
2+-channel in patients with atrial fibrillation of a
duration >6 months (Van Gelder 1999a). Comparable results were obtained by23
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Lai et al., who showed that atrial fibrillation with a long duration (>3 months)
was associated with a reduced mRNA expression of the L-type Ca
2+-channel
(Lai 1999a). In addition, this group observed an up-regulated mRNA expression
of the I
f(unny) channel (pacemaker current) in human atrial fibrillation (Lai
1999b). In patients with persistent atrial fibrillation scheduled for maze surgery
we demonstrated depressed mRNA levels of genes encoding for I
CaL, I
to, I
KAch
(acetylcholine dependent potassium channel), and I
KATP. mRNA expression of
the Na
+-channel was also decreased, although to a moderate extent. No changes
were found for I
KR and I
KUR (ultra rapid component of the delayed rectifier)
(Brundel 1999b).
All these changes are in accordance with an important role of the L-type
Ca
2+-channel in electrical remodeling after longstanding atrial fibrillation, but
cannot sufficiently explain acute action potential shortening and impaired rate
adaptation. Only recently, however, Bosch et al demonstrated increased I
K1
and I
KAch in patients with a relatively short duration of atrial fibrillation which
would be in accordance with the acute electrophysiological changes (Bosch
1999). Pertaining to intracellular calcium handling, mRNA expression of SERCA
(sarcoplasmatic reticulum Ca
2+-ATPase), phospholamban, and the Na
-/Ca
2+-
exchanger appear to be unchanged in persistent (>6 months) atrial fibrillation
(Van Gelder 1999a). In another set of patients, however, we did observe
decreased mRNA and protein expression of SERCA (Brundel 1999a). Lai et al
showed a reduced gene expression of SERCA as well (in patients with atrial
fibrillation >3 months duration), but without changes in mRNA expression of
phospholamban and the ryanodine receptor (Lai 1999a).
These data on cellular calcium handling and ion channel function in atrial
fibrillation point to profound effects. Still, it is important to separate influences
of the arrhythmia from underlying cardiac disease, which may not be always
as easy. Although it seems clear that atrial fibrillation produces ultrastructural
atrial changes, the signaling pathways remain to be clarified.
Autonomic nervous system and neurohormonal aspects
Both sympathetic and parasympathetic (or vagal) nerve fibers supply the atria.
The right hand part of the autonomic nervous system subserves the right atrium
(and SA-node), whereas the left hand part subserves the left atrium (and AV-24
node). Right-left differences in atrial autonomic innervation are therefore
intrinsic. Furthermore, the distribution of vagal innervation of the atria is
nonuniform (Alessi 1958). The afferent cardiac nerve fibers conduct impulses
from the heart to the brain stem, where integration with other signals elicit
cardiopulmonary reflex mechanisms. The efferent cardiac nerve fibers release
neurotransmitters enacting on the myocardial cells.
Influences of the autonomic nervous system on the arrhythmia
Sympathetic stimulation moderately decreases the refractory period, enhances
automaticity, but hardly affects conduction velocity in the atria (Zipes 1974,
Shimizu 1994). Vagal stimulation, on the other hand, markedly shortens atrial
refractoriness (Zipes 1974, Prystowsky 1983, Shimizu 1994). Furthermore,
automaticity will be suppressed. Again, conduction velocity is hardly altered,
but anisotropic conduction and dispersion will become more pronounced. Both
limbs of the autonomic nervous system thus heighten susceptibility to atrial
arrhythmia. Moreover, sympathetic and vagal activity do not exclude one
another; both may be active at the same time. In fact, vagal effects are more
pronounced in the presence of a high sympathetic tone and vice versa
(“accentuated antagonism”) (Levy 1971). When a premature atrial beat “hits”
the atria at a point in time when autonomic tone has created favourable
conditions for atrial arrhythmia to occur (in particular shortened refractoriness),
both initiation and perpetuation of atrial fibrillation are facilitated. In addition
to the above, vagal stimulation produces a marked variability in atrial
refractoriness, which also facilitates atrial fibrillation (Liu 1997). To illustrate
the importance of autonomic influences, artificially mimicked vagal stimulation
of the atria with acetylcholine or methylcholine is known to strongly facilitate
atrial fibrillation and is therefore used in experimental settings.
Onset of (paroxysmal) atrial fibrillation in a vagal setting, or vagally
mediated (paroxysmal) atrial fibrillation, is a concept first described by Coumel
in 1978. According to his description, atrial fibrillation typically occurs at night
or at rest, and is preceded by bradycardia with frequent atrial premature beats.
During the course of the disease, this pattern may disappear (personal
observation). Conversely, sympathetically mediated onset of atrial fibrillation
typically occurs during exercise or emotional stress (Sopher 1997). Of note, the
conditions which elicit sympathetically mediated onset of atrial fibrillation25
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are similar to those which elicit ischemia in patients with coronary artery
disease. This is illustrated by a case-control study in a large group of patients
undergoing exercise testing; of the patients in whom atrial fibrillation was
induced 26% suffered from ischemic heart disease (Van den Berg 1994). Apart
from the typical clinical examples, however, the incidence of purely neurally
mediated atrial fibrillation is unknown. Nevertheless, evidence is accumulating
that alterations in autonomic tone (as assessed by heart rate variability
analysis) may precede paroxysms of atrial fibrillation (Hnatkova 1998, Sopher
1998). Vagal conditions at night appear to be of particular importance. However,
in the above mentioned “CRAFT” trials, single patients did not show one
consequent mode of onset. Clearly, this inconsistency hampers the translation
to a clinical strategy. Therefore, controlled studies are needed to identify optimal
treatment of patients with paroxysms of atrial fibrillation preceded by
alterations in autonomic tone (Andresen 1998).
The substrate for the susceptibility to atrial fibrillation in the setting of
autonomic changes is not evident. Nonuniformity in autonomic innervation
facilitates atrial fibrillation in animal experiments (Olgin 1998). It is conceivable
that atrial myocarditis or fibrosis may produce nonuniformity in autonomic
innervation (or nervous damage), thus facilitating atrial fibrillation later in
life (Lie 1997). Other possibilities include imbalance between vagal tone and
sympathetic tone or anatomical aberrations such as pronounced right-left
differences of autonomic pathways.
Limited data are available on circulating neurohormones and/or catecholamines
in relation to predisposition to atrial fibrillation. Examples of neurohormones
with cardiac effects are renin, angiotensin-II, atrial natriuretic peptide, brain
natriuretic peptide, endothelin, dopamine, epinephrine, and norepinephrine.
Theoretically, premature atrial beats may be induced by these catecholamines,
favouring atrial fibrillation when a substrate is present. Although these
neurohormones play an important role in the pathophysiology of (congestive)
heart failure, it is unclear which hormonal profile predicts the onset of atrial
fibrillation. Recently, however, higher N-terminal atrial natriuretic peptide
levels in patients with advanced heart failure demonstrated to be predictive
for developing atrial fibrillation (Crijns 2000). In line with these findings,
elevated plasma atrial natriuretic peptide also seems to have prognostic value26
(Yamada 2000). No data are available on abnormalities of the hormonal profile
in the absence of heart failure.
Influences of the arrhythmia on the autonomic nervous system
In general, tachycardia often cause a blood pressure fall at onset, eliciting
compensatory sympathetic activation and vagal withdrawal (Waxman 1995).
These effects are mainly mediated through stimulation of baro- and
mechanoreceptors. Of interest, autonomic modulation (for instance carotid sinus
pressure) may terminate atrial tachycardia, but in atrial fibrillation it is
ineffective due to the multiple reentry character of the arrhythmia. More
specifically, autonomic effects in atrial fibrillation are hard to measure with
heart rate variability techniques, given the irregularity of ventricular rate.
Nevertheless, heart rate variability during atrial fibrillation reflects to some
extent vagal modulation of AV-node function (Van den Berg 1997). However,
comparing these data to sinus rhythm (SA-node function) is as yet impossible.
Using heart rate variability analysis, rebound vagal activity was observed after
termination of 24 hours of rapid atrial pacing (mimicking atrial fibrillation) in
a goat model (Blaauw 1999). In line with general observations on tachycardia,
these data suggest attenuation of vagal activity during atrial fibrillation. Even
more recently, it was demonstrated that atrial fibrillation is associated with a
nonuniform increase in atrial sympathetic innervation, especially of the right
atrium (Jayachandran 2000). These changes parallel the disparate effects of
atrial fibrillation on atrial electrophysiology. The relevance of these findings
(suggesting autonomic remodeling) in relation to the intractability of atrial
fibrillation remains to be analyzed.
In contrast to predisposition to atrial fibrillation, more data are available on
neurohormonal effects as a consequence of atrial fibrillation. Circulating atrial
natriuretic peptide rises after the onset of atrial fibrillation (Roy 1987), and it
is responsible for the often reported symptom of polyuria during or shortly
after a paroxysm. A complete “family” of natriuretic peptides has been identified
(including brain natriuretic peptide, and C-type natriuretic peptide), but the
effects are best described for atrial natriuretic peptide. The stimulus for its
production is atrial stretch. The hormone exercises fluid balance regulation on
the level of the kidney (natriuresis) and hemodynamic correction through27
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vasodilatation (mediated by vagal action), whereas its cardiac effects involve
decreased cellular calcium loading, action potential shortening, and slowing of
phase 4 depolarization (thus prolonging myocyte relaxation) (Clemo 1996). The
cardiac effects of atrial natriuretic peptide might therefore be summarized as
“protective” when cellular calcium overload is concerned. It should be noted
that besides atrial tachycardia, stretch secondary to heart failure and
cardiovascular medication influence atrial natriuretic peptide levels as well. A
new approach to investigate neurohormonal changes is molecular biology,
enabling the investigation of gene and/or protein expression. With these
techniques, it was found that atrial mRNA expression of both atrial natriuretic
peptide and brain natriuretic peptide correlate with atrial pressure (Doyama
1998). Still, the molecular mechanism on a (ultra)cellular level remains to be
clarified, specifically how atrial fibrillation triggers the above mentioned
neurohormonal release.
Few data exist on other neurohormonal systems. So far, in the setting of
atrial tachycardia, the acute effects do not appear to involve general activation
of the renin-angiotensin-aldosterone system (Kojima 1988, Nicklas 1989).
Possibly, the elevated atrial natriuretic peptide depresses aldosterone secretion.
Recently, however, blocking the angiotensin II type 1 receptor (AT
1-R) proved
to prevent electrical remodeling, suggesting involvement of a local tissue renin-
angiotensin-aldosterone mechanism in atrial fibrillation (Nakashima 2000).
Only very recently, it was shown that atrial fibrillation is associated with down-
regulation of atrial AT
1-R and up-regulation of AT
2-R proteins (Goette 2000).
How these findings would translate to a general role of the renin-angiotensin-
aldosterone system in remodeling in atrial fibrillation remains unclear. As
observed in a clinical study, renin-angiotensin-aldosterone system inhibition
with an ACE-inhibitor might have favourable effects on arrhythmia outcome
(Van den Berg 1995). It can be hypothesized that ACE-inhibition or AT
1-R
blockade may modulate arrhythmia intractability through inhibition of both
local tissue and systemic renin-angiotensin-aldosterone systems. Although it
has been suggested that other vasoactive compounds such as vasopressin,
prostaglandin E2, endothelin, and cyclic-AMP are involved in the
pathophysiology of atrial fibrillation (Imanishi 1990, Li 1995, Theodorakis
1996), this remains to be fully clarified. Of note, in case of development of
tachycardia-induced cardiomyopathy (associated with heart failure), other28
neurohormones besides the natriuretic peptides will become elevated (Shinbane
1997). Importantly, advanced neurohormonal activation may contribute to atrial
remodeling and disease progression to significant extent.
Another aspect of the autonomic nervous system relates to symptoms in atrial
fibrillation. So far, only a few studies have systematically addressed complaints
and quality of life in patients with atrial fibrillation (Jenkins 1996, Jung 1998).
Moreover, most available studies pertain to highly symptomatic patients who
underwent AV-node ablation for “drug refractory” atrial fibrillation (Brignole
1994, Brignole 1998). Conversely, data on the “average” symptomatic patient
are lacking. At present, large clinical trials randomizing to different treatments
for atrial fibrillation (AFFIRM, PIAF, RACE) have incorporated quality of life
measurement in their design (AFFIRM Investigators 1997, Hohnloser 1997,
Verdoes 2000). In addition, it is conceivable that ones personality plays a role
in this connection. In the presence of a “neurotic” personality, the perception of
the effect of the arrhythmia may be amplified. In turn, such a perception could
promote unfavourable autonomic modulation, thus enhancing arrhythmia
susceptibility. There is some indication that an abnormal autonomic response,
arrhythmia susceptibility, and impaired quality of life correlate, though this
pertains to selected patients with orthostatically induced supraventricular
arrhythmias (Braune 1999).
Heart failure
Atrial fibrillation and heart failure are associated disorders, especially in elderly
patients, owing to common risk factors (Wolf 1996). On the one hand, the
arrhythmia emerges in the presence of (progressing) heart failure. A poor
ventricle loads the atria and induces stretch. In turn, this may result in action
potential prolongation and stretch-activated after-depolarizations of the atrium,
or, “mechano-electric feedback” (Kamkin 2000). At the same time, chronic
stretch may eventually result in atrial enlargement (Solti 1989). Structural
changes like interstitial fibrosis may also contribute to an arrhythmogenic
environment (Li 1999). In addition, elevated neurohormone levels in response
to heart failure may initiate atrial after-depolarizations and hereby trigger
atrial fibrillation. In accordance with these considerations, many of the patients
in heart failure trials have atrial fibrillation. Table 3 shows a number of29
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Table 3. Prevalence of atrial fibrillation in studies on heart failure
Predominant Mean Prevalence
NYHA class LVEF AF
SOLVD-prevention 1992 I 0.28 4%
SOLVD-treatment 1991 II-III 0.25 10%
CHF-STAT 1995 II-III n.a. 15%
MERIT-HF 1999 II-III 0.28 16%
Middlekauff 1991 III-IV 0.19 20%
Stevenson 1996 III-IV 0.23 22%
GESICA 1994 III-IV 0.20 29%
CONSENSUS 1987 IV n.a. 50%
AF = atrial fibrillation, CHF-STAT = Survival Trial of Antiarrhythmic Therapy in Conges-
tive Heart Failure, CONSENSUS = Cooperative North Scandinavian Enalapril Survival
Study, GESICA = Grupo de Estudio de la Sobrevida en la Insufficiencia Cardiaca en Argen-
tina, MERIT-HF = Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart
Failure, n.a. = not available, NYHA = New York Heart Association, SOLVD = Studies On
Left Ventricular Dysfunction.
prominent trials on heart failure. The prevalence of atrial fibrillation increases
with more advanced heart failure (as assessed by NYHA class). On the other
hand, as discussed earlier, the arrhythmia per se may mediate in the
deterioration of cardiac performance. Table 4 summarizes the underlying
mechanisms. In line with the latter concepts, atrial fibrillation independently
increases the risk for subsequent heart failure (Krahn 1995). Thus, the relation
between atrial fibrillation and heart failure appears reciprocal; one aggravating
the other. Finally, the influence of (progressing) underlying heart disease should
be considered. In this connection, it seems reasonable to assume a deleterious
effect on both heart failure and atrial fibrillation.
The impact of atrial fibrillation on survival in the setting of heart failure is
the subject of controversy. Atrial fibrillation and heart failure both limit
prognosis, but the impact of the arrhythmia superimposed on heart failure is
not completely clear. In the past, it was common practice to treat atrial
fibrillation with class I antiarrhythmic drugs, including patients with heart
failure. Only later it became clear that survival was reduced when such
antiarrhythmics were used in patients with heart failure (CAST Investigators
1989, Coplen 1990). More specifically, when patients with atrial fibrillation30
were treated with class I antiarrhythmic drugs in the presence of heart failure,
mortality was markedly increased as compared to mortality in patients without
heart failure (Flaker 1992). Hence, the earlier reported negative impact of
atrial fibrillation on survival in patients with heart failure might be the result
of adverse effects of class I antiarrhythmics and not due to the arrhythmia
itself (Middlekauff 1991, Stevenson 1995). Conversely, a class III antiarrhythmic
drug such as amiodarone is of value in the setting of atrial fibrillation and
heart failure. The CHF-STAT trial showed that patients converting to sinus
rhythm on amiodarone have a lower mortality than nonconverters (Deedwania
1998). In addition, the drug is potent in maintaining sinus rhythm after
cardioversion in patients with a compromised left ventricular function
(Gosselink 1992).
Another essential therapy for improving cardiac condition is ACE-inhibition.
In the first place, an ACE-inhibitor may prevent atrial fibrillation in the
presence of heart failure (Pedersen 1999). Secondly, when ACE-inhibition is
initiated before cardioversion, subsequent restoration and maintenance of sinus
rhythm may improve (Van den Berg 1995). Thirdly, ACE-inhibition may reduce
mortality in the setting of atrial fibrillation and heart failure (Dries 1998),
comparable to its effects in patients with heart failure in sinus rhythm (SOLVD,
SAVE, and other trials). At present, the arrhythmia appears not to have a
significant independent impact on survival when therapy including ACE-
inhibition and amiodarone is instituted (Stevenson 1996, Crijns 2000).
Although the value of cardiac unloading drugs seems evident, this is less well
defined for serial cardioversion therapy. Essentially patients with true
Table 4. Mechanisms underlying deterioration of cardiac performance in
atrial fibrillation
1. Loss of organized atrial contraction
2. High ventricular rate
- decreased diastolic filling time
- decreased stroke volume
3. Irregularity of ventricular rate
4. Ventricular tachycardiomyopathy
5. Progressive neurohormonal derangement
6. Progressive underlying cardiac disease31
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tachycardiomyopathy benefit from restoration of sinus rhythm or adequate
lowering of ventricular rate alone. Yet, it can be difficult to recognize
tachycardiomyopathy in the setting of atrial fibrillation and heart failure. As
an adjunct to routine diagnostics, low-dose dobutamine stress echocardiography
may help to identify patients benefitting from restoration of sinus rhythm with
recovery of left ventricular function (Paelinck 1999). Still, it is unclear whether
a cardioversion strategy is of real long-term use for these and other patients
with atrial fibrillation and heart failure. Can serial cardioversion prevent the
recurrence of either heart failure or atrial fibrillation, and, can it improve
survival? Therefore, we need to focus on patients with atrial fibrillation and
heart failure who undergo serial cardioversion. Anticipating on the results,
such a strategy might be of limited value as it is indicated that long-term
maintenance of sinus rhythm is only possible in a minority of patients (Van
Gelder 1996). Obviously, alternative treatment strategies are pharmacological
rate-control therapy or AV-nodal ablation. The latter seems to be useful in a
highly symptomatic patient (Brignole 1998), but is not suited for every patient
with atrial fibrillation and heart failure. Thus, the optimal arrhythmia therapy
in the presence of heart failure is still undetermined.
In heart failure, elevated plasma and tissue neurohormones such as
angiotensin-II mediate in the pathophysiology of disease progression. Increased
neurohormonal levels bring about ventricular hypertrophy, cellular
dedifferentiation, and interstitial fibrosis which in turn causes progression of
heart failure and ventricular arrhythmia (Cohn 2000). As stated in the previous
section, atrial fibrillation is also associated with neurohormonal activation,
although atrial natriuretic peptide is the main actor in this setting. Comparable
to heart failure, the altered neurohormonal (and autonomic) status in atrial
fibrillation might procure cellular adaptations in the ventricles. Thus, the
occurrence of heart failure secondary to atrial fibrillation might be mediated
through neurohormonal effects of the arrhythmia on a ventricular level. Until
now, specific data on the neurohormonal profile of patients with atrial
fibrillation and heart failure are lacking. Such data are of interest as they may
indicate the importance of atrial fibrillation in the setting of heart failure.
Atrial natriuretic peptide is of special interest since this neurohormone is mainly
produced in the atria and exercises “protective” properties acting as a diuretic32
and as an opponent of the renin-angiotensin system. During the time course of
atrial fibrillation, however, atrial natriuretic peptide production progressively
declines to a point where levels become undetectably low (Seino 1991, Van den
Berg 1998). One might argue that loss of such a protective mechanism
contributes to heart failure. Possibly, patients developing heart failure during
atrial fibrillation can be identified by declining atrial natriuretic peptide levels.
Nevertheless, the pathophysiology of atrial natriuretic peptide (and other
natriuretic peptides) in general needs to be investigated to greater extent in
patients with atrial fibrillation either with or without accompanying heart
failure.
Therapeutic aspects
At present, antiarrhythmic drugs are still the cornerstone of therapy for atrial
fibrillation (Van Gelder 1998), either by aiming at sinus rhythm (usually a
Vaughan Williams class I or III drug) or by aiming at adequate ventricular
rate control (usually a Vaughan Williams class II or IV drug, or digoxin).
Cardioversion therapy for atrial fibrillation
Restoring sinus rhythm with external electrical cardioversion is considered
standard therapy for atrial fibrillation, and is widely practiced. Terminating
human cardiac arrhythmias with electricity (R-wave synchronized capacitor
discharge) was introduced by Lown in 1962. Only in patients with short-term
(<24 hours) atrial fibrillation, pharmacological cardioversion with an
intravenous class Ic antiarrhythmic drug is worth trying; it effectively restores
sinus rhythm in >90% of the patients (Crijns 1988, Van Gelder 1999b).
Currently, it is still a matter of debate whether sinus rhythm should be restored
in every patient with atrial fibrillation. However, patients with atrial fibrillation
of a duration less than 36 months, age below 57 years, left atrial size <60 mm
(long axis view), and NYHA class I or II are generally considered suitable
candidates for cardioversion therapy or at least one attempt (Van Gelder 1996,
Van Gelder 1997). In general, all antiarrhythmic drugs for prophylaxis of atrial
fibrillation are equal but they are only moderately effective (Crijns 1991). Only
amiodarone (possessing class I,II and IV properties on top of a class III effect)
is more effective (Roy 2000), but its non-cardiac adverse effects and abnormal
pharmacokinetics pose important disadvantages. When applying serial33
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electrical cardioversion combined with serial antiarrhythmic drug therapy
(including amiodarone), only 27% of the patients maintain sinus rhythm after
4 years of therapy (Van Gelder 1996). It should be stressed that during this
strategy, antiarrhythmic drugs were not only discontinued due to inefficacy
(recurrent atrial fibrillation despite adequate doses), but also because of cardiac
and non-cardiac side effects.
The currently used serial electrical cardioversion strategy is probably not
optimal. Preparatory anticoagulative therapy and waiting lists hamper its
potential effectiveness. Early cardioversion of atrial fibrillation (“as soon as
possible”), may increase eventual efficacy by early interruption of processes of
atrial remodeling. Indeed, the “MEDCAR” study from our institute indicates
that, in case of an arrhythmia recurrence, prompt re-cardioversion facilitates
the efficacy of antiarrhythmic drug use in restoring sinus rhythm (Tieleman
2000). In addition, drugs preventing or delaying atrial remodeling (for instance,
a calcium entry blocker) could enhance the success-rate of cardioversion therapy.
The “VERDICT-NHS” study is a prospective clinical trial investigating these
issues; patients will receive either verapamil or digoxin >4 weeks prior to
cardioversion and will be re-cardioverted either immediately (<24 hours) or
scheduled (<4 weeks) in case of an arrhythmia recurrence. The primary end-
point is permanent (accepted) atrial fibrillation after 1.5 years of follow-up.
On the one hand, rhythm-control may lower the incidence of heart failure,
thromboembolism, bleeding, and improve quality of life, but is rather ineffective
and time consuming. In addition, patients remain at risk for thromboembolism
at the very moment the arrhythmia recurs. On the other hand, rate-control
therapy also may lower the incidence of heart failure, but it necessitates
continued anticoagulation and quality of life might be reduced. Still, it is void
of the dangers of (prophylactic) antiarrhythmic drug therapy and usually easy
to carry out. Consequently, striving for sinus rhythm may not be the right goal
in the treatment of atrial fibrillation. Several large scale clinical studies
(AFFIRM, PIAF, RACE), comparing “rhythm-control versus rate-control” with
a focus on survival, complications, and quality of life, are currently in progress
(AFFIRM Investigators 1997, Hohnloser 1997, Verdoes 2000). Preliminary
results of the PIAF study indicate that both strategies yield similar
improvement in symptoms and quality of life (after 1 year of treatment) but34
exercise tolerance is better in the group of patients with restored sinus rhythm
(Hohnloser 1999). It should be emphasized, however, that the aforementioned
projects (AFFIRM, PIAF, RACE) utilize “non-optimal” serial cardioversion.
Unconventional therapy for atrial fibrillation
Acceptance of the arrhythmia is the first option after failure of serial
antiarrhythmic drug and cardioversion treatment (rhythm-control). Still, in
some patients conventional rate-control therapy fails or is not feasible due to
persisting symptoms despite optimal rate-control management (including
adequate rate-response to exercise) or rate-control drug intolerance. Therefore,
new, unconventional treatment strategies mainly aiming at symptom reduction
have been developed.
1. Permanent cardiac pacing (with or without AV-node ablation)
Catheter-guided RF-ablation of the AV-node with subsequent permanent
ventricular pacing is a relatively new and promising concept. A recent meta-
analysis of 21 studies on AV-node ablation and permanent pacing indicates
improvement for a broad range of clinical outcomes (Wood 2000). Most data,
however, pertain to selected, highly symptomatic patients (Fitzpatrick 1996,
Brignole 1997, Marshall 1999). These studies indicate (moderate) improvement
of quality of life and symptom reduction. Patients with left ventricular
dysfunction are of particular interest, since small-size studies have indicated
improvement of left ventricular function after AV-node ablation and permanent
pacing (Rodriguez 1993). Other studies, however, could not demonstrate such
an effect (Brignole 1998). So, it is not proven that AV-node ablation is
advantageous in every patient with heart failure and a large scale investigation
seems mandatory (Saxon 1997). Preventive single or dual site atrial pacing is
another, relatively new, promising concept (Murgatroyd 1994). Such a strategy
may be worth trying in patients who are candidates for AV-node ablation. If
sinus rhythm is maintained, AV-node ablation can be avoided whereas it can
still be executed in case of failure of pacing. The rationale is that permanent
atrial pacing will reduce premature atrial beats, conduction delay, abrupt
changes in heart rate, or dispersion in refractoriness (related to bradycardia),
hereby attenuating the induction of atrial fibrillation (Ramdat Misier 1999).
The initial trials determining optimal pacing mode are promising, particularly35
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in patients with a tendency towards bradycardia or sick-sinus syndrome (Ricci
1996). At present, a trial (AF-therapy project) comparing different algorithms
of preventive pacing is in progress.
2. Catheter-guided radiofrequency ablation of the initiating focus
Catheter-guided RF-ablation of a single site of premature atrial complexes or
fast atrial tachycardia may prevent the onset of atrial fibrillation in selected
patients (Haissaguerre 1998, Haissaguerre 2000). The region of the pulmonary
veins in the left atrium and the crista terminalis in the right atrium are of
special interest. Particularly in patients with lone atrial fibrillation these
locations are associated with premature atrial complexes or fast atrial
tachycardia. Although selected series report high success rates of catheter-
guided RF-ablation, this has not been obtained in other centers. It appears
that the technique to eliminate foci in the pulmonary veins must be improved.
3. Implantable atrial defibrillator (or atrioverter)
Another recent development is the implantable atrial defibrillator. Initial
experience with this “atrioverter” device is very promising (Wellens 1998,
Timmermans 2000). It should be noted that this treatment is not primarily
preventive; it only operates once atrial fibrillation occurs. The duration of
episodes of atrial fibrillation can thus be shortened. The prevention of electrical
remodeling would be an additional effect, thereby reducing the susceptibility
to atrial fibrillation. Pain perception of the DC-shock may limit general use;
even at low energy levels (below atrial fibrillation threshold) shock delivery is
rather discomforting.
4. Atrial arrhythmia surgery
Another resort for pharmacologically refractory atrial fibrillation is atrial
arrhythmia surgery. Table 5 summarizes a number of studies on atrial
arrhythmia surgery. Compartment surgery, left atrial isolation, and corridor
surgery are moderately effective techniques (64-70% sinus rhythm after follow-
up) that do not restore normal sinus rhythm in both atria (Graffigna 1992,
Shyu 1994, Van Hemel 1994). These techniques create a pathway from sinus
node to AV-node, either with or without inclusion of the right atrium, reducing
atrial mass and hence atrial fibrillation susceptibility. Consequently, bi-atrial36
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function and AV-synchrony is not restored. The maze procedure, introduced in
1987 by Cox, consists of a labyrinth of atrial incisions (preventing reentry) and
bilateral atrial appendage removal (reducing critical mass). After the procedure,
sinus rhythm is propagated to both atria, by predetermined routes, imposed
by the discrete incisions (“ablative sutures”). This procedure is rather extensive,
with multiple incision lines in both atria, the interatrial septum, and around
the pulmonary veins. Usually, local cryoablation is applied where the incisions
approach the AV-ridge. The procedure has been applied to patients with and
without structural heart disease, with long-term success rates of 73-96% in
terms of maintenance of sinus rhythm (Gregori, Jr. 1995, Kosakai 1995, Kamata
1997, Cox 1998, Jessurun 2000). However, the original maze procedure (maze
I) was associated with postoperative sinus node dysfunction (Sundt 1997). The
technique was therefore modified two times (maze II, maze III) to enlarge the
“free” region of the sinus node. A second motive was better exposure of the left
atrium to improve contractile function. Maze III is now the preferred technique;
a blunted sinus node response is present in only 8% and left atrial contractile
dysfunction in only 9% of the patients (Sundt 1997). More recently, several
prominent thoracic surgeons have evaluated their personal experience with
maze surgery over the past years. They all conclude that, in selected patients,
it is a feasible alternative (Arcidi, Jr. 2000, Cox 2000, Kosakai 2000, McCarthy
2000, Schaff 2000).
Some surgeons have made modifications with more extensive cryoablation
(Kosakai 1994). In theory, an approach exclusively using cryo- or RF-ablation
would address the “Achilles heel” of maze surgery, that is bleeding from atrial
sutures necessitating reoperation. On the other hand, Cox’s group report that
reoperation for bleeding is nowadays “uncommon” in their center (Sundt 1997),
but this might be related to vast experience. In an animal model, a non-cutting,
RF-catheter ablation technique reduced the inducibility and duration of atrial
fibrillation (Elvan 1995). When closed-chest RF-ablation in man proves to be
effective (and safe), open-chest maze procedures might not be necessary
anymore. “Hybrid-procedures” with open-chest cutting of the appendages, and
cryo- or RF-ablation are being developed. Preliminary data indicate that such
an approach might be successful and safe; of 78 patients undergoing
intraoperative RF-ablation, 5% died in hospital while 69% were in sinus rhythm
after a follow-up of 21±9 months (Beukema 1999).38
Questions remain about the maze (III) procedure. The nature and origin of the
postoperative sinus node problems might not be solely explained by the location
of the sutures. Recently, it was shown that heart rate variability is depressed
after the maze III procedure, but improves after 12 months (Pasic 1998),
implying transient autonomic dysfunction. Presumably, the extensive cuts
produce a degree of autonomic denervation with subsequent reinnervation over
time. Another matter of debate is what “minimal” set of sutures will suffice. In
an animal experiment, removal of the appendages with pulmonary vein isolation
proved to be effective against the induction of atrial fibrillation (Fieguth 1997).
The latter appears to be of crucial importance for success, presumably either
by isolating foci or by modifying autonomic innervation. A reduction of the
number of cuts is very appealing with respect to procedure simplification, and
perhaps reduction of postoperative bleeding. In addition, less extensive cutting
might (further) reduce sinus node dysfunction.
5. Hybrid therapy
Combination of therapies or “hybrid” therapy is another option (Van Gelder
1999b). Atrial fibrillation can be reduced to a flutter with a class Ic
antiarrhythmic drug; subsequent radiofrequency ablation of the flutter circuit
with continuation of the antiarrhythmic drug appears highly effective (Nabar
1999). Cardioversion success-rate can be enhanced by pre-treatment with
antiarrhythmic drugs (Bianconi 1996, De Simone 1999, Oral 1999). Other
possibilities are preventive atrial pacing with continuation of antiarrhythmic
drug therapy or an atrioverter with preventive atrial overpacing. However,
specific data on the feasibility of hybrid approaches are lacking.39
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ABSTRACT
Introduction During recent years, experimental research on atrial fibrilla-
tion (AF) has focused on tachycardia-induced shortening of the atrial refrac-
tory period during AF. Limited data exists on whether this tachycardia-in-
duced atrial electrical remodeling plays a role in clinical chronic AF (CAF).
The role of the underlying heart disease and medication on the atrial refrac-
tory period is unknown. Furthermore, no patients with paroxysmal AF (PAF)
have been studied yet.
Methods We measured the atrial effective refractory period (AERP) at 5 cycle
lengths between 250 and 600 ms using temporary epicardial pacing leads in
42 patients (15 sinus rhythm (SR), 16 PAF, 11 CAF) during cardiac surgery.
The role of the underlying heart disease, arrhythmia history, and medication
on the AERP was investigated by uni- and multivariate regression analysis.
Furthermore, the role of the atrial AERP on the occurrence of postoperative
AF was investigated.
Results During surgery, patients with CAF and PAF had significantly shorter
AERPs with less rate adaptation than patients in sinus rhythm. In PAF the
AERP was related to the duration of sinus rhythm after the last episode of
PAF (at 500 ms; R=0.71, p<0.002). Medication and underlying heart disease
did not influence the AERP, except for the presence of mitral regurgitation
which prolonged the AERP in all 3 patient groups (p=0.006). The AERP during
surgery did not predict the occurrence of postoperative AF.
Conclusion CAF and PAF are associated with short AERPs, whereas mitral
regurgitation seems to prolong the AERP. The logarithmic correlation between
the AERP and the duration of sinus rhythm after the last episode of PAF indi-
cates the importance of the AERP for the occurrence of AF, but could also be an
expression of recovery from electrical remodeling. By contrast, a short refrac-
tory period during surgery does not predict the occurrence of postoperative AF.
INTRODUCTION
During recent years, animal experiments have proposed the concept of atrial
fibrillation (AF)-induced atrial electrical remodeling, which could explain why
“AF begets AF”
1. Repetitive induction of AF in chronically instrumented goats58
induced shortening of the atrial effective refractory period (AERP) with loss of
the physiologic rate adaptation, leading to an increased duration of the in-
duced episodes of AF, until AF finally became sustained
1. Limited data exist on
whether electrical remodeling plays an important role in clinical AF. Although
previous studies demonstrated short atrial refractory periods
2,3 and loss of rate
adaptation
4-6 in patients with atrial tachyarrhythmias, it remained controver-
sial whether the presented electrophysiological abnormalities were a cause or
a consequence of AF.
We provided indirect evidence of recovery from electrical remodeling after
cardioversion of chronic AF (CAF) in humans
7. This was confirmed by invasive
measurements by Yu et al.
8, which made the concept of electrical remodeling
occurring in patients as a consequence of AF more plausible. The aim of the
present study was to evaluate the influence of underlying heart disease and
medication in combination with AF-induced atrial electrical remodeling on the
atrial refractory period in patients with chronic as well as paroxysmal AF un-
dergoing cardiac surgery. Furthermore, we investigated the role of the atrial
refractory period during surgery on the occurrence of postoperative AF.
METHODS
The medical ethical committee of the University Hospital Groningen approved
the study and informed consent for participation in the study was obtained
from all patients.
Patients  We implanted temporary epicardial pacing leads to measure the
AERP in 46 patients during cardiac surgery for various indications. Before
surgery, clinical characteristics of the patients were assessed by 1 investigator
(AET). Presence, type and duration of AF were determined by the patients’
complaints, medical chart, electrocardiograms and Holter monitoring before
surgery. Table 1 depicts the baseline characteristics of the included patients.
The patients’ arrhythmia history was classified according to Gallagher and
Camm
9. Fifteen patients were in permanent chronic AF (CAF), while 16 pa-
tients had a history of persistent or paroxysmal AF, but were all in sinus rhythm
at the time of surgery (PAF). The remaining 15 patients had no history of AF
and were in sinus rhythm (SR). Atrial and ventricular dimensions and left59
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Table 1. Patient characteristics
CAF PAF SR
Number of patients 15 16 15
Age (years) 56 ± 9 47 ± 9* 62 ± 10
Male/ female 11 / 4 13 / 3 12 / 3
Underlying heart disease; n  (%)†
- Coronary heart disease 1 (7)* 0* 9 (60)
- Hypertension 1 (7)* 2 (13)* 6 (40)
- Mitral valve disease 7 (47) 7 (44) 6 (40)
- Aortic valve disease 0 1 (6) 0
- Rheumatic heart disease 0 1 (6) 0
- Congenital heart disease 0 1 (6) 0
- Cardiomyopathy 1 (7) 0 0
- Lone AF 6 (40) 7 (44) -
AF history
- Duration last paroxysm: median, range (hours) - 11 (0.2-24) -
- Duration sinus rhythm after AF (days) - 7 (0.5-210) -
- Duration chronic AF: median, range (months) 11 (0.1-87) - -
Primary surgery (n)
- Mitral valve repair/ replacement 7 7 6
- MAZE operation 8 9 0
- CABG 0 0 9
Medication; n  (%)
- Digitalis 6 (40)* 1 (6) 0
- Verapamil 3 (20) 3 (19) 4 (27)
- Beta-blocker (no sotalol) 4 (27) 4 (25) 7 (47)
- Diuretics 6 (40)* 3 (19) 3 (20)
- Ace-inhibitors 7 (47) 7 (44) 7 (47)
NYHA classification (n)
- I 6 6 10
- II 3 7 5
- III 6 3 0
Echocardiography
- LA-long-axis (mm) 46 ± 7 41 ± 7 45 ± 5
- LA- apical (mm) 72 ± 8 60 ± 9 67 ± 5
- RA- apical (mm) 65 ± 8 54 ± 9 55 ± 9
- LVEDD (mm) 52 ± 5 51 ± 7 56 ± 9
- LVESD (mm) 35 ± 7 36 ± 6 37 ± 6
- LV function (1=normal - 4=depressed) 1.3 ± 0.6 1.1 ± 0.3 1.0 ± 0
Data expressed as mean ± standard deviation, or median (range);
* p<0.05 compared to patients in sinus rhythm;
† more than 1 per patient possible.
LA, left atrium; RA, right atrium; LV, left ventricle; EDD, end-diastolic diameter; ESD, end-
systolic diameter.60
ventricular function were determined by echocardiography and angiography
within 4 weeks before surgery. Coumarin therapy was interrupted 3 days be-
fore surgery and class I and III anti-arrhythmic drugs were discontinued for at
least 5 half-times.
Anesthetic procedures  Anesthesia was induced with midazolam. sufentanyl,
and pancuronium bromide, and maintained thereafter with an infusion of
midazolam and sufentanyl, occasionally supplemented by isoflurane. All
patients received dexamethasone (1mg/kg). St. Thomas solution was used to
induce cardioplegia, subsequent cardiopulmonary bypass was performed at
28-30 degrees Celsius.
Cardioversion In case of AF during surgery, atrial fibrillatory intervals were
recorded, followed by intra-thoracic epicardial electrical cardioversion deliver-
ing 2-20 Joules of R-wave synchronized DC-current directly to the atria. After
successful cardioversion we waited at least 10 minutes before determination
of the AERP. In 4 patients with CAF (median duration 27 months, range 1 - 63
months) electrical cardioversion was unsuccessful  and refractory periods were
not measured.
Electrophysiologic study In the remaining 42 patients, the AERP was de-
termined at 5 different basic cycle lengths (BCL; 600, 500, 400, 300 and 250
ms) at the right and left atrial appendage and the lateral right atrial free wall
using programmed electrical stimulation. Eight basic drive stimuli were fol-
lowed by one single premature stimulus, all of 2x diastolic threshold, with
current pulses 2 ms in duration. The S1S2 coupling interval was increased in
steps of 10 ms, starting from well within the refractory period. The longest
S1S2 coupling interval that failed to result in a propagated atrial response was
taken as the local AERP. The maximal spatial difference in refractoriness at a
given BCL was defined as the AERPmax-AERPmin. Rate-adaptation at a given
site was defined as AERP600ms-AERP250ms. All electrophysiologic measurements
were performed before cardiopulmonary bypass was instituted and lasted ap-
proximately 25 minutes. After induction of AF during measurement of the AERP,
immediate re-cardioversion was instituted when necessary, after which we
waited another 10 minutes before continuing the AERP measurements.61
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The electrophysiologic study was stopped in case its duration exceeded 45 min-
utes or AF was induced repeatedly.
Surgical procedures and follow-up  In addition to the primary surgery,
the right atrial appendage was removed for purposes of research in all pa-
tients. In patients with mitral valve disease and an enlarged left atrium, also
the left atrial appendage was removed. In case of a history of AF and mitral
valve disease, additional anti-arrhythmic surgery was performed. This so-called
“mini-MAZE” procedure resembles the Cox MAZE III procedure
10, but is with-
out the incisions at the posterior right atrium and the intra-atrial septum. In
addition, local cryo-ablation was performed where the incisions approached
the tricuspid and mitral valve annulus
11.
During recovery from surgery the patients were treated according to in-
hospital standard post-operative procedures including forced mechanical ven-
tilation, positive inotropics, diuretics, analgesics (NSAIDs and pethidine), and
antibiotics (48 hours cefamandol in all patients). As part of routine, all pa-
tients started or continued low dose beta-adrenergic blocking drugs at day 1
after surgery. No class I or class III anti-arrhythmic drug therapy was insti-
tuted.
Statistical analysis  All data are expressed as mean ± SEM. Group variables
were compared using Students-t-test, Fisher-exact or chi-square tests when
appropriate. Time series were analyzed by repeated measurements, using a
random coefficient model. The correlation studies on the duration of AF or
sinus rhythm and the AERP were performed with simple linear regression
analysis. For the correlation studies, the AERP at a BCL of 500 ms was used,
since this could be determined in most patients. Multivariate regression analysis
was performed to evaluate the influence of medication and underlying heart
disease on AERP, and of the AERP on the occurrence of post-operative AF. A
p-value < 0.05 was considered statistically significant.
RESULTS
Electrophysiologic measurements during surgery Figure 1 shows
the AERP at the different BCLs in relation to the arrhythmia history62
Figure 1. The atrial refractory period in patients with a history of atrial fibrillation compared to
patients in sinus rhythm. AERP, atrial effective refractory period; SR, sinus rhythm; PAF, history
of atrial fibrillation but in sinus rhythm during surgery; CAF, chronic permanent atrial fibrilla-
tion. *p<0.05, **p<0.01, ***p<0.001
(CAF, PAF, SR), as measured during surgery. Patients with CAF had shorter
AERPs than the SR patients without a history of AF, and rate-related shorten-
ing of the AERP was less (49 ± 4 versus 76 ± 6 ms, respectively; p=0.002).
Patients with PAF also had shorter AERPs than the SR patients, and a re-
duced rate adaptation (44 ± 4 versus 76 ± 6, respectively; p<0.001). The 4 pa-
tients with permanent CAF that could not be cardioverted during surgery had
shorter mean atrial fibrillatory intervals than the patients in whom AF could
be converted successfully (133 ± 10 ms versus 167 ± 7 ms, p=0.01).
In the patients with PAF, the AERP during surgery appeared to be loga-
rithmically related to the duration of sinus rhythm after the last episode of AF,
which ranged from 0.5 to 210 days (median 4 days). Figure 2 illustrates this
relation for AERPs measured at 500 ms, but it was also true for the AERPs at
BCLs of 600 ms (n=11, R= 0.85, p< 0.001), 400 ms (n=16, R= 0.68, p< 0.01) and
300 ms (n=16, R= 0.57, p= 0.02), but not at 250 ms (n=12, R= 0.31, p=0.32). In
fact, figure 2 shows that in case the duration of sinus rhythm after the last
episode of PAF had been shorter than 4 days, the AERP in the PAF patients
(214 ± 12 ms) resembled the AERP in patients with permanent CAF63
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Figure 2. The atrial refractory period at a BCL of 500 ms in the CAF, PAF and SR patients. In
patients with PAF the AERP was correlated with the logarithmically transformed duration of
sinus rhythm after the last AF episode. Abbreviations as in figure 1.
Figure 3. Mitral regurgitation is associated with longer AERPs, irrespective of the arrhythmia
history. MR, mitral regurgitation; other abbreviations as in figure 1.64
(224 ± 6 ms; p=0.44), but was significantly shorter than the AERP in the sinus
rhythm patients (273 ± 8 ms; p<0.001). In case the last episode of PAF had
converted > 4 days ago, the AERP in the PAF patients (257 ± 11 ms) was com-
parable to that in sinus rhythm patients (273 ± 8 ms; p= 0.25) but longer than
the AERP in the CAF patients (224 ± 6 ms; p<0.02). There was no relationship
between the duration of the last episode of AF and the AERP during surgery,
neither in patients with PAF (R=0.01, p=0.97), nor in patients with CAF (R=0.41,
p=0.21).
Multivariate analysis did not reveal any significant relation between the
AERP during surgery and medication, ventricular function or underlying heart
disease, except for the presence of mitral regurgitation, which appeared to
prolong the AERP (p=0.006). Figure 3 illustrates that irrespective of the
Table 2. Echocardiographic and hemodynamic parameters and left- and right
atrial refractory periods in patients with and without mitral regurgitation
Mitral No mitral
regurgitation regurgitation P-value
Number of patients 20 26
Echocardiography (mm)
- LA long axis 46 ± 7 39 ± 5 0.005
- LA apical long 69 ± 9 60 ± 6 0.001
- LA apical wide 50 ± 6 41 ± 6 0.003
- RA apical long 59 ± 9 55 ± 9n s
- RA apical wide 40 ± 6 39 ± 7n s
- LVEDD 56 ± 6 47 ± 6 <0.001
- LVESD 37 ± 6 34 ± 8n s
Hemodynamic measurements
 (pressures in mmHG)
- Heart rate (bpm) 75 ± 14 78 ± 16 ns
- Central venous pressure 8 ± 48  ±  3n s
- Pulmonary capillary wedge pressure 14 ± 51 1  ±  3n s
- Diastolic pulmonary art. pressure 15 ± 7 12 ± 3n s
- Systolic pulmonary art. pressure 29 ± 12 21 ± 4 0.004
- Mean pulmonary art. pressure 21 ± 9 16 ± 4 0.04
- Diastolic arterial pressure 57 ± 10 64 ± 10 ns
- Systolic arterial pressure 105 ± 14 108 ± 12 ns
- Mean arterial pressure 73 ± 10 78 ± 9n s
- Cardiac output (l/min) 4.6 ± 1.0 5.0 ± 1.3 ns
AERP at BCL 500 (ms)
- Left atrium 253 ± 32 227 ± 36 0.02
- Right atrium 265 ± 43 239 ± 38 0.006
Data expressed as mean ± standard deviation;
Bpm, beats per minute; other abbreviations as in table 1.65
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arrhythmia history, the AERP in the patients with mitral regurgitation ap-
peared to be prolonged. Table 2 shows the differences in echocardiographic
and hemodynamic parameters in patients with and without mitral regurgita-
tion and the average left and right atrial AERP at a BCL of 500 ms. The left
atrial diameters, left ventricular end-diastolic diameter and the systolic and
mean pulmonary artery pressures were significantly increased in the patients
with mitral regurgitation. However, there were no correlations between these
parameters and the right and left AERPs, and the longer AERPs in the mitral
regurgitation patients were present in both the left as well as the right atria.
Finally, the maximal spatial difference in refractory periods was not sig-
nificantly different between the 3 groups, although figure 4 shows that both
patients with permanent CAF, as well as patients with PAF had a trend to-
wards an increased spatial difference compared to the sinus rhythm patients.
When all patients with a history of AF were combined (CAF+PAF) this became
borderline significant (p=0.065).
Figure 4. The maximal difference in AERP was slightly increased in patients with CAF or PAF,
compared to patients in sinus rhythm although this did not attain statistical significance. Abbre-
viations as in figure 1.66
Post-operative AF in relation to the AERP  Post surgery, all patients left
the operating room in sinus rhythm, but during 1 week of  follow-up, 15 out of
the 46 patients (33%) developed a supraventricular tachycardia (SVT; AF in
10 patients, atrial tachycardia in 3 patients, both in 2 patients). These SVTs
occurred in 33% of the CABG patients, 18% of the patients following a MAZE
procedure, and in 45% of the patients with mitral valve surgery (57% of pa-
tients with a concomitant “mini-MAZE”). There was no difference in the occur-
rence of these SVTs among the 3 patient groups divided according to pre-op-
erative rhythm (CAF: 6/15, PAF: 5/16, SR: 4/15). At discharge, 12 out of these
15 patients with a post-surgery SVT had converted spontaneously to sinus
rhythm. The AERP during surgery did not predict the occurrence of a SVT,
and neither did the spatial difference in AERP, medication, atrial or ventricu-
lar dimensions, or ventricular function.
DISCUSSION
Main results Patients with permanent CAF had short AERPs with reduced
rate adaptation compared to the sinus rhythm patients, but the AERP was not
related to the duration of AF. Patients with PAF seemed to exhibit an “inter-
mediate state” of electrical remodeling. In these patients with a history of AF,
but in sinus rhythm at the time of surgery, an increased duration of sinus
rhythm after the last episode of AF was associated with a longer AERP. In all
patients the presence of mitral regurgitation was associated with a prolonged
AERP, irrespective of the arrhythmia history. The occurrence of post-operative
AF was not related to the AERP during surgery.
Electrical remodeling of the atria As stated above, animal experiments
have shown that prolonged episodes of AF induce shortening of the atrial re-
fractory period, with loss of the physiological rate-related shortening, which
increases the susceptibility of the atria to fibrillate after cardioversion of AF
1,12.
This so-called electrical remodeling of the atria explains why paroxysmal AF
often deteriorates into persistent or permanent AF
13 and why the efficacy of
anti-arrhythmic treatment decreases with an increased arrhythmia duration
in patients with AF
14,15. However, direct evidence is still lacking that electrical
remodeling occurs in clinical AF. Daoud et al. showed in humans that only67
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minutes of pacing induced AF shortened the atrial refractory period
16. How-
ever, it is not known to what extent these artificially induced short episodes of
AF resemble clinical AF, and whether the described shortening of the refrac-
tory period is an expression of electrical remodeling, or rather an example of
the normal physiologic rate-adaptation
17,18.
The present study demonstrated that patients with permanent CAF had
short atrial refractory periods and diminished rate-related shortening, which
is in agreement with earlier studies. Olsson et al. already demonstrated in
1971 the occurrence of short right atrial monophasic action potentials after
cardioversion of CAF, and the monophasic action potential duration was re-
lated to the tendency of the arrhythmia to recur
2. In 1982, Attuel et al. were
the first to discuss the importance of loss of rate-related shortening in patients
with atrial tachyarrhythmias
4,5. This was confirmed by Boutjdir et al. who
studied the action potential duration in atrial appendages from AF patients
undergoing surgery
6. All these studies considered the short atrial refractory
periods and loss of rate adaptation as pathological mechanisms causing AF.
More recently, in search for evidence of electrical remodeling in humans, Franz
et. al demonstrated short atrial monophasic action potentials with loss of rate-
related shortening in patients with atrial flutter and AF as compared to con-
trol patients
3. However, like in the present study, they could not find any rela-
tion between the duration of AF or flutter and the AERP, and this raises the
question whether the described electrophysiologic abnormalities in patients
with AF represent a consequence of AF or simply are a prerequisite causing
AF. On the other hand, the absence of this relation can be explained by the
long duration of AF in the present and previous studies, whereas in goats
1 and
dogs
19 electrical remodeling was complete within 1 week. Therefore, all CAF
patients in the present study and the study by Franz
3 will have been com-
pletely remodeled, whereas a relation between AF duration and the AERP is
only expected to exist within the first days after onset of the arrhythmia.
AERP in relation to medication or underlying heart disease Animal
studies have suggested that tachycardia-induced electrical remodeling is re-
lated to intracellular calcium overload, since calcium lowering by verapamil
reduced electrical remodeling
20,21 and calcium loading 
20 or digoxin
22 delayed
the recovery from electrical remodeling. Furthermore, patients who had been68
using intracellular calcium-lowering drugs during CAF experienced signifi-
cantly less early recurrences after electrical cardioversion, suggesting a reduc-
tion of electrical remodeling during AF by these drugs
7. In the present study,
we could not demonstrate any relation between medication and the atrial re-
fractory period in the patients with CAF, which was possibly due to the long
arrhythmia duration in these patients.
As is shown in figure 3, mitral regurgitation was associated with longer
refractory periods, irrespective of the arrhythmia history. This could be due to
chronic volume overload with increased atrial wall stress, which in some ex-
perimental studies caused prolongation of the atrial refractory period
23-25 al-
though other studies described no change or shortening of the AERP in re-
sponse to increased atrial pressures
26,27. Recently, another human study showed
that long-term loss of AV-synchrony also caused an increase in atrial refracto-
riness, presumably due to a long-standing increased atrial wall stress.
28 As
has been shown very recently, this may lead to activation of stretch activated
ion-channels which prolong atrial refractoriness.
29
While in the present study the atrial filling pressures (central venous pres-
sure and diastolic pulmonary artery pressure or wedge) were not significantly
different in patients with or without mitral regurgitation, the former patients
had a clear increase in left atrial and left ventricular end diastolic diameter,
and increased systolic and mean pulmonary artery pressures. This could rep-
resent an increased wall stress in the left and right atrium of the mitral regur-
gitation patients. As a result, AERP prolongation occurred in both the right
and left atrium. However, a direct correlation between pressures, diameters,
and AERP could not be established, and wall stress could not be calculated
because of missing data on wall thickness.
Recovery from electrical remodeling In goats with CAF for up to 1 month,
Wijffels et al. demonstrated that electrical remodeling was completely revers-
ible within 1 week after restoration of sinus rhythm
1. Furthermore, the in-
creased incidence of recurrences of AF during the first week after cardioversion,
with a sharp decline thereafter, could be a clinical illustration of recovery from
electrical remodeling
7. The present study revealed that in the PAF patients
who had experienced an episode of AF in the past, but were in sinus rhythm at
the time of surgery, there was a strong logarithmic correlation between the69
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AERP and the duration of sinus rhythm after the last episode of AF. On one
hand, this correlation could be a representation of the increased tendency to
fibrillate in case of a short AERP. A high vulnerability for AF will result in
short inter-episode intervals and therefore a short duration of sinus rhythm
after the last AF episode. However, this correlation may also be caused by
recovery from electrical remodeling after restoration of sinus rhythm. The find-
ing that the AERP in the PAF patients with a duration of sinus rhythm shorter
than 4 days resembled the CAF patients, while a duration of sinus rhythm
longer than 4 days was associated with an AERP comparable to the SR pa-
tients is in agreement with a report by Yu et al.,
8 which described a recovery
from electrical remodeling within 3 days after electrical cardioversion of pa-
tients with chronic AF, using repeated invasive electrophysiologic measure-
ment of the AERP.
Post-operative supraventricular tachycardia The incidence of post-sur-
gery SVTs in the present study is in agreement with previously described stud-
ies
30-32. In patients with a history of pre-operative AF, the combination with
mitral valve disease is a known risk factor for the development of acute or
even permanent AF after surgery
30,32,33. To prevent post-operative AF recur-
rences in these high-risk patients, the “mini-MAZE” procedure was performed.
Nevertheless, the post-operative incidence of SVTs in these patients was still
high. However, most of the SVTs in these patients converted spontaneously to
sinus rhythm with good overall long-term arrhythmia prognosis, as described
elsewhere
11.
Limitations of the study The AERPs were measured in anaesthetized open-
chest patients, which might have influenced our results. However, there is no
reason to believe that the different patient groups responded differently to
these circumstances. The AERP measurements could only be performed at a
limited number of sites, since during surgery the experiments would be too
time-consuming in case more sites were tested. This is of importance since the
results on the maximal difference in AERP (figure 4) indicate that dispersion
of refractoriness might be different in patients with or without AF.
Another possible confounding factor is that due to patient selection, the
sinus rhythm patients more often had ischemic heart disease. Furthermore,70
the increased frequency of digitalis in the CAF patients may have shortened
the AERP.  However, multivariate analysis revealed that medication or the
presence of ischemic heart disease did not influence the AERP, in contrast to
the presence of mitral regurgitation. Unfortunately, atrial pressures were not
recorded in all patients before surgery during cardiac catherization. Conse-
quently,  the pressures as recorded during surgery were evaluated in relation
to the AERP.  Since it is known that these pressures are largely influenced by
surgery and anaesthesia
34,35, the recorded differences in pressures may under-
estimate the pre-operative differences between patients with and without mi-
tral regurgitation. Therefore, increased wall stress as an explanation for the
increased AERP in patients with mitral regurgitation could not really be veri-
fied or disapproved.
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ABSTRACT
Introduction  Circulating cardiac natriuretic peptides play an important role
in maintaining volume homeostasis, especially during conditions affecting he-
modynamics. During atrial fibrillation (AF), plasma atrial natriuretic peptide
(ANP) becomes elevated. It was the aim of the study to gather information
about gene expression of the natriuretic peptide system on the level of the
atrium in patients with AF.
Methods and Results Right atrial appendages of 36 patients with either
paroxysmal or persistent AF were compared with 36 case matched controls in
sinus rhythm for mRNA expression of pro- atrial natriuretic peptide (pro-ANP),
pro-brain natriuretic peptide (pro-BNP), and their natriuretic peptide recep-
tor type-A (NPR-A). We investigated patients without (n=36) and with (n=36)
valvular disease. Persistent AF was associated with higher mRNA expression
of pro-BNP (+66%, p=0.04, in patients without valvular disease, and +69%,
p<0.01, in patients with valvular disease) and lower mRNA expression of NPR-
A (-58%, p=0.02, in patients without valvular disease, and -62%, p<0.01, in
patients with valvular disease). The mRNA content of pro-ANP was only in-
creased in patients with valvular disease (+12%, p=0.03). No changes were
observed in patients with paroxysmal AF.
Conclusion This study demonstrates that persistent AF, but not paroxysmal
AF, induces alterations in gene expression on the level of the atrium of pro-
BNP and NPR-A. Although AF is generally associated with an increase of
plasma ANP, a change in mRNA content of pro-ANP is only observed in the
presence of concomitant valvular disease and is of minor magnitude.
INTRODUCTION
The pathophysiological mechanisms contributing to the perpetuation of atrial
fibrillation (AF), e.g. electrical remodeling and (ultra)cellular changes, are
slowly being unravelled.
1-5 Abnormal calcium handling by the atrial myocyte,
6-10
in response to tachycardia induced intracellular calcium overload,
11-13 is of piv-
otal importance in this respect. However, the signaling pathways involved in
these processes remain to be clarified.
The cardiac natriuretic peptide system plays an important role in78
maintaining volume homeostasis via renal and cardiovascular actions, espe-
cially in conditions that affect hemodynamics.
14,15 In response to cardiac vol-
ume or pressure overload, either caused by valvular disease, left ventricular
dysfunction, hypertension, or AF, resultant atrial stretch induces cardiac natri-
uretic peptide production. Data in AF, however, pertain mainly to circulating
atrial natriuretic peptide (ANP).
16-19 Studies about brain natriuretic peptide
(BNP) in relation to AF are sparse and observational,
20,21 merely stating that
AF (without specification) is one of the factors explaining plasma BNP level.
ANP and BNP modulate cardiac calcium handling indirectly via the autonomic
nervous system,
22 and directly through cyclic guanosinemonophosphate (cGMP)
mediated pathways (via the cardiac natriuretic receptor), leading to reduced
intracellular concentrations of cyclic adenosinemonophosphate (cAMP), in turn
lowering cAMP-dependent ion channel activation.
23 Among others, the L-type
calcium channel becomes inactivated, whilst the acetylcholine dependent po-
tassium channel (KACh) becomes potentiated. Furthermore, ANP stimulates
calcium efflux from isolated atrial myocytes,
24 underscoring the involvement
of natriuretic peptides in cellular calcium handling.
We hypothesized that AF would enhance gene expression of pro-atrial natri-
uretic peptide (pro-ANP) and pro-brain natriuretic peptide (pro-BNP), and at-
tenuate gene expression of the cardiac natriuretic peptide receptor type-A (NPR-
A) on the level of the atrium. Therefore, it was our aim to investigate alter-
ations in mRNA (messenger ribonucleic acid) expression of pro-ANP, pro-BNP,
and their NPR-A in the right atrial appendage (RAA) of patients with paroxys-
mal and persistent AF undergoing cardiac surgery. To single out the effect of
AF, case matched control patients in SR were used. Since hemodynamic over-
load of the heart per se is known to cause changes in natriuretic peptides,
25-27
patients with and without valvular disease were investigated.
METHODS
Study patients Patients were enrolled by using the in-house waiting list for
cardiac surgery. The day before elective cardiac surgery, the clinical character-
istics of each patient (including medication use and exercise tolerance accord-
ing to the New York Heart Association classification) were assessed by one
investigator (AET). Patients with renal dysfunction (serum creatinine79
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> 150 mmol/L) were excluded from the study. Presence, type, and duration of
AF were assessed based on the patient’s history and previous electrocardio-
grams. Echocardiographic data were obtained while patients were on the wait-
ing list, but within 3 months prior to cardiac surgery. RAA was obtained from
36 patients with (paroxysmal or persistent) AF and from 36 controls in sinus
rhythm who were optimally case matched for age, sex, and left ventricular
function. During cardiac surgery, RAA was removed, immediately snap-frozen
in liquid nitrogen, and stored at -85
0C. The RAA’s were analyzed separately in
two series: one series consisting of patients without valvular disease, and an-
other series with patients with mitral or aortic valve disease of hemodynamic
significance to such extent that valvular surgery was deemed indicated. The
investigation conforms to the principles outlined in the Declaration of Helsinki,
was approved by the Institutional Review Board, and written informed con-
sent was given by all patients.
RNA isolation and cDNA synthesis Total RNA (ribonucleic acid) was iso-
lated from RAA’s using the method of acid guanidinium thiocyanate/phenol/
chloroform extraction followed by a RNeasy kit for RNA minipreps for tissues
(Qiagen). The amount of RNA was evaluated by absorption at 260 nm, using a
GeneQuant II (Pharmacia LKB Biotechnology, The Netherlands). The ratio of
absorption (260-280 nm) of all preparations was between 1.8 and 2.0. First
strand cDNA (copy-deoxyribonucleic acid) was synthesized by incubation of 1
mg of total RNA, reverse transcription 10x buffer and 200 ng of random hexamers
with 200 units of Moloney Murine Leukemia Virus Reverse Transcriptase, 1mM
of each dNTP (dinucleotidetriphosphate) and 1 unit of ribonuclease (RNAse)
inhibitor (Promega, The Netherlands) in 20 ml. The synthesis reaction lasted
10 minutes at 20°C, 20 minutes at 42°C, 5 minutes at 99°C and 5 minutes at
4°C, respectively. All the products were checked on contaminating DNA (data
not shown).
Semiquantitative polymerase chain reaction analyses We decribed these
methods before.
28,29 Validation of the present semi-quantitative polymerase
chain reaction (PCR) was performed by determination of the absolute
alterations of mRNA.
28,29 In short, the cDNA of interest and the cDNA of the
ubiquitously expressed housekeeping enzyme glyceraldehyde-3-phosphate80
Table 1. Primer sequences
Sequence Cycles Annealing
Temperature
Glyceraldehyde-3-phosphate dehydrogenase:
F 5'-CCC ATC ACC ATC TTC CAG GAG CG-3' 26 -
R 5'-GGC AGG GAT GAT GTT CTG GAG AGC C-3'
Pro-ANP:
F 5'-CCA TGT ACA ATG CCG TGT CC-3' 26 56 °C
R 5'-GCT CCA ATC CTG TCC ATC CT-3'
pro-BNP:
F 5'-GTT ACA GGA GCA GCG CAA CC-3' 26 56 °C
R 5'-AGG CCA CTG GAG GAG CTG AT-3'
NPR-A receptor:
F 5'-CTT GCT CGG CAT TCT GAT TG-3' 26 56 °C
R 5'-CAC GCA GTT GGA TGA CTT GA-3
ANP= atrial natriuretic peptide, BNP= brain natriuretic peptide,
NPR-A= natriuretic receptor type-A
dehydrogenase (GAPDH) were coamplified in a single PCR. Primers were de-
signed for pro-ANP, pro-BNP, the NPR-A receptor, and the housekeeping gene
GAPDH (Table 1). The oligonucleotides were synthesized by Eurogentec (Bel-
gium).
For the semi-quantitative PCR co-amplification 1 ml of cDNA mixture, 0.5
unit of Taq polymerase (Eurogentec, Belgium) was added to 17.5 nM of dNTP’s,
10x PCR buffer provided with Taq polymerase, 2.5 mM MgCl
2
, 40 pmol of sense
and antisense primer for the gene of interest, 40 pmol of sense and antisense
GAPDH primer and water to bring the final volume to 50 ml. All reaction mix-
tures were overlaid with 50 ml of mineral oil (Sigma, The Netherlands). After 3
min denaturation at 94°C, n cycles of amplification (Table 1) were performed,
each for 1 min at 94°C , 1 min at annealing temperature (Table 1), 1 min at
72°C, using the thermocycler Perkin Elmer 480 (The Netherlands). After the
last cycle, the 72°C elongation step was extended to 5 min. The PCR products
were separated on a 1.5% agarose gel by gel-electrophoresis and stained with
ethidium bromide. The densities of the PCR products were quantified by den-
sitometry (Aldus PhotoStyler 2.0, Graphic Workshop and ImageQuant Ver-
sion 3.3). Linearity for the PCR reactions was established by making a correla-
tion between the number of cycles and the ratio of the densities of gene of
interest / GAPDH (data not shown).81
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Definitions Persistent AF: continuous presence of AF until the moment of
cardiac surgery, i.e. at least two consecutive electrocardiograms with AF more
than 24 hours apart, without intercurrent SR. Persistent AF does not sponta-
neously convert to SR, but is considered cardiovertible.
30 Previously, this type
of AF was classified as chronic AF. Paroxysmal AF: AF typically occurring
in episodes of shorter duration than 24 hours (though paroxysms may
Table 2. Characteristics of the 36 patients without valvular disease
Chacteristic PaAF SR1 PeAF SR2
Patient number 8 8 10 10
Male / female (n) 6/2 6/2 6/4 6/4
Age (years) 51±75 6 ± 11 63±11 65±8
Cardiac surgery
Coronary bypass grafting (n)   2 † 8 4 10
Cox’s MAZE III procedure (n)  6 † 0 6 0
Underlying heart disease **
Coronary artery disease (n)   2 † 8 4 10
Hypertension (n) 1 1 3 2
Lone AF (n) 6 † - 5 -
Concomitant systemic disease
Diabetes (n) 0 1 0 3
COPD (n) 1 2 1 4
Rhythm characteristics
Duration PeAF (months) * - - 16 (8-64) -
Duration SR (days) * 1.5 (0-30) - - -
NYHA class I / II / III
For exercise tolerance (n) 7/1/0 5/3/0 6/4/0 5/5/0
For angina (n) 6/0/2 † 1/2/5  6/1/3 † 1/4/5
Echocardiographic parameters
LA long axis view (mm) 43±74 1 ± 34 5 ± 74 4 ± 5
LA apical view (mm) 60±66 4 ± 36 3 ± 46 4 ± 6
RA long axis view (mm) 54±95 4 ± 46 2 ± 75 7 ± 4
LVEDD (mm) 48±44 9 ± 85 3 ± 35 3 ± 6
LVESD (mm) 35±43 5 ± 73 3 ± 63 5 ± 4
Medication
ACE inhibitor (n) 0 1 4 2
Betablocker (n)   1 † 5 3 6
Calcium entry blocker (n) 0 3 3 3
Digoxin (n) 0 1 5 3
* = values are presented as median with range. ** = per patient, more than one underlying
disease might have been present. † = p value < 0.05 compared to the control group.
ACE = angiotensin converting enzyme, ASD = atrial septal defect, COPD = chronic obstructive
pulmonary disease, LA = left atrium, LVEDD = left ventricular end diastolic diameter, LVESD
= left ventricular end systolic diameter, ND = not done, NYHA = New York Heart Association,
PaAF = paroxysmal atrial fibrillation, PeAF = persistent atrial fibrillation, RA = right atrium,
SR = sinus rhythm, SR1 = are sinus rhythm control patients for PaAF, SR2 = are sinus rhythm
control patients for PeAF.82
occasionally last longer) with intermittent sinus rhythm. Paroxysmal AF ei-
ther converts spontaneously or can be terminated with an intravenously ad-
ministered antiarrhythmic drug.
30 Due to its spontaneous character, paroxys-
mal AF might be present at the moment of cardiac surgery. The intensity of
the arrhythmia was scored using a recently proposed classification.
31
Statistical analysis All PCRs were performed twice. Mean values of the ra-
tios are presented. Unless stated otherwise, mean values and standard devia-
tions are reported. For the comparison between groups, a Student’s t-test was
used for normally distributed variables and a Wilcoxon-Mann-Whitney test
for non-normally distributed variables. In case of categorical variables, a chi-
square test with continuity correction or a Fisher’s exact test was used, when
appropriate. For determination of correlation, the Spearman correlation test
was used. A two-sided probability level < 0.05 was considered to indicate sta-
tistical significance. The analysis was performed by SAS statistical software
(SAS, version 6.12, Cary, NC).
RESULTS
Patients without valvular disease Eight patients with paroxysmal AF and
10 patients with persistent AF were included. These two groups were com-
pared with their case matched control groups in sinus rhythm (Table 2). The
distribution of underlying heart disease and type of surgery in the AF groups
differed from the control groups; most AF patients (6 and 6 patients, respec-
tively) underwent atrial arrhythmia surgery (Cox’s MAZE III procedure
32) for
intractable, symptomatic AF whilst all control patients underwent coronary
bypass surgery. Despite these unavoidable differences, patient groups were
otherwise comparable for left ventricular function, atrial dimensions, and func-
tional class for exercise tolerance according to the New York Heart Association
classification (NYHA class I and II).
In the persistent AF group, the median duration of AF before surgery was
16 months, with a range of 8 months to 64 months. In the paroxysmal AF
group, the median duration of sinus rhythm before surgery was 1.5 days, and
the median frequency of paroxysms was once a day with a median duration
of 3 hours. These patients can be categorized as the most severe type of83
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Figure 1. cDNA ratios for pro-ANP / GAPDH (Figure 1a), pro-BNP / GAPDH (Figure 1b), and
NPR-A / GAPDH (Figure 1c) of individual patients without valvular disease. SR1 are sinus rhythm
control patients for the patients with PaAF (paroxysmal atrial fibrillation), SR2 are sinus rhythm
control patients for the patients with PeAF (persistent atrial fibrillation). All data are represented
in density units / density units. • = individual value,    = mean value of group ± standard error of
the mean.
paroxysmal AF (type IIIc; symptomatic, > 1 attack / 3 months under treat-
ment). Of note, 3 patients with paroxysmal AF were in AF at the moment of
harvesting of the RAA during surgery.
Changes in transcription of the genes of interest were determined by com-
parison of gene of interest / GAPDH cDNA ratios between the paroxysmal AF
group and the control group (SR1), and between the persistent AF group and
the control group (SR2) (Figure 1). Patients with persistent AF showed a sig-
nificant change of the cDNA ratios of pro-BNP / GAPDH (increase, +66%, p=0.04,
Figure 1B) and NPR-A / GAPDH (decrease, -58%, p=0.02, Figure 1C). No sig-
nificant correlation was found between the duration of persistent AF and the
cDNA ratios of pro-BNP / GAPDH or NPR-A / GAPDH. In contrast to the pa-
tients with persistent AF, no changes were observed in the paroxysmal AF
group.
Patients with valvular disease By coincidence, no patients with paroxys-
mal AF were available. Eighteen patients with persistent AF were included,
and compared with their case matched control patients in sinus rhythm (Table
3). Types of underlying heart disease, concomitant heart disease, concomitant
systemic disease, and surgery were equally distributed among both groups.
Patients were also comparable for NYHA functional class, left ventricular func-
tion, and hemodynamic parameters. However, in the persistent AF group left
atrial dimension (long axis view) was larger, and angiotensin converting84
Figure 2. cDNA ratios for pro-ANP / GAPDH (Figure 2a), pro-BNP / GAPDH (Figure 2b), and
NPR-A / GAPDH (Figure 2c) of individual patients with valvular disease. SR are sinus rhythm
control patients, PeAF are the patients with persistent atrial fibrillation. All data are represented
in density units / density units. • = individual value,   = mean value of group ± standard error of
the mean.
Figure 3. Typical agarose gel showing the cDNA levels of pro-BNP and GAPDH of patients with
valvular disease. SR are sinus rhythm control patients for the patients with PeAF (persistent
atrial fibrillation).
enzyme inhibitors and digoxin were used more frequently. Clearly, the latter
was used for rate-control during AF. The median duration of AF before surgery
was 6 months, with a range of 0.5 months to 240 months.
Changes in transcription of the genes of interest were determined by com-
parison of gene of interest / GAPDH cDNA ratios between the persistent AF
group and the control group (SR) (Figure 2). A representative agarose gel with
cDNA levels of pro-BNP and GAPDH is shown in Figure 3. Patients with per-
sistent AF showed a significant change of the cDNA ratios of all the genes of
interest; a minor increase of pro-ANP / GAPDH (+12%, p=0.03, Figure 2A), a
substantial increase of pro-BNP / GAPDH (+69%, p<0.01, Figure 2B) and sub-
stantial decrease of NPR-A / GAPDH (-62%, p<0.01, Figure 2C). Also for the85
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Characteristic PeAF SR
Patient number 18 18
Male / female (n) 11/7 14/4
Age (years) 70 ±9 66 ±11
Cardiac surgery **
Valvular surgery (n) 18 18
Coronary bypass grafting (n) 7 6
ASD closure (n) 2 0
Primary heart disease
Aortic stenosis (n) 6 8
Aortic regurgitation (n) 0 1
Aortic stenosis & regurgitation (n) 3 0
Mitral stenosis (n) 0 0
Mitral regurgitation (n) 7 3
Mitral stenosis & regurgitation (n) 1 3
Aortic and mitral valve disease (n) 1 3
Concomitant heart disease **
Coronary artery disease (n) 7 6
ASD (n) 2 0
Hypertension (n) 6
Concomitant systemic disease **
Diabetes (n) 4 2
COPD (n) 3 4
Rhythm characteristics
Duration PeAF (months) * 6 (0.5-240) -
NYHA class I-III
For exercise tolerance (n) 1/1/16 1/6/11
For angina (n) 13/3/2 10/4/4
Echocardiographic parameters
LA long axis view (mm) 52±10 ‡ 44±5
LA apical view (mm) 72±96 6 ± 7
RA long axis view (mm) 64±55 7 ± 4
LVEDD (mm) 54±96 0 ± 10
LVESD (mm) 38±74 3 ± 15
Hemodynamic parameters
LV pressure max (mmHg) 167±40 178±64
LV pressure min (mmHg) 5±93
Wedge pressure (mmHg) 16±61 2 ± 9
RA pressure (mmHg) 5±53 ± 2
LV function I-III (n) † 13/1/3 14/0/4
Medication
ACE inhibitor (n)    11 ‡ 1
Betablocker (n) 3 4
Calcium entry blocker (n) 4 2
Digoxin (n) 14 ‡ 3
* = values are presented as median with range. ** = per patient, more than one surgical
procedure might have been performed or more than one concomitant disease might have
been present. † = I indicates normal, II indicates slightly impaired, and III indicates moder-
ately impaired. ‡ = p value < 0.05 compared to the control group.
LV = left ventricular, SR = are sinus rhythm control patients for PeAF. Other abbreviations
are the same as in Table 2.
Table 3. Characteristics of the 36 patients with valvular disease86
patients with valvular disease, no significant correlation was found between
the duration of persistent AF and the cDNA ratios of pro-ANP / GAPDH, pro-
BNP / GAPDH or NPR-A / GAPDH.
DISCUSSION
The main findings of the study are that persistent AF induces evident changes
in mRNA content of pro-BNP and NPR-A. The extent to which these changes
occur are of the same magnitude for patients with and without valvular dis-
ease. A change in mRNA content of pro-ANP is only observed in the presence of
concomitant valvular disease and is of minor magnitude. Paroxysmal AF, al-
though almost occurring daily in the present patient group and therefore of
clinical importance (6 of the 8 patients with paroxysmal AF underwent Cox’s
MAZE III procedure), was not associated with any change in expression of the
genes of interest.
The cardiac natriuretic peptides ANP (28-amino-acid peptide) and BNP
(32-amino-acid peptide) are produced in myocardium in the precursor forms
pro-ANP and pro-BNP that are spliced into an inactive and active peptide (N-
terminal ANP / ANP and N-terminal BNP / BNP respectively), which are re-
leased into the circulation.
14 The third, more recently discovered member of
the natriuretic peptide family, C-type natriuretic peptide or CNP (22-amino-
acid peptide) is not considered to be produced in significant amounts in the
myocardium (not even in disease states),
33 and was therefore not investigated
in the present study. ANP is generally considered to be primarily of atrial ori-
gin.
14  BNP, on the other hand, is mainly produced in the ventricles, and is
considered to reflect left ventricular function.
34,35 ANP and BNP exercise their
effects on myocardial electrophysiology and contractility indirectly via the au-
tonomic nervous system, and directly via the natriuretic receptor type-A (NPR-
A), which is the principal receptor for natriuretic peptides in the heart.
22,23,36
NPR-A activates cGMP release, which in turn initiates activation of intracel-
lular protein kinase G.
23 The pathways by which the natriuretic peptides
modulate cellular electrophysiology, calcium handling, and contractility are
complex.
23,24,37,38 The eventual effects are most well described for ANP, being a
decrease in intracellular calcium loading, shortening of the action potential,
an increase in conduction velocity, and a decrease in phase 4 atrial87
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depolarization, thus enhancing myocyte relaxation properties.
22
mRNA expression of pro-ANP was unchanged in patients without valvular
disease, although the occurrence of AF is associated with a rise in plasma
ANP.
39,40 It should be emphasized, however, that these observations pertain to
acute AF. It is conceivable that enhanced release of ANP from the atria, but
not an altered gene expression, is responsible for the rise in plasma ANP. A
minor augmentation in mRNA content of pro-ANP was observed only in the
presence of valvular disease. In these patients, the hemodynamic data of the
AF group were comparable with the control group, but echocardiography showed
a significantly larger left atrium in the AF group, indicating higher atrial vol-
ume. This difference was not observed in the patients without valvular dis-
ease, and might explain the increased mRNA expression of pro-ANP in pa-
tients with valvular disease. This possibility is supported by studies in pa-
tients with heart failure in sinus rhythm that indicate the importance of atrial
volume (stretch) for ANP release into the circulation.
27 It should also be noted
that the (median) duration of AF was shorter in the presence of valvular dis-
ease (shorter than 8 months in 10 of the 18 patients), as compared to group
without valvular disease (at least 8 months in all patients). Temporal deple-
tion effects of plasma ANP during the time course of longstanding AF (in a
matter of months) have been described.
16,18 Pro-ANP gene expression might
have been influenced the same way, thus contributing to the differences in
gene expression between patients with and without valvular disease.
In contrast to pro-ANP, mRNA content of pro-BNP was increased irrespec-
tive of valvular disease (+66% versus +69%, respectively). This is a surprising
finding suggesting that pro-BNP production in RAA is affected by the fibrillatory
activity per se (a “load-independent mechanism”), rather than by atrial stretch
resulting from hemodynamic overload. Analogous, during heart failure, the
presence of atrial tissue-BNP is much more pronounced as compared to ANP.26
Therefore, independent of the type of heart disease, the atria might have the
capability to vastly enhance BNP production, but not ANP production. An-
other issue is that BNP seems to have a different atrial processing and release
in the circulation, as compared to ANP, especially during heart failure.
26,41 The
latter might also be partly responsible for the differences in gene expression of
pro-BNP versus pro-ANP in response to AF. Only recently, a correlation be-
tween mRNA levels of BNP and ANP, changing concomitantly with mean right88
atrial pressure, was reported for right atrial appendage specimens of patients
undergoing cardiac surgery, suggesting a common regulation of tissue BNP
and ANP.
42 It should be noted, however, that patients with and without valvu-
lar disease were mixed in this study, and that no data were given on atrial
rhythm.
Our study demonstrates that mRNA content of NPR-A is downregulated in
patients with persistent AF, either in the absence or presence of hemodynamic
overload, i.e. valvular disease. Receptor downregulation could be a result of an
increase in signaling agonists, in this case plasma ANP and BNP. mRNA ex-
pression of pro-BNP is clearly increased in the present study, which would be
in line with the observed downregulation of mRNA content of NPR-A. Similar
to the alterations of mRNA expression of pro-BNP, AF itself is likely to be
responsible for changes in mRNA content of NPR-A, because the magnitude of
change is comparable for patients with and without valvular disease (-58%
versus -62%, respectively).
In patients with frequently recurring attacks of paroxysmal AF under an-
tiarrhythmic treatment, to be assessed as a relevant arrhythmia burden, no
changes in gene expression of pro-ANP, pro-BNP, or NPR-A were found. It
should be noted that most patients were in sinus rhythm at the moment of the
operation, with a median duration of 1.5 days (range 0-30 days). These data
suggest that intercurrent sinus rhythm between the attacks of paroxysmal AF
was enough to protect against gene alterations in the natriuretic peptide sys-
tem.
Limitations of the study The present study has several important limita-
tions. Firstly, atrial mRNA expression was investigated without protein ex-
pression, binding experiments, ventricular mRNA expression, or plasma level
determinations. Such additional data might have provided more insight in the
pathophysiology. Secondly, patients with valvular disease used “unloading”
drugs, aimed at lowering of cardiac pressures and clinical stabilization. These
drugs, and differences in use of these drugs, might have interfered with the
results, but the clinical condition of most patients did not allow discontinua-
tion (of more than 5x half-time life) for study purposes.89
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MINI-ABSTRACT
Plasma atrial natriuretic peptide and endothelin are further elevated in pa-
tients with congestive heart failure and atrial fibrillation, compared to those
with sinus rhythm. The higher plasma endothelin suggests that vasoconstric-
tion is an important mechanism for hemodynamic compensation in these pa-
tients.
INTRODUCTION
A large number of studies have shown that neurohumoral activation plays an
important role in the pathophysiology of congestive heart failure (CHF). How-
ever, these studies have mainly focused on patients with sinus rhythm (SR)
and not on patients with atrial fibrillation (AF) since patients with AF were
either excluded from these studies or not separately analyzed. Yet, AF is very
common in CHF patients (up to 40%), and there is reason to presume that AF
has an additional effect on neurohumoral activation because AF as such has
potentially important hemodynamic consequences in the setting of CHF.
1 The
present study investigates neurohumoral activation in a large group of pa-
tients with advanced CHF, comparing patients with AF and SR.
METHODS AND RESULTS
We studied 269 patients who participated in a neurohumoral substudy of the
PRIME II study, a survival study with ibopamine in moderate to severe CHF.
2
Baseline data of the PRIME II study were used in this neurohumoral substudy,
i.e., before any study medication was given. To eliminate effects on neurohor-
mone values by differences in etiology of CHF, only patients with ischemic
heart disease underlying CHF were included. CHF had to be characterized by
symptoms at rest or a recent hospital admission for CHF, equivalent to func-
tional class III-IV according to the New York Heart Association. Left ventricu-
lar dysfunction had to be proven by one of the following: A) left ventricular
ejection fraction < 0.35, B) left ventricular internal end-diastolic diameter > 60
mm, C) left ventricular fractional shortening < 20% or D) cardiothoracic ratio
on standard chest X-ray > 0.50. Patients were on optimal medical treatment96
Table I. Clinical characteristics comparing patients with sinus rhythm and atrial
fibrillation
Characteristic SR patients AF patients p-value
(n=225) (n=44)
Age (years) 67±87 1 ± 6 0.01
Male 179 (80%) 39 (89%) NS
NYHA Functional Class NS
III 157 (70%) 28 (64%)
III/IV 63 (28%) 14 (32%)
IV 5 (2%) 2 (4%)
Duration of CHF (months) 35±35 43±43 NS
Left Ventricular Ejection Fraction 0.23±0.07 0.23±0.07 NS
Heart Rate (beats min-1)8 0 ± 14 78±11 NS
Systolic Blood Pressure (mm Hg) 126±18 121±19 NS
Diastolic Blood Pressure (mm Hg) 76±97 4 ± 10 NS
Creatinine (mmol/l) 120±42 122±29 NS
Medication
ACE Inhibitor 216 (96%) 42 (95%) NS
Anti-Arrhythmic Drug 35 (16%) 9 (20%) NS
Anti-Platelet Drug 44 (20%) 7 (16%) NS
Beta-Blocker 25 (11%) 5 (11%) NS
Calcium Entry Blocker 14 (6%) 3 (7%) NS
Digoxin 116 (52%) 38 (86%) < 0.001
Diuretic 224 (100%) 44 (100%) NS
Long Acting Nitrate 122 (54%) 26 (59%) NS
Warfarin 154 (68%) 34 (77%) NS
ACE= Angiotensin Converting Enzyme, AF= Atrial Fibrillation, CHF= Congestive Heart
Failure, NS= Not Significant, NYHA= New York Heart Association, SR= Sinus Rhythm.
for CHF, including angiotensin converting enzyme inhibitors and diuretics.
The diuretic dose was either = 40 mg furosemide or = 80 mg furosemide (or
equivalent) if angiotensin converting enzyme inhibitors were not prescribed.
Use of digoxin or a vasodilator was allowed. The exclusion criteria included
obstructive valve disease, obstructive or restrictive cardiomyopathy, transient
heart failure (e.g. acute myocarditis), myocardial infarction or cardiac surgery
within the preceding 3 months, uncontrolled arrhythmias and need for intra-
venous inotropic support. To be designated as AF patient, AF had to be chronic
and electrocardiographically documented on two separate occasions at least97
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24 hours apart. Patients with ventricular pacemakers were excluded from the
study. Blood sampling for plasma neurohormone determination was done from
an intravenous canula after resting for at least 30 minutes in the supine posi-
tion. Samples for measurement of norepinephrine, epinephrine, dopamine, renin
and aldosterone were poured into chilled heparinized tubes containing glu-
tathione; for measurement of atrial natriuretic peptide, N-terminal atrial natri-
uretic peptide, and endothelin, chilled tubes containing EDTA and aprotonin
were used. After centrifugation the plasma samples were deep frozen at -70 °C
and sent to the core laboratory at the University Hospital Dijkzigt, Rotterdam,
The Netherlands. Norepinephrine, epinephrine and dopamine were analyzed
using high-performance liquid chromatography with fluormetric detection.
Renin was determined according to a method previously described.
3 Atrial natri-
uretic peptide and endothelin were determined with commercially available
radioimmunoassay kits from the Nichols Institute, Wijchen, The Netherlands,
as previously described.
4,5 Commercially available radioimmunoassay kits were
also used for determination of N-terminal atrial natriuretic peptide (Biotop,
Oulo, Finland) and aldosterone (Coat-a-Count, Diagnostic Products Corpora-
tion, Los Angeles, CA). Data are presented as mean ± standard deviation; me-
dian values with ranges are used in case of a non-parametric distribution.
Table II. Neurohormone plasma concentrations in patients with sinus rhythm
versus atrial fibrillation
Neurohormone * Normal SR patients AF patients Uni Multi
range variate variate
(n=225) (n=44) p-value p-value
Norepinephrine (pg/ml) (100-500) 519 (74-1911) 506 (139-1570) NS NS
Epinephrine (pg/ml) (10-70) 36 (5-271) 47 (9-163) NS NS
Dopamine (pg/ml) (5-50) 20 (1-172) 17 (1-133) NS NS
Renin (mU/ml) (5-50) 74 (3-2516) 100 (6-3598) NS NS
Aldosterone (pg/ml) (50-250) 100 (8-933) 116 (1-715) NS NS
ANP (pmol/l) (15-35) 285 (37-2445) 380 (151-1500) <0.001 0.04
N-ANP (nmol/l) (0.15-0.50) 1.00 (0.13-4.21) 1.46 (0.44-2.99) <0.001 NS
Endothelin (pg/ml) (1-5) 4.9 (0-35.0) 7.0 (0-30.7) 0.01 0.008
* = Values are expressed as median with range.
AF= Atrial Fibrillation, ANP= Atrial Natriuretic Peptide, N-ANP= N-terminal Atrial
Natriuretic Peptide, SR= Sinus Rhythm.98
Data were analyzed using univariate and multiple regression analysis. To re-
alize a constant variance in these analyses, the neurohormone values were
logarithmically transformed. A p-value < 0.05 was considered statistically sig-
nificant. Clinical characteristics are given in Table I, comparing AF patients
with SR patients. The AF and SR groups were comparable for general charac-
teristics of CHF (New York Heart Association class for exercise tolerance, left
ventricular ejection fraction, and blood pressure). Ventricular rate was con-
trolled in AF patients and their heart rate was comparable with heart rate in
SR patients. Medication use was equally distributed between the two groups,
with the exception of digoxin. Not surprisingly, digoxin was used more fre-
quently in the AF group. Also, AF patients were slightly older, but renal func-
tion, as assessed by serum creatinine level, was comparable with SR patients.
Neurohumoral data are presented in Table II. In the univariate analysis, atrial
natriuretic peptide, N-terminal atrial natriuretic peptide and endothelin were
significantly higher in AF patients. In the multiple regression analysis, only
the levels of atrial natriuretic peptide and endothelin remained significantly
higher in AF patients.
DISCUSSION
Our main finding is that AF in patients with advanced CHF is associated with
an additional increase in plasma endothelin. Three isoforms endothelin have
been identified (endothelin-1, endothelin-2 and endothelin-3), from which
endothelin-1 exercises the most important effects. This 21-amino acid peptide
is predominantly produced in the endothelium, and causes potent vasocon-
striction, myocyte cell growth and positive inotropy. Different cardiovascular
conditions are associated with an increase in endothelin, including CHF.
6,7 In
addition to the endothelium, the myocardium itself appears to be an impor-
tant site of production in CHF.
8 Since vasoconstriction is one of the compensa-
tory mechanisms in CHF, it is conceivable why CHF leads to higher endothelin
concentrations.
The question remains why AF is associated with an additional increase in
endothelin in patients with CHF. The design of our study did not allow inves-
tigation of the underlying mechanism, but it seems reasonable to presume
that the hemodynamic effects of AF play a crucial role in this connection.99
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AF per se, i.e. irrespective of CHF, may cause hemodynamic deterioration due
to loss of atrial contractile function, irregularity of ventricular rhythm and an
altered chronotropic response. Importantly, however, further worsening of he-
modynamic function has been observed in patients with CHF who develop AF.
1
It is thus conceivable that the already elevated endothelin production increases
even more in case of concomitant AF. This explanation is supported by our
previous work which showed altered peripheral flow after electrical
cardioversion of AF.
9 A reduced calf blood flow was found in patients with AF
(functional class I-II according to the New York Heart Association), but this
normalized after restoration of SR, suggesting that vasoconstriction plays an
important role as a compensatory mechanism in AF patients.
Atrial natriuretic peptide and N-terminal atrial natriuretic peptide were
significantly elevated in the univariate analysis, and to the same extent as
endothelin (factor ± 1.4). In the multivariate analysis, atrial natriuretic pep-
tide remained significantly higher in AF patients. Previous data showed that
AF is associated with an increase in atrial natriuretic peptide,
10 but this obser-
vation pertained to acute AF without concomitant CHF. We have shown re-
cently that atrial natriuretic peptide levels in patients with AF and CHF are a
function of time, longer duration of AF being associated with lower atrial natri-
uretic peptide levels.
11 During the course of AF, atrial atrophy and fibrosis
develop, which may cause this decline in atrial natriuretic peptide production.
In fact, during atrial standstill, after long standing AF, atrial natriuretic pep-
tide falls to even undetectably low levels (“endocrinologic silence”).
12 The dura-
tion of AF is unknown in our patients, so a relation between atrial natriuretic
peptide level and the duration of AF could not be made. It is shown though
that atrial natriuretic peptide levels are higher in AF patients with a duration
of CHF comparable with SR patients.
The clinical relevance of our findings is that, in addition to well known
other considerations, attempts should be undertaken to restore and maintain
SR, as neurohormone levels (endothelin in particular) are lower during SR.
The results from the univariate analysis might be attributed to differences
in clinical characteristics. However, the multivariate analysis points out
that these differences in clinical characteristics do not explain the higher
endothelin and atrial natriuretic peptide levels in the AF group. Furthermore,
the study is observational in design, and therefore has its limitations;Appendix 3
Comparison of plasma neurohormones in congestive heart
failure patients with atrial fibrillation versus patients with
sinus rhythm
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pathophysiological mechanisms and hemodynamics were not analyzed. Finally,
the results are only applicable to patients with ischemic heart disease.
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ABSTRACT
Aims  To determine the impact of paroxysmal atrial fibrillation on quality of
life and to determine the predictors of quality of life, particularly the role of
symptomatology and autonomic function.
Methods and Results The study group comprised 73 patients with paroxys-
mal atrial fibrillation (mean age 54.1 years, 51 males). On average, patients
had a 3-year history of one paroxysm per week lasting 2 hours. Quality of life
was assessed using the SF-36 (Medical Outcomes Study Short-Form Health
Survey) and compared with age-matched controls. Autonomic function was
assessed using Holter-monitoring with analysis of heart rate variability and
autonomic function tests. Also, symptoms during paroxysms of atrial fibrilla-
tion were scored. Multivariate analysis was performed to identify independent
predictors of quality of life. Quality of life scores were markedly lower in pa-
tients than in controls in 4 of the 8 subscales (p<0.001): physical role function,
emotional role function, vitality and general health. Structural heart disease
did not predict quality of life, whereas frequency of paroxysms was predictive
only of physical role function. In contrast, autonomic variables (baroreflex-
sensitivity, total power (heart rate variability), response to deep breathing, 30-
15 ratio (standing up)) were predictive in all 4 respective subscales (p<0.05),
depressed vagal function being predictive of low scores. Symptoms, particu-
larly severe perspiration, were also predictive of low scores (p<0.05).
Conclusion  This study shows that paroxysmal atrial fibrillation causes sig-
nificant impairment of quality of life. Further, symptomatology and autonomic
function are important predictors of quality of life in this patient group.
INTRODUCTION
Atrial fibrillation is a very common arrhythmia, and its prevalence is still in-
creasing.
1 In recent years, numerous studies have attested to the impact of
atrial fibrillation on life expectancy, hemodynamics, left ventricular function,
risk of thrombo-embolism, and on atrial electrophysiology, histology and mo-
lecular biology. In contrast, a paucity of data exists as to the impact on quality
of life.
2,3 Several studies have reported on the beneficial effect of His bundle
ablation on quality of life in patients with medically-refractory atrial104
fibrillation.
4-6 However, generally findings were not compared to those of sub-
jects without atrial fibrillation and sample-size was small. Moreover, these
patients represent an extreme part of the spectrum since they were highly
symptomatic. We therefore conducted a quality of life study in a sizeable group
of patients with paroxysmal atrial fibrillation, using a large control group. The
first aim of the study was to determine the impact of paroxysmal atrial fibril-
lation on quality of life. The second aim was to determine which factors within
the group of atrial fibrillation patients are independent predictors of quality of
life. In addition to clinical characterisctics, medication and arrhythmia bur-
den we considered the role of symptomatology and autonomic nervous system
function. We hypothesized that severe symptoms would be associated with low
quality of life. Further, since autonomic function presumably plays an impor-
tant role in mitigating the potentially adverse hemodynamic effects of atrial
fibrillation, impaired autonomic function also was hypothesized to be associ-
ated with low quality of life.
METHODS
Patient selection and definitions  All consecutive patients from the out-
patient clinic with paroxysmal atrial fibrillation, aged >18 years, were
considered eligible for the study. Paroxysmal atrial fibrillation was defined as
recently proposed by Gallagher and Camm; paroxysms had to terminate either
spontaneously or after treatment with an anti-arrhythmic drug.
7 Patients with
significant extra-cardiac or systemic disease were excluded to prevent
interference with quality of life.
8 Patients with diabetes mellitus and autonomic
neuropathy were also excluded. Lone atrial fibrillation was inferred when
routine cardiac investigations (echocardiogram, ergometry) did not reveal
structural heart disease. Patients with hypertension were considered to have
structural heart disease. Vagal atrial fibrillation was presumed present in case
of atrial fibrillation occuring predominantly at rest or during sleep, preceded
by heart rate slowing as documented by Holter monitoring (if available).
Determination of frequency and duration of paroxysms of atrial fibrillation
was based on subjective assessment by the patient. Although the concept of
quality of life is inherently subjective and no universal definition exists, there
is consensus that quality of life should be assessed on the basis of several105
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components, including physical condition, psychological well-being, social ac-
tivities, and everyday activity
2,3. Thus, quality of life can be viewed as a multi-
dimensional concept that is best approached through a multi-attribute mea-
surement technique. Patients who agreed to participate in the study under-
went additional investigations consisting of questionnaires, Holter monitor-
ing, and autonomic function testing. Cardioactive medication was stopped at
least 5 half-lives prior to testing if deemed acceptable by the attending physi-
cian. Sotalol was categorized as both a class III antiarrhythmic and a ß-blocker.
The study was approved by the institutional ethics committee and informed
consent was obtained from all patients.
Quality of life Quality of life was measured by the SF-36 (Medical Outcomes
Study Short-Form Health Survey).
9,10 The SF-36 is a widely-used, thoroughly
validated, standardized, generic health survey, consisting of 8 subscales that
measure physical functioning, bodily pain, role limitations due to physical or
emotional problems, social role functions, as well as sense of vitality and of
mental and general health. Scores of each subscale are normalized to a scale
ranging from 0 to 100, with lower scores representing a lower quality of life.
The SF-36 was developed to exclude potential bias due to age and gender. Pa-
tients were asked to fill out the questionnaire, and to return it by mail. Since
this was not a longitudinal study, nor did we assess any treatment effect, we
did not incorporate a disease-specific questionnaire.
Holter monitoring Twenty-four-hour ambulatory electrocardiographic moni-
toring (Holter-monitoring) was performed using a 3-channel Marquette Holter
recorder (series 8500). The recordings were processed by an experienced ana-
lyst using a Marquette Holter system (Marquette Laser Holter Systems, se-
ries 8000XP). We analyzed heart rate variability using Marquette software
(version 002A), in accordance with recommendations from the Task Force of
the European Society of Cardiology and the North American Society of Pacing
and Electrophysiology.
11 Recordings with >5% noise or ectopic beats, including
atrial fibrillation, were excluded from analysis. In case of atrial fibrillation,
the tapes were used to get an impression of the ventricular rate response. The
following time-domain parameters were calculated: the standard deviation of
all normal-to-normal RR-intervals during 24 hours (SDNN) and the root mean106
square of successive differences between normal RR-intervals (rMSSD). The
first parameter reflects overall heart rate variability and represents vagal as
well as sympathetic function, whereas the latter parameter is more specific for
vagal function. Discrete Fourier transformation was used for the analysis of
the frequency (spectral) domain parameters. The following parameters were
calculated: low-frequency power (0,04-0,15 Hz), high-frequency power (0,15-
0,40 Hz), and total power (0,0033-0,40 Hz). High frequency power reflects va-
gal function, whereas low frequency power is taken to represent combined va-
gal and sympathetic function.
Autonomic function testing A battery of 4 tests was performed: deep breath-
ing, isometric handgrip, standing up and head up tilting. Methods have been
described recently.
12 Briefly, tests were performed in the morning after hook-
ing up the Holter recorder. Blood pressure and heart rate were measured con-
tinuously (beat-to-beat) with the Finapress system with a cuff around the middle
finger of the right hand.
13 During the tests the patient was lying on a bed,
which could be tilted to an 80
0 upright position. After signal stabilization a 10-
minute baseline recording was taken. A stabilization period of 5 minutes was
allowed after each maneuver. The data were digitized and stored in a personal
computer for subsequent analysis. Although most tests influence vagal and
sympathetic function simultaneously, the extent to which each part of the au-
tonomic nervous system is activated, is variable.
14 Deep breathing is consid-
ered mainly a test of vagal function, whereas isometric handgrip is used to test
sympathetic function. Standing up and head up tilting reflect both vagal and
sympathetic function. Baseline data were used to calculate baroreflex-sensi-
tivity (see below).  Deep breathing: Using a metronome, the patient was in-
structed to breathe deeply in and out 6 times during 1 minute. The mean of all
6 breaths was taken to calculate the ratio between in- and expiratory heart
rate. Isometric handgrip: During 3 minutes a handgrip was held at 30% of the
previously established maximum force in the hand contralateral to the hand
used for the Finapress. The maximal increase in diastolic blood pressure was
determined Standing up: The patient was asked to stand up from the bed. The
30-15 ratio was calculated as the ratio between the highest heart rate after
standing up (usually around the 15th beat) and the lowest heart rate (usually
around the 30th beat).107
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Head up tilting: The bed on which the patient was positioned was tilted to the
80
0 upright position. Tilting was continued for 30 min or terminated earlier in
case of symptoms (pre-syncope). A positive response was defined as a sudden
drop in systolic blood pressure >30 mmHg (with or without concomitant brady-
cardia) accompanied by symptoms. Baroreflex-sensitivity: The baseline blood
pressure and heart rate data were used for noninvasive determination of
baroreflex-sensitivity, according to the method by Robbe et al.
15,16 First, the
baseline recording was plotted to select the longest portion of signals free from
artifacts or large transients having a minimal length of 4.5 minute. Then, by
performing cross-spectral analysis between the blood pressure and heart rate
time series the coherence function and the transfer function modulus were
computed. The mean value of the transfer function modulus in the frequency
band 0.07 to 0.14 Hz, considering only those points where coherence was >0.3,
was taken as the measure of baroreflex-sensitivity.
Symptomatology To examine the influence of symptoms during the parox-
ysms of atrial fibrillation on quality of life the patient was asked at entry into
the study to quantify these symptoms according to severity. Given our focus on
autonomic function we asked the patient to consider the following symptoms,
some of which supposedly reflect some degree of adrenergic activation (par-
ticularly the last 3 items): palpitations, dizziness, chest pain, perspiration,
coldness, and anxiety. Symptoms were scored on a 5-point scale, ranging from
1 to 5: 1=none, 2=light, 3=mild, 4=moderate, 5=severe.
Data analysis Mean values ± the standard deviation were calculated for
normally distributed variables, whereas median values with range were used
for non-normal distributions. In order to determine the relative quality of life
of the patients, scores in each of the 8 subscales of the SF-36 were compared
with scores in a previously established control group using Student’s t-test.
The control group consisted of a predefined stratum of 180 persons, age 45-55
years, taken from a random population sample of 1063 healthy adults.
17 Then,
to identify the predictors of quality of life, univariate analysis was performed
on the separate SF-36 subscales with particularly low scores. Studied variables
comprised clinical characteristics as well as data obtained during the additional
investigations. To limit the number variables we made a selection, focussing108
the hypothesis, i.e. the importance of symptomatology and autonomic function.
The analysis was performed using the proportional odds model for ordered
categorical data.18 To examine linearity, continuous variables were divided in
quartiles (or quintiles in case of the symptoms during the paroxysms). If the
quartiles showed a linear relation with quality of life the variable was taken in
the model as continuous. If a nonlinear relation was apparent, quartiles were
combined and the variable was included in the model as a dichotomous variable.
Variables with a univariate p-value <0.1 were selected for multivariate
regression analysis. Using backward selection, a model was constructed to
identify the independent predictors of quality of life. P-values <0.05 were
considered statistically significant. All statistical analyses were carried out
using the Statistical Analysis System (SAS) program, version 6.12.
Table 1. Clinical characteristics
Number 73
Age (years)* 54.1 ± 13.4
Gender*
Male (%) 51 (70)
Female (%) 22 (30)
Underlying heart disease*
Ischemic heart disease (%) 12 (16)
Valvular heart disease (%) 7 (10)
Hypertension (%) 11 (15)
Lone atrial fibrillation (%) 43 (59)
Echo-parameters
Left ventricular-enddiastolic dimension (mm) 47 ± 5
Left ventricular-endsystolic dimension (mm) 32 ± 6
Left atrial-dimension, parasternal (mm) 35 ± 6
Left atrial-dimension, apical (mm) 54 ± 7
Medication*
Class I antiarrhythmics (%) 27 (37)
Class III antiarrhythmics (%) 24 (33)
ß-blockers (%) 25 (34)
Digoxin (%) 7 (10)
No medication (%) 17 (23)
Arrhythmia burden*
Total duration (years) 3.0, 0.2-30
Frequency of paroxysms/week 0.99, 0.04-5.00
Duration of paroxysms (hours) 2.00, 0.15-48.00
Vagal arrhythmia (%)* 24 (33)
*Variables entered in the analysis of the determinants of quality of life109
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Table 2. Quality of life measurements
 Patients  Controls            P-value
Physical functioning 76.6 ± 21.5 79.9 ± 24.7 0.044
Social role function 78.1 ± 22.6 86.1 ± 21.8 0.001
Physical role function 49.7 ±  41.7 78.9 ± 37.0            <0.001
Emotional role function 64.9 ± 43.8 83.6 ± 34.1            <0.001
Mental health 72.2 ± 16.4 76.7 ± 19.6 0.022
Vitality 55.1 ± 21.9 67.5 ± 20.3            <0.001
Pain 81.1 ± 20.8 80.5 ± 26.7 0.73
General health 59.6 ± 16.9 71.6 ± 19.8            <0.001
RESULTS
Patient characteristics The study group comprised 73 patients. Clinical
characteristics are given in Table 1. Most patients were male and in the major-
ity no structural heart disease was apparent (lone atrial fibrillation). None of
the patients had congestive heart failure. Mean echo-parameters were within
the normal range. Arrhythmia burden in terms of total duration, frequency of
paroxysms and duration of paroxysms varied considerably. On average, pa-
tients had a 3-year-history of one paroxysm per week lasting 2 hours. Vagal
atrial fibrillation was observed in one third of the patients. Most patients (77%)
used medication to suppress their arrhythmia or control ventricular rate dur-
ing atrial fibrillation. In 9 patients medication was stopped prior to the addi-
tional investigations, leaving 47 patients on medication.
Quality of life All patients completely filled out the SF-36 questionnaire. Scores
given in Table 2. Compared to the age-matched control group, patients with
atrial fibrillation had statistically significantly lower scores on all SF-36
subscales, with the exception of the pain subscale. Scores in 4 subscales were
markedly lower (p<0.001): physical role function, emotional role function, vi-
tality, and general health.
Holter monitoring  All recordings were technically adequate. However, in 20
recordings >5% ectopy was present due to paroxysms of atrial fibrillation, pre-
cluding further analysis. Mean ventricular rate during atrial fibrillation in110
Table 3. Holter monitoring and autonomic function testing
Patients Normal
values*
Holter monitoring
Heart rate (beats/minute) 69 ± 10 72
SDNN (ms) 127.6 ± 27.0 141
rMSSD (ms) 28.3 ± 11.5 29.9
Total power (ms) 28.7 ± 11.3 36
Low frequency power (ms) 18.3 ± 8.1 24
High frequency power (ms) 9.7 ± 4.2 11
Autonomic function testing
Deep breathing (beats/minute) 14 ± 9 >15
Isometric handgrip (mm Hg) 21 ± 11 >15
Standing up, 30-15 ratio 1.19 ± 0.16 >1.04
Head up tilting, positive response 9 -
Baroreflex sensitivity (ms/mm Hg) 7.8 ± 5.8 10.5
*Normal values in our laboratory, corrected for age.
SDNN=standard deviation of all normal-normal RR-intervals; rMSSD=root mean square of
successive differences between normal RR-intervals
these patients was 99 ± 16 beats/min. Results from the remaining 53 patients
are listed in Table 3. All mean heart rate variability parameters were below
normal values, though to a varying degree.
Autonomic function testing In 3 patients autonomic function testing was
not feasible due to atrial fibrillation, including a patient in whom atrial fibril-
lation was elicited by standing up. Results from the remaining 70 patients are
listed in Table 3. Mean responses to isometric handgrip and standing up were
normal, whereas the response to deep breathing was marginally depressed.
Head up tilting caused hypotension in 19 patients, which was associated with
symptoms in 9 patients. Coherence was >0.3 in all patients, allowing reliable
calculation of the modulus, that is, baroreflex-sensitivity. Mean baroreflex-
sensitivity was below the normal value.
Symptomatology Scores on symptoms during paroxysms were as follows:
palpitations 4.2 ± 0.2; dizziness 3.4 ± 0.2; chest pain 2.5 ± 0.2; pers-piration
2.7 ± 0.2: coldness 2.6 ± 0.2: and anxiety 3.0 ± 0.2.111
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Table 4. Multivariate predictors of physical role function, emotional role function,
vitality, and general health
  95% Confidence limits
Odds ratio lower upper   P-value
Physical role function
Frequency of paroxysms-1* 4.69 1.29       17.24 0.019
Dizziness-4,5† 0.29 0.10 0.89 0.030
Chest pain-4,5† 0.28 0.10 0.80 0.018
Baroreflex sensitivity‡ 1.18 1.05 1.32 0.004
Emotional role function
Perspiration-5† 0.10 0.03 0.38 0.001
Total power-4* 5.32 1.09 26.31 0.039
Vitality
ß-blocker use 0.30 0.11 0.86 0.025
Vagal atrial fibrillation 4.17 1.46 11.90 0.008
Deep breathing-1* 0.21 0.07 0.65 0.007
General health
Perspiration-4,5† 0.30 0.11 0.86 0.025
30-15 ratio-4* 6.90 2.43 22.36   <0.001
* refers to quartile
† refers to quintile
‡ Unlike all the other variables, baroreflex sensitivity was taken in the model as continuous.
The odds ratio in this case refers to increase per unit of measurement (ms/mm Hg).
Predictors of quality of life Based on the high statistical significance we
choose the following 4 subscales for the analysis of the independent predictors
of quality of life: physical role function, emotional role function, vitality and
general health. Results are given in Table 4. High baroreflex sensitivity and
low frequency of paroxysms (1
st quartile: <0.25/week) were associated with
preserved physical role function, whereas moderate to severe dizziness and
chest pain during paroxysms (4
th and 5
th quintile) were associated with im-
paired physical role function. Emotional role function was preserved in case of
high total power (4
th quartile) and impaired in case of severe perspiration (5
th
quintile). Vitality was low in case of ß-blocker use and poor response to deep
breathing (1
st quartile), and preserved in patients with vagal atrial fibrilla-
tion. Finally, general health was poor in case of moderate to severe perspira-
tion (4
thand 5
th quintile) and good in case of a high 30-15 ratio (4
th quartile).112
DISCUSSION
This study shows that paroxysmal atrial fibrillation causes significant impair-
ment of the quality of life as measured by the SF-36, even in the absence of
structural heart disease. In particular, physical role function, emotional role
function, vitality and general health appear to be impaired. The results also
indicate that symptomatology and autonomic function are independent pre-
dictors of quality of life in patients with paroxysmal atrial fibrillation.
There is an increasing awareness that quality of life is important and quality
of life has become a major endpoint in clinical trials. However, despite the fact
that atrial fibrillation is a very common disorder with profound impact in terms
of morbidity and mortality, data on the quality of life in patients with atrial
fibrillation are sparse. Overviews on this issue have recently been published,
2,3
stressing the need for controlled, large-volume studies in representative pa-
tients. In fact, several studies are ongoing including an international study
(International Study on Quality of Life in Atrial Fibrillation) which focuses on
the effect of atrial fibrillation on quality of life over time. The first results
indicate that atrial fibrillation is associated with impaired quality of life, as
measured by the SF-36, and that no significant changes occur over time (12
months).
19 Quality of life was impaired irrespective of arrhythmia burden (fre-
quency and duration of paroxysms), type of atrial fibrillation (paroxysmal,
persistent or permanent) and other indices of illness (New York Heart Associa-
tion functional class, left ventricular ejection fraction).
20,21 Quality of life was
as impaired as in coronary artery disease patients who had recently had
angioplasty, and perceived  “illness burden” was comparable to that of renal
failure patients on dialysis.
20 We herein present the first full report on a con-
trolled, large-volume study on quality of life in patients with paroxysmal atrial
fibrillation. The study group consisted of 73 patients, the majority of whom
had no structural heart disease. On average, patients had a 3-year-history of
one paroxysm per week lasting 2 hours. The results support the aforemen-
tioned finding in that paroxysmal atrial fibrillation was found to be associated
with impaired quality of life, as measured by the SF-36.
19 In fact, scores were
statistically significantly lower compared to the controls in as many as 7 of the
8 SF-36 subscales, scores being particularly low with respect to physical role
function, emotional role function, vitality and general health.113
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Comparing data from different studies in patients with different disorders is
inherently difficult, particularly since the SF-36 lacks a composite score.
Nevertheless, it seems that patients with life-threatening ventricular
arrhythmias have a lower quality of life, though it should be realized that
severe underlying heart disease is often present in these patients which may
be presumed to account to a large extent for the low quality of life, rather than
the arrhythmia.
22  On the other hand, the effect of angina pectoris on quality of
life would appear to be comparable with the findings in our patients.
23
This study also sought to determine which factors within the group of atrial
fibrillation patients are independent predictors of quality of life. We considered
clinical characteristics, medication, and arrhythmia burden. In addition, we
argued that autonomic function and symptomatology might have an impact.
The role of the autonomic nervous system in atrial fibrillation is complex. On
the one hand, autonomic factors play a role in the genesis of atrial fibrillation,
24-
26 particularly vagal activity (vagal atrial fibrillation). On the other hand, atrial
fibrillation may affect autonomic function through its potential effect on
hemodynamics.
27 In particular, arterial baroreflex activation may occur in the
setting of acute atrial fibrillation to ensure hemodynamic homeostasis.  In
other words, intact autonomic function is presumably needed to mitigate the
potentially adverse hemodynamic effect of atrial fibrillation, analogous to its
role in the setting of ventricular tachyarrhythmias.
28,29 Notwithstanding these
considerations, the relation between the clinical history (vagal arrhythmia?)
and autonomic function is far from straightforward. In fact, some patients with
vagal atrial fibrillation experience intense adrenergic activation whereas in
others no such response is clinically apparent. Finally, atrial fibrillation may
elicit a vasovagal response in susceptible patients.
30 Symptomatology varies
substantially among patients with atrial fibrillation, some patients reporting
severe symptoms whereas others are virtually asymptomatic despite substantial
arrhythmia burden.
31,32 Also, some symptoms may be more disruptive than
others. We hypothesized that these differences have a bearing on quality of
life. The results seem to support the previous data that neither structural heart
nor arrhythmia burden have an independent impact on quality of life in patients
with atrial fibrillation (with the exception of frequency of paroxysms).
 20,21 In
contrast, our hypothesis was confirmed that both autonomic function and
symptomatology were independently related to quality of life. In all 4 studied114
subscales autonomic variables emerged as significant predictors. Taken
together, depressed autonomic function, particularly vagal function, was
predictive of impaired quality of life function. However, caution is necessary,
since the data do not prove a causal relation; in fact, previous studies have
shown that affective disorders (including depression) may cause  impairment
of autonomic function.
33,34 In other words, low quality of life (of whatever cause),
might have been the initial problem in our patients, impaired autonomic
function and paroxysmal AF being secondary phenomena. Of note, a positive
response to head up tilting was not predictive of impaired quality of life.
However, the observed high prevalence (12%) is intriguing as such and of
potential interest with respect to the genesis of atrial fibrillation.
25 In addition
to autonomic function, symptomatology played a role. As expected, scores on
palpitations were highest, but palpitations were not predictive of impaired
quality of life. Rather, the secondary symptoms dizziness, chest pain, and
perspiration were predictive of low quality of life.  Though a causal relation is
again hard to establish, it thus appears that the impact of symptoms extends
beyond the actual paroxysms of the arrhythmia. Possibly, anticipation of
disruptive symptoms has a depressant effect on quality of life. The importance
of symptomatology is supported by the recent findings that asymptomatic atrial
fibrillation does not significantly deteriorate quality of life
35 and that quality
of life improves following medical treatment of atrial fibrillation.
36
The majority of patients was on medication during Holter monitoring and
autonomic function testing, which may have influenced the results. However,
the different classes of drugs did not emerge as independent predictors of quality
of life in the multivariate analysis, with the exception of ß-blockers. Also,
exclusion of 20 Holter recordings from further analysis because of >5% ectopy
might have introduced a selection bias. Finally, since our institute is a tertiary
referral center, the patient group may not be entirely representative of clinical
practice. In fact, due to a referral effect, quality of life in our patients with
atrial fibrillation may be lower than in patients in a primary care setting.
Further selection occurred due to exclusion of patients with extra-cardiac or
systemic disease. This is probably reflected by the high proportion of  patients
with lone atrial fibrillation and vagal atrial fibrillation. On the other hand,
given the fact that on average patients were relatively “healthy”, their low
quality of life is even more striking.115
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The available data unequivocally show that quality of life is impaired in
patients with atrial fibrillation. Quality of life should therefore be added as a
target for therapeutic intervention. Though there is much yet to learn, the
present study provides insight into the potential causes of impaired quality of
life, symptomatology and autonomic function playing an important role.
Apparently, the autonomic nervous system is not only implicated in the genesis
of atrial fibrillation, but also in its consequences, including the way the
arrhythmia is experienced.
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SUMMARY
Heart failure and atrial fibrillation are very common, particularly in the
elderly. Owing to common risk factors both disorders are often present in the
same patient. In addition, there is increasing evidence of a complex, reciprocal
relation between heart failure and atrial fibrillation. Thus heart failure may
cause atrial fibrillation, with electromechanical feedback and neurohumoral
activation playing an important mediating role. On the other hand, atrial
fibrillation may promote heart failure; in particular, when there is an uncon-
trolled ventricular rate tachycardiomyopathy may develop and thereby heart
failure. Eventually, a vicious circle between heart failure and atrial fibrillation
may form, in which neurohumoral activation and subtle derangement of rate
control are involved. Treatment should aim at unloading of the heart, adequate
control of ventricular rate and correction of neurohumoral activation. Angio-
tensin converting enzyme inhibitors may help to achieve these goals. Treat-
ment should also include an attempt to restore sinus rhythm through electri-
cal cardioversion, though appropriate timing of cardioversion is difficult.
His bundle ablation may be used to achieve adequate rate control in drug-
refractory cases.
BACKGROUND
Congestive heart failure is a large epidemiologic problem, particularly in the
elderly. The same holds for atrial fibrillation, another very common disorder
especially affecting elderly subjects. The two disorders profoundly limit life-
expectancy. Another important epidemiologic feature is that both are often
present in the same patient. This is partly due to the fact that heart failure
and atrial fibrillation share important risk factors. On the other hand, a causal,
reciprocal relation exists between heart failure and atrial fibrillation. In this
review relevant epidemiologic aspects as well as pathophysiologic and clinical
aspects of this interplay between heart failure and atrial fibrillation will be
discussed.122
EPIDEMIOLOGICAL ASPECTS
The Framingham Study estimated the mean prevalence of heart failure to be
approximately 1% of its local population.
1 The prevalence of heart failure rose
sharply with age; it doubled every decade, exceeding 10% above the age of 80
years. Importantly, based on the number of hospitalizations, the prevalence of
heart failure would appear to increase over time. The epidemiologic signifi-
cance of heart failure is also reflected by its profound adverse effect on progno-
sis, especially in severe cases. In the Framingham Study, one-year mortality
was 43% and 5-year mortality 75%.
The Framingham Study has also provided insight into the epidemiology of
atrial fibrillation; the overall chance that subjects 30 to 62 years old in the
Framingham population would develop atrial fibrillation during 22 years of
follow-up was 2%.
2 However, the incidence was strikingly age-dependent, older
age age (>55 years) conferring a chance >3% of developing atrial fibrillation.
Unfortunately, there are as yet no reliable data as to whether the epidemiol-
ogy of atrial fibrillation is changing, i.e. whether atrial fibrillation is becoming
more common, though this would seem likely, given the fact that elderly are
increasing in number. The prognostic implications of atrial fibrillation are grave.
In the Framingham Study, development of atrial fibrillation was associated
with a relative risk of 1.8 for overall mortality and 2.7 for cardiovascular mor-
tality, compared to subjects with sinus rhythm. The average time to death was
6 years.
Heart failure and atrial fibrillation From an epidemiologic point of view, a
strong association exists between heart failure and atrial fibrillation. Whereas
atrial fibrillation is relatively rare in mild heart failure, it is a common con-
comitant disorder in patients with more advanced disease (table 1). In one
smaller study, as many as 35% of the patients with heart failure were reported
to have concomitant atrial fibrillation.
7 The impact of atrial fibrillation on
mortality in patients with heart failure is controversial. In the largest study,
combining data from the V-HeFT I and II Studies, no effect of atrial fibrillation
on mortality was demonstrable. Conversely, heart failure is a common finding
in patients with atrial fibrillation,
2 and one which adversely affects their prog-
nosis (as could be expected, given the grim prognosis of heart failure per se).
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PATHOPHYSIOLOGICAL ASPECTS
The similarity of the epidemiologic profile of heart failure and atrial fibrilla-
tion and their frequent coexistence can readily be explained by considering the
risk factors of either disorder. Heart failure and atrial fibrillation share to a
considerable extent the same risk factors, i.e. predisposing conditions. The
importance of old age has already been mentioned, and the significance of is-
chemic heart disease, hypertension and valve disease is well established.2,9
Finally, specific factors such as diabetes mellitus and left ventricular hyper-
trophy on the electrocardiogram also prognosticate the development of both
heart failure and atrial fibrillation. There is, however, also evidence of a causal
relation between the two disorders.
Heart failure as a cause of atrial fibrillation Heart failure is an estab-
lished predisposing condition for development of atrial fibrillation.2,9 In fact, in
the Framingham Study heart failure was the most powerful independent pre-
cursor of atrial fibrillation, with a relative risk of approximately sixfold. Inter-
estingly, in another report from the Framingham Study even asymptomatic
left ventricular dysfunction was found to be predictive of atrial fibrillation.10
Data from cardioversion studies provide another line of evidence substantiat-
ing the importance of heart failure in the development of atrial fibrillation.
Thus, it has been shown that heart failure increases the likelihood of recur-
rence of atrial fibrillation after electrical cardioversion to sinus rhythm.11
Whereas the empirical evidence that heart failure may cause atrial fibril-
lation is irrefutable, the underlying pathophysiologic mechanism is only partly
Table 1.  Studies of atrial fibrillation in heart failure with >200 patients
No of Mean LVEF AF Impact on
Reference patients (%) (%) mortality
Likoff et al3 201 20 18 none
Keogh et al4 232 16 NA none
Middlekauff et al5 395 19 19 increased
Carson et al6 1427 30 14 none
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; NA, not available.124
understood. “Mechano-electrical feedback” at the atrial level presumably plays
an important role. As a result of increased cardiac loading due to heart failure,
the atria stretch, which in the experimental setting has been shown to produce
profibrillatory changes in atrial conduction and refractoriness.
12,13 In particu-
lar, the dispersion in atrial refractoriness increased secondarily to acute atrial
loading, which was associated with enhanced inducibility of atrial fibrillation.
These findings in animals have been confirmed in humans, acute changes in
atrial load similarly affecting atrial electrophysiologic properties.
14 In addi-
tion to these acute, transient effects of atrial loading, it may be surmised that
sustained atrial overload in the setting of chronic heart failure causes struc-
tural atrial enlargement, which in turn would strongly facilitate atrial fibrilla-
tion. Supporting this possibility, we found that left atrial volume in a group of
atrial fibrillation patients with overt heart failure was larger than in randomly
selected atrial fibrillation patients, other factors known to affect left atrial
volume being comparable; mean left atrial volume was 86 ml and 74 ml re-
spectively.
15,16
Secondly, it may be hypothesized that atrial fibrillation in the setting of
heart failure is also promoted by associated neurohumoral activation. In par-
ticular, activation of the sympathetic nervous system might facilitate the on-
set of atrial fibrillation by directly modifying atrial electrophysiologic
No. of LV function LV function
Total patients before after
no. of with EF <50% His bundle His bundle
Reference patients or FS <27% ablation (%)* ablation (%)*
Rosenqvist et al22 5 5 EF:27 EF:45
Heinz et al23 10 5 FS:21 FS:31
Rodriguez et al
24 30 12 EF:43 EF:54
Twidale et al
25 14 10 EF:42 EF:47
Brignole et al26 23 9 FS:23 FS:31
Edner et al27 29 14 EF:32 EF:45
*The data pertain only to the subgroup of patients with the depressed left ventricular func-
tion prior to His bundle ablation (except the study of Twidale et al in which the effect was not
specified according to the two subgroups); no significant changes were observed after His
bundle ablation in the subgroup of patients with preserved left ventricular function.
EF, ejection fraction; FS, fractional shortening; LV, left ventricular.
Table 2.   Studies on the effect of His bundle ablation on left ventricular function
in selected patients with atrial fibrillation or flutter126
Figure 1. Change in peak oxygen consumption during follow-up in the V-HeFT II Study compar-
ing patients with sinus rhythm and atrial fibrillation. After 2 years patients with atrial fibrilla-
tion showed a significant decline in peak oxygen consumption, whereas peak oxygen consumption
in patients with sinus rhythm remained unchanged (Reproduced with permission from Carson et
al., The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT
Studies. Circulation 1993;87(suppl VI):102-110. Copyright 1993 American Heart Association6).
tachycardiomyopathy this would affect many patients with atrial fibrillation,
even when ventricular rate is adequately controlled, i.e. according to clinical
practice. Thus, in the V-HeFT II Study,6 patients with atrial fibrillation showed
a significant decline in peak oxygen consumption compared to patients with
sinus rhythm starting after 2 years of follow-up (Figure 1). Recently, we ob-
served a comparable phenomenon in a 2-year follow-up study after electrical
cardioversion:28 despite similar clinical characteristics at baseline, patients who
maintained sinus rhythm showed a gradual, sustained increase in peak oxy-
gen consumption, whereas patients with recurrence of atrial fibrillation dem-
onstrated a clear decrease after 2 years. Furthermore, it was shown that elec-
trical cardioversion of atrial fibrillation is associated with a discrepancy in the
time course of recovery of atrial systole and ventricular function:29 while the
atrial contribution to ventricular filling normalized within one week after
cardioversion, left ventricular ejection fraction continued to increase beyond
that time frame, reaching peak values after one month. It was noteworthy
that the increase in peak oxygen consumption was parallel to the increase in
ejection fraction.
Taken together, these observations suggest the presence of a subtle form
of cardiomyopathy, inherent to chronic atrial fibrillation. The underlying125
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properties, thereby promoting atrial ectopy necessary for initiation of atrial
fibrillation.
17,18 Furthermore, elevated catecholamine and angiotensine II lev-
els produce structural changes in the myocardium (myocyte hypertrophy, col-
lagen accumulation, fibrosis), which in turn may promote arrhythmias,
19 pre-
sumably including atrial fibrillation. Underscoring the importance of sympa-
thetic activation, Borzak et al. have demonstrated in a dog model of heart
failure that the propensity for development of atrial fibrillation was strongly
related to the level of plasma norepinephrine.
20 In fact, in that study develop-
ment of atrial fibrillation was not predicted by any measure of left ventricular
performance, but exclusively by plasma norepinephrine. Finally, in a recent
study we found that plasma norepinephrine prior to electrical cardioversion
tended to be higher in heart failure patients with subsequent recurrence of
atrial fibrillation (after cardioversion) than in patients who maintained sinus
rhythm.
15
Atrial fibrillation as a cause of heart failure Besides the fact that heart
failure can cause atrial fibrillation, atrial fibrillation may also cause heart
failure. Among clinicians it is common knowledge that acute atrial fibrillation
may precipitate overt heart failure in the setting of asymptomatic left ven-
tricular dysfunction. Impaired diastolic filling secondary to loss of atrial sys-
tolic function and to rapid, irregular ventricular rhythm plays a crucial role in
this connection. However, if ventricular rate is inadequately controlled, atrial
fibrillation may also depress systolic function, which may eventually result in
severe heart failure, even without prior structural heart disease.
21-27 This phe-
nomenon has been termed “tachycardiomyopathy”. The clinical evidence for
this type of cardiomyopathy stems from the observation that left ventricular
function often markedly improves after alleviation of high ventricular rate per
se. Radiofrequency ablation of the His bundle may be used to this end (table
2). Numerous animal studies support the concept of tachycardiomyopathy; in
fact, rapid cardiac pacing was already an established means of producing ex-
perimental heart failure long before appreciation of the concept by clinicians
became widespread.
In addition to the aforementioned (sub)acute effects of atrial fibrillation,
there is also evidence of a more subtle, insidious long-term deleterious effect of
atrial fibrillation on left ventricular function. Unlike straightforward127
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Figure 2.  Relation between stage of exercise and heart rate comparing 21 patients with chronic
atrial fibrillation with peak oxygen consumption =20 ml/min/kg (open circles) and 24 patients
with peak oxygen consumption >20 ml/min/kg (closed circles). All patients were on digoxin and/or
calcium antagonists for control of ventricular rate; no patients used antiadrenergic agents, in-
cluding angiotensin converting enzyme inhibitors or beta-blockers. Patients with preserved func-
tional capacity (peak oxygen consumption >20 ml/min/kg) showed a gradual increase in heart rate
as a function of exercise. In contrast, though heart rate at rest was reasonably well controlled, in
patients with impaired functional capacity (peak oxygen consumption =20 ml/min/kg) a marked
heart rate increase was observed at low levels of exercise compared to patients with preserved
functional capacity. In addition, maximal heart rate was attenuated (Reproduced with permission
from Van Den Berg et al., Chronotropic response to exercise in patients with atrial fibrillation:
relation to functional state. Br Heart J 1993;70:150-153. Copyright 1993 BMJ Publishing Group31).
mechanism is as yet unknown. However, two factors might be involved, the
first of which is “concealed” tachycardiomyopathy; though ventricular rate at
rest may be well controlled (<100 beats/min), patients with atrial fibrillation
often exhibit disproportionately high rates (>120 beats/min) during minor ex-
ercise, corresponding with normal daily activities. Particularly patients in whom
the left ventricular function is already impaired exhibit such responses, due to
excessive sympathetic activation early during exercise (Figure 2).
15,30,31 It is
conceivable that in the long run this has a deleterious effect on left ventricular
systolic function, considering the fact that tachycardiomyopathy may develop
in patients with paroxysmal atrial fibrillation and with ventricular rates as
“low” as 120 beats/min or even lower.
21-27
Second, depletion of atrial natriuretic peptide may play a role. Whereas in
the acute stage atrial fibrillatory activity per se (i.e. irrespective of concomi-
tant hemodynamic changes) may enhance atrial natriuretic peptide secretion,
32
long-standing atrial fibrillation is associated with atrial natriuretic peptide
depletion; as a result of extensive atrophy and fibrosis of the atria, the produc-
tion of atrial natriuretic peptide gradually diminishes in long-standing atrial128
fibrillation, which may result in complete “endocrinologic silence”.
33 Recently,
we found that this phenomenon may also be operative in patients with con-
comitant heart failure by observing the presence of an inverse relation be-
tween plasma atrial natriuretic peptide and the duration of atrial fibrillation
in these patients (unpublished results). Though diminished atrial natriuretic
peptide production does not directly affect left ventricular systolic function, it
may contribute to eventual hemodynamic deterioration, i.e. heart failure.
CLINICAL MANAGEMENT
Traditionally, many clinicians rely on cardioversion (either chemical or electri-
cal) as a first therapeutic measure in patients with atrial fibrillation, irrespec-
tive of concomitant heart failure. This approach is supported by the very con-
sistent finding that the duration of atrial fibrillation is a prime determinant of
the likelihood of maintenance of sinus rhythm after cardioversion: the longer
the duration of atrial fibrillation the higher the risk of relapse of atrial fibrilla-
tion.
11 However, irrespective of the duration of atrial fibrillation, it is impor-
tant that untreated hypertension, myocardial ischemia, thyrotoxicosis or heart
failure should be treated before attempting cardioversion. In addition, it should
be realized that the prophylactic use of antiarrhythmic drugs is hazardous in
cases of heart failure; while the efficacy in maintaining sinus rhythm after
cardioversion is low, these agents may actually increase mortality, due to nega-
tive inotropic and proarrhythmic effects.
35 Hence, unless in cases of emergency
(hemodynamic shock) in which cardioversion may prove beneficial,
cardioversion is generally not suited as a first measure in patients presenting
with heart failure and atrial fibrillation; treatment should instead focus on
heart failure.
We have shown recently that treatment with an angiotensin converting
enzyme inhibitor is useful to this end.
15 Also, adequate control of ventricular
rate is crucial. Though classically digoxin is widely used, it is often necessary
to add another (intravenous) agent, the options being a beta-blocker or a cal-
cium-antagonist. Diltiazem has been shown to be generally safe in the setting
of acute heart failure and atrial fibrillation, and to rapidly and effectively con-
trol ventricular rate.
36 Alternatively, a case can be made for the betablocker
esmolol.
37 Due to its ultrashort half-life (9 minutes) this agent is theoretically129
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well suited for the critical care setting, including acute heart failure and atrial
fibrillation. Rate control with digoxin as monotherapy is often also insufficient
beyond the acute stage; though by virtue of its vagomimetic effect it may con-
trol ventricular rate reasonably well at rest, rate control during exercise, in-
cluding low levels of exercise, is usually inadequate. Hence, like in the acute
stage, it is often necessary to add another agent. The efficacy of calcium an-
tagonists and beta-blockers in this connection is unknown; previous studies
have included mainly atrial fibrillation patients with (near) normal cardiac
function, and have focussed on heart rate at maximal exercise rather than
heart rate at lower levels of exercise. Furthermore, the duration of treatment
in most studies was relatively short (2-3 weeks). These considerations, together
with those mentioned before, provide a rationale for adding a beta-blocker to
digoxin rather than a calcium-antagonist. The dose will probably have to be
relatively low to allow for a sufficient rise in heart rate during heavy exercise,
and treatment should presumably be continued for a long time before a benefical
effect can be expected. However, anecdotal experience suggests that patients
may indeed benefit.
38 Finally, when the patient proves drug-refractory despite
the use of a combination of negative dromotropic agents, His bundle ablation
is an option.
Acronyms: V-HeFT: Vasodilator Heart Failure Trial
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ABSTRACT
Objective—To investigate the occurrence of heart failure complications, and
to identify variables that predict heart failure in patients with (recurrent)
persistent atrial fibrillation, treated aggressively with serial electrical
cardioversions and antiarrhythmic drugs to maintain sinus rhythm.
Design—Non-randomised controlled trial; cohort; case series; mean (SD) fol-
low up duration 3.4 (1.6) years.
Setting—Tertiary care centre.
Subjects—Consecutive sampling of 342 patients with persistent atrial fibril-
lation (defined as > 24 hours duration) considered eligible for electrical
cardioversion.
Interventions—Serial electrical cardioversions and serial antiarrhythmic drug
treatment, after identification and treatment of underlying cardiovascular dis-
ease.
Main outcome measures—Heart failure complications: development or pro-
gression of heart failure requiring the institution or addition of drug treat-
ment, hospital admission, or death from heart failure.
Results—Development or progression of heart failure occurred in 38 patients
(11%), and 22 patients (6%) died from heart failure. These complications were
related to the presence of coronary artery disease (p < 0.001, risk ratio 3.2,
95% confidence interval (CI) 1.6 to 6.5), rheumatic heart disease (p < 0.001,
risk ratio 5.0, 95% CI 2.4 to 10.2), cardiomyopathy (p < 0.001, risk ratio 5.0,
95% CI 2.0 to 12.4), atrial fibrillation for < 3 months (p=0.04, risk ratio 2.0,
95% CI 1.0 to 3.7), and poor exercise tolerance (New York Heart Association
class III at inclusion, p < 0.001, risk ratio 3.5, 95% CI 1.9 to 6.7). No heart
failure complications were observed in patients with lone atrial fibrillation.
Conclusions—Aggressive serial electrical cardioversion does not prevent heart
failure complications in patients with persistent atrial fibrillation. These com-
plications are predominantly observed in patients with more severe underly-
ing cardiovascular disease. Randomised comparison with rate control treat-
ment is needed to define the optimal treatment for persistent atrial fibrilla-
tion in relation to heart failure.136
INTRODUCTION
Atrial fibrillation is the most common cardiac arrhythmia, with an estimated
prevalence of up to 0.89% in the general population.
1-3 Its incidence increases
strongly with age and with the presence of cardiovascular disease.
1,4,5 The rela-
tive risk on the development of heart failure (HF) during atrial fibrillation in
large cohort studies is approximately threefold.
1,5 Conversely, in patients with
more advanced heart failure, atrial fibrillation is a common concomitant disor-
der,
6-9 but the impact of atrial fibrillation on mortality in patients with moder-
ate to severe heart failure is still uncertain.
6,7,10 These data, however, pertain
to “general” atrial fibrillation for which treatment is not specified. At present,
it is unknown whether patients with persistent AF treated intensively with a
serial electrical cardioversion and serial antiarrhythmic drugs (which is still
common practice), with the intention of maintaining sinus rhythm, also show
heart failure complications. This may be important, as recent data suggest
that the arrhythmia prognosis is relatively poor with such an approach, espe-
cially in those already suffering from heart failure,
11 favouring acceptance of
atrial fibrillation earlier during the course of the disease. However, such a
decision should be guided not only by arrhythmia outcome, but also by morbid-
ity and mortality in relation to the therapeutic strategy adopted. Our aim in
this study was therefore to investigate the occurrence of heart failure compli-
cations during long term follow up in patients suffering from (recurrent) per-
sistent atrial fibrillation who were treated intensively with serial electrical
cardioversion and serial antiarrhythmic drugs to maintain sinus rhythm. In
addition, we also investigated clinical variables predicting heart failure dur-
ing the course of (recurrent) persistent atrial fibrillation.
METHODS
Study population In the course of 7 years (January 1986 to January 1993)
426 consecutive patients with persistent atrial fibrillation were referred to our
hospital for treatment and included in our prospective cardioversion database.
Neither age nor previous arrhythmia duration were exclusion criteria for par-
ticipation in the study. Exclusion criteria were New York Heart Association
(NYHA) class IV for exercise tolerance (n=60), unstable angina pectoris (n=10),137
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and acute myocardial infarction less than four weeks previously (n=14). The
remaining 342 patients constituted the present study group, from which sub-
sets (with more stringent criteria with respect to arrhythmia history) have
been described previously.
11-14 The study was approved by the institutional re-
view board.
Serial electrical cardioversion The protocol has been described before.
11-15
In short, electrical cardioversion was the principal treatment of atrial fibrilla-
tion, after treatment of any present underlying cardiovascular disease (see
section on treatment of underlying cardiovascular disease below). In case of
failure to re-establish sinus rhythm with serial electrical cardioversion, the
rate control alternative was adopted. All cardioversions were performed on an
elective basis. Patients received warfarin or another coumarin at least four
weeks before the procedure. If the international normalised ratio (INR) on
admission was below 2.4 (see section on antigoagulant treatment below), the
cardioversion procedure was postponed for another four weeks.
Electrical cardioversion was performed without antiarrhythmic drug pre-
treatment. A calibrated Hewlett Packard 43120-A defibrillator (Hewlett Packard
Inc, Andover, Massachusetts, USA) which could store 360 Joules of energy was
used as the cardioverter device. According to the protocol, we started with 50
Joules of stored energy. Thereafter, energy load of successive shocks was doubled
until sinus rhythm was restored or after two attempts with 360 Joules. Post-
shock rhythm monitoring was secured by telemetry for eight to 24 hours. If
after the first electrical cardioversion procedure sinus rhythm was accom-
plished, patients did not receive an antiarrhythmic drug. If atrial fibrillation
relapsed, electrical cardioversion was repeated as soon as possible. Those pa-
tients who clearly felt that the recurrence of atrial fibrillation lasted less than
24 hours underwent cardioversion without preceding anticoagulation; the oth-
ers were given warfarin (or another coumarin) for at least four weeks.
Patients with successive arrhythmia recurrences, were treated consecu-
tively with three different antiarrhythmic drugs (serial prophylactic antiar-
rhythmic drug strategy). Until 1989 we used flecainide as initial agent but
because of the results of the cardiac arrhythmia suppression (CAST) trial,
16
we changed our preference to sotalol (160 to 320 mg daily), followed by flecainide
(200 to 300 mg daily), and finally amiodarone (600 mg daily for four weeks138
followed by 200 to 300 mg daily). Both flecainide and sotalol were started dur-
ing 24 hour telemetric rhythm monitoring. After 1989, the use of flecainide
was discontinued in patients with ischaemia, previous myocardial infarction,
impaired left ventricular function, and moderate to severe valvar heart dis-
ease. Amiodarone was given four weeks or more before repeated electrical
cardioversion. Patients with a relapse of atrial fibrillation after more than one
year of sinus rhythm, a so called late recurrence, underwent electrical
cardioversion without the subsequent use of prophylactic antiarrhythmic drugs
or without change in the antiarrhythmic drug in use at the time. Patients in
whom a particular antiarrhythmic drug was contraindicated proceeded to the
next agent in the sequence. The inclusion in the study began on the day of the
first cardioversion and follow up was completed at death or at 1 January 1994,
whichever came first. Follow up was at least one year in all patients.
Conditions for acceptance of atrial fibrillation included failure of response
to amiodarone, drug related side effects, completely asymptomatic arrhyth-
mia recurrence after (multiple) cardioversion, or refusal to undergo another
electrical cardioversion. In these patients, control of the ventricular response
to atrial fibrillation was pursued by digitalis and if necessary with additional
verapamil, diltiazem or a beta blocker with the aim of obtaining a resting heart
rate under 100 beats/min. Additionally, 24 hour ambulatory ECG (Holter)
monitoring was performed to control ventricular rate during daily activity and
was repeated after adjustment of rate control treatment. His bundle ablation
with implantation of a pacemaker was offered to the patient if symptoms of
palpitations were severe or in case of progression or persistence of tachycardia
related heart failure.
Anticoagulant treatment Anticoagulant treatment with dose adjusted war-
farin or another coumarin was initiated at least four weeks before (re-)
cardioversion and continued after restoration of sinus rhythm for at least four
weeks. In the event that atrial fibrillation persisted, and in patients who re-
quired prolonged anticoagulation for other indications (for example, mitral valve
stenosis), anticoagulant treatment was continued. During treatment, the tar-
get INR was 2.4 to 4.8. Anticoagulation was monitored at a regional centre of
the Dutch Thrombosis Services, which specialise in monitoring coumarin treat-
ment in outpatients.139
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Treatment of underlying cardiovascular disease Before acceptance for
serial electrical cardioversion, any underlying disease was treated as adequately
as possible according to clinical practice at that time (see below). Patients
suffering from hyperthyroidism were only included after at least three months
of adequate treatment. Treatment of ischaemic heart disease: Ischaemic heart
disease was treated stepwise starting with a beta blocker, and then adding a
calcium channel blocker and/or nitrates. When contraindications or adverse
drug effects were present, other combinations were prescribed. Surgical inter-
vention for ischaemic heart disease was considered, and if feasible performed,
when antianginal drugs became ineffective. Treatment of heart failure: Since
data from studies on the efficacy of angiotensin converting enzyme (ACE)
inhibitors became available, all patients with impaired left ventricular func-
tion were treated with ACE inhibitors with or without digoxin and diuretics.
Treatment of hypertension: Calcium channel blockers, diuretics, beta blockers,
or ACE inhibitors were prescribed alone, or in combination, to achieve a sys-
tolic blood pressure < 160 mm Hg and a diastolic blood pressure < 95 mm Hg.
Treatment of valve disease: Patients with aortic or mitral valve disease were
treated with diuretics, ACE inhibitors, and/or vasodilators depending on the
severity of valve dysfunction and the type of valve disease. Valve replacement
or repair was considered whenever symptoms, echocardiographic findings, and
cardiac catheterisation data indicated the need for surgical intervention.
17-19
Echocardiography All measurements were averaged from three cardiac
cycles. Left atrial size (anteroposterior dimension) was obtained from the
parasternal long-axis view. All measurements were taken at end systole with
the inner edge to inner edge convention. Left ventricular diastolic and systolic
dimensions were measured in the parasternal long axis view, in accordance
with standard recommendations.
20 Fractional shortening was calculated as the
difference between end diastolic and end systolic dimensions divided by end
diastolic dimension.
Follow up procedure One, three, and six months after discharge, patients
were scheduled for outpatient department visits. Thereafter patients were seen
every six months. During each visit, the following items were assessed: com-
plaints, rhythm and rhythm history, drug use, NYHA class for exercise140
tolerance, and complications—for example, thromboembolic events, bleeding
events, admission for heart failure. Routinely, it also included a physical ex-
amination and a 12 lead ECG. Additional investigations (for example, a 24
hour ambulatory ECG) were performed depending on clinical status. In case of
death, data on the circumstances were obtained from hospital records, the
treating physician, the family doctor or a close relative.
Defenition of terms Persistent atrial fibrillation—Documentation of atrial
fibrillation on at least two occasions without intercurrent sinus rhythm at
consecutive outpatient visits, and continuous presence of atrial fibrillation
on a 24 hour Holter recording. Persistent atrial fibrillation has a non-sponta-
neously converting character and restoration of sinus rhythm is desirable,
in contrast to permanent atrial fibrillation when the arrhythmia is accepted
and cardioversion is no longer (or not) indicated.
21 Previously, both types of
atrial fibrillation were classified as chronic atrial fibrillation. Successful
cardioversion—Maintenance of sinus rhythm by the time of hospital discharge—
that is, more than eight hours after cardioversion. Heart failure complication—
Development or progression of heart failure during follow up requiring the
institution or addition of drug treatment, or hospital admission, including valve
surgery. Also included is death from progressive heart failure. Death from heart
failure—(Rapidly) progressive heart failure leading to death.
Data analysis and statistical methods For normally distributed variables,
values are given as mean (SD). Categorical variables are presented by fre-
quencies and percentages. In case of skewed distribution, the median values
and ranges are given. Comparison between groups with normally distributed
variables was performed by one way analysis of variance, and skewed vari-
ables by the Wilcoxon two sample test. Group comparison for categorical vari-
ables was performed by the Chi-square test with continuity correction or Fisher’s
exact test as appropriate. Univariate Cox regression analysis was used to iden-
tify the variables determining event-free survival. Continuous variables were
categorised in quartiles, and linearity of the calculated odds ratios with re-
spect to the response was assessed. If no linearity was demonstrated, quartiles
with comparable odds ratios were combined. From the univariate Cox regres-
sion analysis, variables with p values < 0.20 were selected for the multivariate141
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Cox regression analysis, and relevant first order interactions were tested, us-
ing the backward selection method. Survival curves were constructed using
the Kaplan-Meier method, and the p values from the Cox multiple analysis
are reported in the resulting survival plots. All p values are two sided, and a p
value < 0.05 was considered statistically significant. SAS version 6.12 (Cary,
North Carolina, USA) was used for all statistical evaluations.
RESULTS
Patients The baseline characteristics of the 342 study patients are given in
table 1. Mean follow up was 3.4 (1.6) years (range 1.0-6.9).
Table 1. Baseline characteristics of the 342 patients
Characteristic All patients
Male / female (n) 188 / 154
Age (years) * 62 ±12
< 57 years (n) 89 (26%)
57-64 years (n) 72 (21%)
64-71 years (n) 92 (27%)
> 71 years (n) 89 (26%)
Underlying heart disease ‡
Coronary artery disease (n) 84 (25%)
Rheumatic heart disease (n) 70 (21%)
Mitral valve disease, non rheumatic (n) 28 (8%)
Aortic valve disease, non rheumatic (n) 22 (6%)
Hypertension (n) 58 (17%)
Dilated cardiomyopathy (n) 26 (8%)
Other etiology § (n) 60 (18%)
Lone AF (n) 69 (20%)
Duration of AF (months) † 9 (0.1-420)
< 3 months (n) 79 (23%)
3-9 months (n) 89 (27%)
9-36 months (n) 80 (24%)
> 36 months (n) 87 (26%)
Previous AF episodes * 2 ±1
NYHA class I / II / III (n) 112/155/75
(33%/45%/22%)
Left atrial size (mm) * 46 ±8
LVEDD (mm) * 52 ±8
LVESD (mm) * 37 ±9
Fractional shortening * 0.30 ±0.09
AF = atrial fibrillation, LVEDD = left ventricular end diastolic diameter, LVESD = left ven-
tricular end systolic diameter, NYHA = New York Heart Association. * = mean ± standard
deviation, † = median with range. ‡ = more than one underlying disease per patient was
scored. § = patients with chronic obstructive pulmonary disease and hyperthyroidism.142
Table 2. Characteristics at baseline of patients who developed a heart failure
complication versus those without a heart failure complication
Characteristic HF No HF p-value**
complication complication
Patient number 45 297
Male / female (n) 26 / 19 162 / 135 0.75
Age (years) * 61 ±10 65 ±12 0.22
Underlying heart disease ‡
Coronary artery disease (n) 17 (38%) 67 (23%) 0.04
Rheumatic heart disease (n) 18 (40%) 52 (18%) <0.001
Mitral valve disease (n) 1 (2%) 27 (9%) 0.15
Aortic valve disease (n) 2 (4%) 20 (7%) 0.75
Hypertension (n) 4 (9%) 54 (18%) 0.14
Cardiomyopathy (n) 9 (20%) 16 (5%) <0.001
Other etiology § (n) 9 (20%) 51 (17%) 0.67
Lone AF (n)  0 (0%) 69 (23%) <0.001
Duration of AF (months) † 8 (0.1-192) 9 (0.1-420) 0.89
< 3 months (n) 15 (35%) 64 (22%) 0.08
3-9 months (n) 7 (16%) 82 (28%) 0.14
9-36 months (n) 7 (16%) 73 (25%) 0.25
> 36 months (n) 14 (33%) 73 (25%) 0.35
Previous AF episodes (#) * 2 ±14   ± 1 0.98
NYHA class I / II / III (n) 7/16/22 105/139/53 <0.001
(16%/36%/48%) (35%/47%/18%)
Left atrial size (mm) * 50 ±9 46 ±7 0.01
LVEDD (mm) * 56 ±9 51 ±8 <0.001
LVESD (mm) * 43 ±11 36 ±9 <0.001
FS * 0.25 ±0.10 0.30 ±0.09 0.01
AF = atrial fibrillation, FS = left ventricular fractional shortening, LVEDD = left ventricular
end diastolic diameter, LVESD = left ventricular end systolic diameter, HF complication =
heart failure event (development or progression), or heart failure death, NYHA = New York
Heart Association. * = mean ± standard deviation. † = median with range. ‡ = more than one
underlying disease per patient was scored. § = patients with chronic obstructive pulmonary
disease and hyperthyroidism.** = univariate p-value.
Heart failure complications Forty five patients (13% of all patients) suf-
fered from a heart failure complication during follow up: development or pro-
gression of heart failure occurred in 38 patients (11% of all patients), and 22
patients died from rapidly progressive heart failure (seven died without previ-
ous development or progression of heart failure during follow up). At the time
of the heart failure complication, 35 patients (78% of the 45 patients who de-
veloped such complications) were in atrial fibrillation after unsuccessful serial
electrical cardioversion. Additionally, more than 20 of these 35 patients had a
resting heart rate over 100 beats/min when the heart failure complication was
observed. In two patients, the occurrence of the heart failure complication was
clearly related to acute ischaemia.143
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The results of the univariate comparison of baseline characteristics of pa-
tients with and without a heart failure complication (development or progres-
sion of heart failure or death from heart failure during follow up, or both) are
given in table 2. Multivariate Cox regression analysis showed also that pa-
tients who developed heart failure complications suffered more often from coro-
nary artery disease (p < 0.001, risk ratio 3.2, 95% confidence interval (CI) 1.6
to 6.5), rheumatic heart disease (p < 0.001, risk ratio 5.0, CI 2.4 to 10.2), cardi-
omyopathy (p < 0.001, risk ratio 5.0, CI 2.0 to 12.4). Patients who had atrial
fibrillation for less than three months had a twofold increased risk of heart
failure complications (CI 1.0 to 3.7, p=0.04) compared to those with a duration
of more than three months. Finally, patients with a severely impaired exercise
tolerance at inclusion (NYHA class III for heart failure compared to class I or
II) had a 3.5-fold increased risk of heart failure complications (CI 1.9 to 6.7, p
< 0.001). In contrast, patients with lone atrial fibrillation were unlikely to
develop heart failure during follow up.
Figure 1 shows the probability of survival free from heart failure events—
that is, development or progression of heart failure (fig 1a)—or of not dying
Figure 1. Kaplan-Meier plots showing the probability (fig 1a) of heart failure event-free survival
(that is, free from the development or progression of heart failure) and (fig 1b) of not dying from
heart failure, in relation to the type of underlying disease. AF = atrial fibrillation, CAD = coronary
artery disease, CMP = dilated cardiomyopathy, HF = heart failure, RHD = rheumatic heart dis-
ease, UHD = underlying heart disease.
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Figure 2. Kaplan-Meier plots showing the probability (fig 2a) of heart failure event-free survival
(that is, free from the development or progression of heart failure) and (fig 2b) of not dying from
heart failure, in relation to the functional class for exercise tolerance at inclusion (NYHA class I
and II, versus NYHA class III). HF = heart failure, NYHA = New York Heart Association.
from heart failure (fig 1b) during follow up, in relation to the underlying dis-
ease. Patients with coronary artery disease (p < 0.048), rheumatic heart dis-
ease (p < 0.001), and cardiomyopathy (p < 0.008) suffered more often from
heart failure (fig 1a) than those with lone atrial fibrillation or other underly-
ing disease. Mortality from heart failure, however, was increased only in pa-
tients with coronary artery disease (p = 0.001) and cardiomyopathy (p = 0.02),
but not in patients suffering from rheumatic heart disease (fig 1b). Figure 2
shows the probability of survival free from heart failure events—that is, devel-
opment or progression of heart failure (fig 2a)—or of not dying from heart
failure (fig 2b) during follow up, in relation to the severity of heart failure at
inclusion (NYHA class for exercise tolerance). Patients in functional class III
for exercise tolerance at inclusion had a higher risk of either development or
progression of heart failure (p = 0.004, fig 2a) or death from heart failure (p <
0.001, fig 2b) during follow up. Death due to (rapid) progression of heart fail-
ure was rare in patients with asymptomatic or mild heart failure at inclusion
(functional class I or II).
At the end of follow up, 33 of the 45 patients (73%) who suffered from a
heart failure complication during follow up were in atrial fibrillation In con-
trast, 184 of the 297 patients (62%) without a heart failure complication were
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Figure 3. Kaplan-Meier plots showing the probability of maintenance of sinus rhythm in relation
to the severity of heart failure at inclusion (fig 3a) and the occurrence of a heart failure complica-
tion during follow up (fig 3b). HF-cpl = heart failure complication, NYHA = New York Heart Asso-
ciation, SR = sinus rhythm.
in atrial fibrillation (p = 0.03). Figure 3 shows the success of the serial electri-
cal cardioversion strategy in relation to the severity of heart failure at inclu-
sion (fig 3a), and in relation to the occurrence of a heart failure complication
during follow up (fig 3b). Both the patients with heart failure at inclusion and
those who suffered from heart failure complications during follow up had a
worse arrhythmia outcome—that is, no long term maintenance of sinus rhythm.
Only one patient suffered from progression of heart failure related to anti-
arrhythmic drug use. She started flecainide after successful cardioversion and
developed an exacerbation of heart failure one day later. She recovered after
discontinuation of flecainide and administration of diuretics. Flecainide was
instituted in this patient before the CAST data were published. Her cardiac
function was moderately impaired owing to an old anterior myocardial infarct.
Seven patients died of heart failure while on antiarrhythmic drug treatment
(amiodarone in all cases). All these patients suffered from end stage heart
failure and were on optimal heart failure treatment, including ACE inhibition,
diuretics, and digoxin. Four patients died in hospital and the other three died
at home. Although amiodarone related ventricular proarrhythmia cannot be
excluded for certain, this was unlikely, given the clear presence of end stage
heart failure.
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DISCUSSION
Our study showed that in patients with persistent atrial fibrillation, intensive
arrhythmia treatment with the intention of maintaining sinus rhythm did not
prevent the occurrence of heart failure complications. During follow up, these
complications predominantly occurred in patients with more severe underly-
ing cardiovascular disease and those with heart failure at the time of inclusion
(NYHA class III for exercise tolerance). In contrast, no heart failure complica-
tions occurred in patients with less severe underlying cardiovascular disease—
that is, in case of lone atrial fibrillation. Antiarrhythmic drug treatment, as
prescribed in the present study, did not seem be a significant cause of heart
failure complications.
Heart failure is a common finding in patients with atrial fibrillation.
1,5,22 In
our study group 22% of the patients were suffering from advanced heart fail-
ure (NYHA class III) at inclusion. Progression of, and subsequent death from,
heart failure was observed mainly in this group, despite an aggressive thera-
peutic strategy to maintain sinus rhythm. Interestingly, these patients also
showed a poor outcome of the serial electrical cardioversion approach. In other
words, both the prognosis of the underlying disorder and the outcome of the
arrhythmia were unfavourable in these patients. This could be explained by
the presence of more severe underlying disease and its deleterious effect on
clinical outcome. In addition after failure of the serial electrical cardioversion
approach and acceptance of atrial fibrillation, inadequate control of ventricu-
lar rate
23-26 and the irregularity of the heart rhythm per se
27,28 may have fur-
ther contributed to depressed haemodynamic function. The occurrence of heart
failure in patients with accepted atrial fibrillation was associated with a ven-
tricular rate over 100 beats/min in the majority, but this does not prove which
came first—inadequate control of ventricular rate leading to (additional) ven-
tricular dysfunctioning (that is, tachycardiomyopathy), or the occurrence of
heart failure with neurohumoral activation leading to high heart rates. In this
respect, we want to emphasise that during follow up 24 hour ambulatory elec-
trocardiography was performed to ensure maintenance of mean heart rates
below 100 beats/min in patients with accepted atrial fibrillation.
It is still controversial whether atrial fibrillation independently contrib-
utes to an increased mortality in heart failure patients, and whether atrial147
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fibrillation is an independent risk factor for sudden death or heart failure death.
Recently, it was suggested that survival of heart failure patients with or with-
out atrial fibrillation was comparable,
10 whereas previously a causal relation
between atrial fibrillation and mortality in such patients was suggested.
6 This
change was attributed to the more frequent use of amiodarone and ACE in-
hibitors in heart failure patients with atrial fibrillation, instead of class I anti-
arrhythmic drugs,
6,7,10 which have been associated with excess mortality, espe-
cially in the presence of heart failure.
16,29-31. In other words, survival of heart
failure patients with atrial fibrillation in general has improved over the past
years, confirming the view that the correct treatment of the underlying cardio-
vascular disease is of greater importance than the treatment of atrial fibrilla-
tion.
32 In line with these data are our present findings showing that progres-
sion of heart failure and death from heart failure occur predominantly in pa-
tients with more severe underlying disease or heart failure at entry to the
study.
Whereas patients suffering from coronary artery disease, rheumatic heart
disease, and dilated cardiomyopathy all developed heart failure, only those
with coronary artery disease and dilated cardiomyopathy had a higher mortal-
ity. This is probably related to successful surgical treatment in case of severe
valve disease. Unfortunately, heart failure induced by coronary artery disease
or dilated cardiomyopathy is progressive, and there are only limited prospects
for treatment at present. In the present study, progression of heart failure and
heart failure death could not be related to antiarrhythmic drug use; this prob-
ably reflects our prudent prescription of class IC drugs and in-hospital initia-
tion of antiarrhythmic drug treatment.
33 Only one patient developed heart fail-
ure after initiation of flecainide treatment, and this resolved after flecainide
was discontinued. In addition, we did not prescribe class IA drugs, such as
quinidine, which may also have harmful effects.
29,34
Lone atrial fibrillation was not associated with heart failure nor with death
from heart failure. Our present data compare favourably with those on pa-
tients with lone atrial fibrillation in the Framingham study,
35 and with the
study of Kopecky et al.
36 This implies that atrial fibrillation in the setting of no
or only minor heart disease is a relatively benign condition, with respect to
heart failure and mortality. Rather unexpectedly, atrial fibrillation of short
duration (less than three months) was associated with heart failure148
complications. Perhaps this relates to the fact that the development of atrial
fibrillation in the setting of heart failure may be a consequence of worsening
haemodynamics,6 which in turn may cause further deterioration in the clinical
and haemodynamic situation.9
Limitations of the study This non-randomised study did not compare the
cardioversion strategy with the rate control strategy in patients with persis-
tent atrial fibrillation and heart failure. Such a comparison might have deter-
mined whether cardioversion treatment could be omitted in patients who have
poor success rate with cardioversion. However, our data suggest that instead
of cardioversion therapy as a first line measure, treatment should focus on the
underlying cardiovascular disease. Ongoing randomised studies comparing both
strategies might answer this latter question.37,38 Furthermore, we did not thor-
oughly investigate the effect of inadequate control of ventricular rate (particu-
larly during daily exercise) on the development of tachycardiomyopathy in
patients with accepted atrial fibrillation, although ventricular rate was con-
trolled as far as possible using 24 hour ambulatory electrocardiography.
Finally, the question what is the optimal antiarrhythmic drug for preven-
tion of atrial fibrillation in patients with heart failure cannot be answered
from our study. The benefit of serial antiarrhythmic drugs on the maintenance
of sinus rhythm seems limited, especially in patients with heart failure.
Amiodarone might be a good first line antiarrhythmic drug in heart failure
patients, but this remains to be proven.
Clinical implications Our data indicate that the application of serial electri-
cal cardioversion neither prevents heart failure complications nor is very suc-
cessful in restoring and maintaining sinus rhythm. These findings suggest
that the rate control strategy would be a suitable alternative, but a randomised
comparison of both strategies is needed to draw more definite conclusions. We
are therefore eagerly awaiting data from studies randomising patients to ei-
ther serial electrical cardioversion or rate control therapy, such as the
AFFIRM,37 PIAF,38 and RACE study (currently underway in The Netherlands).
These studies are likely to answer the question of whether the rate control
strategy might be adopted earlier in patients with atrial fibrillation in the
setting of heart failure and underlying disease.149
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ABSTRACT
We investigated the effect of electrical cardioversion of atrial fibrillation in
patients with heart failure. The study group consisted of 24 patients with mild
to moderate heart failure (13 men, mean age 67±7 years, mean peak VO2
16.3±2.8 ml/min/kg) and chronic atrial fibrillation (median duration 19 (1-228)
months). Patients were stable on digoxin, diuretics, nitrates and angiotensin
converting enzyme inhibitors; no prophylaxis with antiarrhythmics was star-
ted after cardioversion. Cardioversion was unsuccessful in 6 patients; of the
18 patients in whom sinus rhythm was obtained 9 had a relapse of atrial
fibrillation within 6 weeks after cardioversion. The remaining 9 patients with
maintenance of sinus rhythm and the 15 (6+9) patients with atrial fibrillation
at follow-up after 6 weeks did not differ with respect to any baseline characte-
ristic, including age, peak VO2, duration of atrial fibrillation, echocardiographic
left ventricular and left atrial dimensions, plasma atrial natriuretic peptide
and norepinephrine. In the patients with maintenance of sinus rhythm, baseline
measurements were repeated at follow-up. Peak VO2 did not change signifi-
cantly (16.7±2.8 to 17.6±3.3 ml/min/kg, P=0.29); also, echo parameters, atrial
natriuretic peptide and norepinephrine were not significantly affected. These
results indicate that it is difficult to achieve lasting sinus rhythm through
electrical cardioversion in patients with atrial fibrillation and mild to moderate
heart failure. Moreover, in patients with maintenance of sinus rhythm after
cardioversion no significant benefit in terms of peak VO2, cardiac dimensions,
and neurohumoral status is to be expected. Hence, indiscriminate cardioversion
of atrial fibrillation in the setting of heart failure does not appear to be useful.
INTRODUCTION
In atrial fibrillation, loss of atrial contraction, deranged mitral and tricuspid
valve closure and the irregular and often fast ventricular rate (particularly
during exercise), may be detrimental to cardiac function.
1-3 As a consequence,
exercise capacity in patients with atrial fibrillation may be reduced.
4 Cardio-
version of atrial fibrillation to sinus rhythm is therefore advocated, and has
indeed been shown to improve exercise capacity. Several studies have thus
demonstrated a substantial increase in peak oxygen consumption (peak VO2)156
after cardioversion of atrial fibrillation. On average, the increase in peak VO2
amounted to at least 10%, ranging from 8% to as much as 25%.
5-9
In the above studies, however, only patients with relatively preserved
exercise capacity were included; mean peak VO2 prior to cardioversion was
>20 ml/min/kg in all 5 studies. The effect of cardioversion of atrial fibrillation
on exercise capacity in patients with heart failure is unknown. Yet, reliable
data are needed since 1) heart failure is very common in patients with atrial
fibrillation,
10 and 2) an increase in exercise capacity would obviously be welcome
in these patients. In the present study, we addressed this issue in a well-defi-
ned group of patients with atrial fibrillation and mild to moderate heart failure.
In addition to the effect on peak VO2, effects of cardioversion on heart rate,
echocardiographic and neurohumoral status were analyzed. Findings were also
related to arrhythmia outcome, i.e. the likelihood of long-term sinus rhythm in
these patients.
METHODS
Patient population The study group consisted of 24 patients with stable
mild to moderate heart failure and chronic atrial fibrillation (duration > one
month). Patient characteristics are listed in Table 1. All patients were on chronic
anticoagulant therapy. The study was approved by the institutional ethics
committee and written informed consent was obtained from each patient.
Study design Patients underwent the following baseline tests: exercise tes-
ting, echocardiography, Holter monitoring, and analysis of neurohumoral sta-
tus. Then, electrical, direct-current cardioversion was performed, according to
a previously described protocol.
11 Briefly, the protocol consisted of subsequent
steps of increasing energy, starting off with 50 J; the next steps were 100 J,
200 J, and 360 J. The procedure was ended after restoration of sinus rhythm
or 2 attempts at 360 J. Failure to obtain sinus rhythm meant completion of the
study; recurrence of atrial fibrillation within one day (i.e. prior to discharge
from hospital) was not considered an immediate failure, but an early relapse.
Patients in whom sinus rhythm was obtained were followed up for 6 weeks. If
sinus rhythm was noted on a 12-lead-electrocardiogram, baseline tests were
repeated. Drug treatment was kept unchanged for the entire duration of the157
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Table 1. Patient characteristics
Patient number 24
Age (years) 67±7
Sex (male/female) 13/11
NYHA functional class II/III 16/8
Duration of atrial fibrillation (months)* 19 (1-228)
No. of prior cardioversions* 0 (0-4)
Underlying heart disease
Coronary artery disease 7 (29%)
Valvular disease 5 (21%)
Hypertension 3 (12%)
Idiopathic dilated cardiomyopathy 9 (38%)
Medication
Digoxin 20 (83%)
Calcium antagonists 7 (41%)
Diuretics 13 (54%)
Long-acting nitrates 4 (17%)
ACE inhibitors 10 (42%)
Blood pressure (mmHg)
At rest 146±23/82±23
At peak exercise 182±34/85±18
Heart rate (beat/min)
At rest 89±18
At intermediate exercise 103±22
At peak exercise 158±22
Peak VO2 (ml/min/kg) 16.3±2.8
% predicted peak VO2 72±19
Exercise duration (s) 772±246
Echocardiographic parameters
LV enddiastolic dimension (mm) 55±6
LV endsystolic dimension (mm) 40±7
LV fractional shortening (%) 27±7
Left atrial volume (ml)* 88 (51-230)
24-hour heart rate (beats/min) 83±11
No.VPC/h* 30 (1-761)
Norepinephrine (nmol/l)
At rest 2.8 (1.3-5.3)
At intermediate exercise 8.9 (3.3-33.0)
At peak exercise 15.6 (2.1-58.6)
Atrial natriuretic peptide (pmol/l)
At rest 71 (14-146)
At intermediate exercise 76 (24-201)
At peak exercise 84 (36-386)
*Values are given as median, with range.
ACE, angiotensin converting enzyme; NYHA, New York Heart Association; Peak VO2, pe-
ak oxygen consumption; VPC, ventricular premature contraction.
study, including drugs used to control ventricular rate during atrial fibrilla-
tion.
Exercise testing Exercise capacity was determined during symptom-limited
exercise testing with gas exchange analysis, as previously described in detail.
12158
In short, tests were performed on a treadmill, according to a modified Naughton
protocol. All patients were familiar with the test, since they had performed at
least one prior test. Oxygen consumption, carbon dioxide production, and expira-
tory exchange ratios were measured continuously during exercise by an auto-
mated gas exchange system. Peak VO2 was defined as oxygen consumption
(ml/min/kg) at peak exercise. Values were also expressed as percentage of
predicted peak VO2 (i.e. corrected for age and sex) using establised formulas.
13
The electrocardiogram was monitored continuously; the heart rate response to
exercise was analyzed by measuring mean heart rate during a period of 15
seconds at the end of each stage of exercise.
14 To investigate specifically heart
rate during intermediate levels of exercise, the mean heart rate from stage 1
to 4 was calculated.
Echocardiography Methods have been detailed elsewhere.
15,16 Briefly, left
ventricular diastolic and systolic dimensions were measured in the paraster-
nal long-axis view. Fractional shortening was calculated as the difference
between enddiastolic and endsystolic dimensions divided by the endsystolic
dimension. Left atrial dimensions were measured in 3 orthogonal directions,
allowing calculation of left atrial volume: anteroposterior dimension
(parasternal long-axis view) and superoinferior and mediolateral dimension
(apical four-chamber view). Left atrial volume was calculated, assuming that
the atrial cavity resembled a prolate ellipse.
15
Holter-monitoring Twenty-four-hour Holter recordings were made using a
Marquette Holter system. The recordings were analyzed for type of rhythm;
the first recording confirmed the presence of chronic atrial fibrillation and the
second recording checked the maintenance of sinus rhythm. Furthermore, the
mean heart rate during 24 hours and ventricular ectopic activity were analyzed
in each recording.
Neurohumoral variables Venous blood for determination of plasma atrial
natriuretic peptide and norepinephrine was obtained after 30 minutes of supine
rest preceding the test and at peak exercise. In addition, to analyze the response
to intermediate exercise, samples were also drawn after 6 minutes of exercise,
i.e. at the end of stage 3 of the exercise protocol (treadmill speed 3.2 km/h and159
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slope 0%). Atrial natriuretic peptide concentration was determined with
radioimmunoassay using a commercially available [
125I]atrial natriuretic
peptide tracer and a highly specific antibody,
17 and norepinephrine concen-
trations were determined with high-performance liquid chromatography.
18
Normal values during supine rest in our laboratory are 3-23 pmol/l and
1.54±0.03 nmol/l, respectively.
Data analysis and statistics Data are expressed as mean ± standard
deviation. Median values with range were used in case of a nonuniform
distribution of variables. Findings in patients who were in sinus rhythm at
follow-up were compared with findings in patients who could not be cardiover-
ted or who had a recurrence of atrial fibrillation. Further, exercise, echocardio-
graphic, and Holter data in patients with maintenance of sinus rhythm were
analyzed, comparing pre and postcardioversion (i.e. baseline and follow-up).
For comparison of groups, continuous, normally distributed variables were
tested by ANOVA. Variables with a nonuniform distribution were tested with
Table 2. Effects of cardioversion in patients with maintenance of sinus rhythm
Pre Post P
cardioversion cardioversion value
NYHA functional class 2.2±0.4 1.9±0.3 0.22
Peak VO2 (ml/min/kg) 16.7±2.8 17.6±3.3 0.29
Exercise duration (s) 853±282 816±196 0.60
LV enddiastolic dimension (mm) 54±55 4 ± 9 0.93
LV endsystolic dimension (mm) 40±84 0 ± 11 1.00
LV fractional shortening (%) 26±92 5 ± 10 0.36
Left atrial volume (ml)* 79 (51-119) 69 (43-103) 0.41
24-hour heart rate (beats/min) 79±97 5 ± 9 0.41
No. VPC/h* 34 (1-761) 14 (0-317) 0.36
Norepinephrine (nmol/l)*
At rest 2.7 (1.5-5.0) 2.4 (1.1-11.1) 0.69
At intermediate exercise 5.2 (4.2-31.2) 7.6 (2.7-10.9) 0.47
At peak exercise 12.6 (7.2-44.8) 10.6 (3.7-37.5) 0.41
Atrial natriuretic peptide (pmol/l)*
At rest 63 (35-146) 57 (26-167) 1.00
At intermediate exercise 66 (35-138) 57 (25-176) 0.44
At peak exercise 137 (49-255) 72 (57-230) 0.44
LV, left ventricular; NYHA, New York Heart Association; VPC, ventricular premature
contraction. Note: neurohormones are based on 7 of the 9 patients, since no samples were
obtained in 2 patients after cardioversion. Data on heart rate are given in Figure 2160
Figure 1. Effect of restoration of sinus
rhythm on peak VO2 in individual patients.
Mean peak VO2 before cardioversion (Pre
CV) and after cardioversion (Post CV) did
not differ significantly. Values were 16.7±2.8
ml/min/kg and 17.6±3.3 ml/min/kg, respecti-
vely (P=0.29).
the Wilcoxon two sample-test. Categorical variables were tested by the 2-tailed
Fisher-exact test or the chi-square test if appropriate. A P-value <0.05 was
considered significant.
RESULTS
Immediate and subsequent results of cardioversion Cardioversion was
uncomplicated in all patients. In 18 of the 24 patients (75%) atrial fibrillation
was successfully cardioverted to sinus rhythm. During the 6-week follow-up
after cardioversion 9 of these 18 patients had a recurrence of atrial fibrillation.
Thus, after 6 weeks 9 patients (37%) of the initial 24 patients were in sinus
rhythm, whereas 15 (6+9) patients (63%) were in atrial fibrillation (either due
to failed cardioversion or to recurrence of atrial fibrillation).
Comparison of patients with sinus rhythm versus atrial fibrillation
Patient characteristics did not differ between patients with initial successful
cardioversion and patients with failed cardioversion. Also, no statistically
significant differences were found in patient characteristics between patients161
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with maintenance of sinus rhythm after cardioversion and those with atrial
fibrillation at follow-up. In particular, age (64±8 versus 69±7, P=0.14), peak
VO2 (16.7±2.8 versus 16.2±2.8 ml/min/kg, P=0.70), and left atrial size (75
(51-119) versus 86 (58-230) ml, P=0.82) did not differ significantly.
Effect of cardioversion The effects of cardioversion in patients with mainte-
nance of sinus rhythm are presented in Table 2, and Fig. 1 and Fig. 2. Mean
New York Heart Association functional class improved, though not significantly.
Similarly, peak VO2 increased in several patients after restoration of sinus
rhythm, however, in other patients peak VO2 did not change, or even decreased
slightly. Mean peak VO2 increased 0.9 ml/min/kg (+5%), which was not signifi-
cant (P=0.29). Exercise duration did not improve either; in fact, it tended to be
even shorter after cardioversion. The other variables also did not change
Figure 2. Effect of restoration of sinus rhythm on heart rate during successive stages of exercise.
Resting heart rate before cardioversion (Pre CV) and after cardioversion (Post CV) did not differ
significantly (87±19 beats/min and 78±19 beats/min, respectively (P=0.21)). However, mean heart
rate decreased significantly during exercise: mean heart rate during intermediate exercise (stage
1 to 4) was 119±27 beats/min before cardioversion and 102±23 beats/min after cardioversion (P=0.03).
Also, heart rate at peak exercise was lower after cardioversion: 168±20 beats/min and 143±17
beats/min, respectively (P=0.04).162
significantly, with the exception of heart rate during exercise; whereas heart
rate at rest did not differ significantly, heart rate during exercise was lower
during sinus rhythm than during atrial fibrillation, both during intermediate
exercise and at peak exercise.
DISCUSSION
The results of this study suggest that limited clinical benefit is to be expected
from indiscriminate electrical cardioversion of chronic atrial fibrillation in
patients with concomitant mild to moderate heart failure. Firstly, it was diffi-
cult to obtain lasting sinus rhythm; even after a relatively short follow-up period
of 6 weeks after cardioversion, only a minority of patients in the present study
was in sinus rhythm, whereas the majority was in atrial fibrillation, either
due to initially failed cardioversion or due to a relapse of atrial fibrillation.
Secondly, patients with successful cardioversion and subsequent maintenance
of sinus rhythm did not differ significantly from the other patients, thus making
it difficult to identify them beforehand. Thirdly, in the patients with successful
cardioversion and maintainance of sinus rhythm, clinical status did not
significantly improve. Though New York Heart Association functional class
and several variables (exercise, echocardiographic and neurohumoral) showed
favorable trends, exercise capacity, both in terms of exercise duration and peak
VO2, did not significantly change.
The Framingham Heart Study has clearly demonstrated that heart failure
significantly increases the likelihood of development of atrial fibrillation.
19,20
Left ventricular function is also an important determinant of both successful
cardioversion and subsequent maintenance of sinus rhythm.
11,21,22 As to the
underlying mechanism, the arrhythmogenic effects of increased atrial filling
pressures (and hence atrial stretch) as well as neurohumoral activation
(especially sympathetic activation) are deemed to play a role.
23,24 The present
study adds to the importance of heart failure in the genesis of atrial fibrilla-
tion. Though several other factors may also have adversely affected arrhythmia
outcome, including the fact that patients were relatively old, the duration of
atrial fibrillation was rather long, and left atrial size was large, it is tempting
to assume that heart failure contributed to poor arrhythmia outcome. Judging
from the elevated plasma atrial natriuretic peptide and norepinephrine levels,163
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both increased atrial filling pressures and sympathetic activation may indeed
have played a role.
The principal importance of heart failure per se is apparent also from the
observed lack of a significant effect of cardioversion on exercise capacity
measured by both exercise duration and peak VO2. Whereas restoration of
sinus rhythm is associated with a substantial increase in peak VO2 in patients
with atrial fibrillation without underlying structural heart disease (“lone” atrial
fibrillation) and those with limited disease and relatively preserved exercise
capacity,
5-9 peak VO2 in the present patient group with heart failure did not
increase significantly after cardioversion. In other words, unlike the role of
atrial fibrillation in patients with less advanced disease, the impact of atrial
fibrillation on peak VO2 in patients with heart failure would appear to be rather
limited. This contention is supported by our observation that left ventricular
shortening was also unaffected by cardioversion. Furthermore, these findings
are in agreement with studies on the effect of atrial fibrillation on mortality in
heart failure patients; overall, atrial fibrillation carries no independent risk.
25,26
Having said that, one may speculate about possible causes for the apparent
insignificance of atrial fibrillation in the setting of heart failure. One possibility
relates to observations that the atrial contribution to ventricular filling may
be diminished rather than increased in patients with heart failure.
27-29 According
to these studies, decreased left ventricular compliance and already-elevated
enddiastolic filling pressures impede further filling through atrial contraction
(“restrictive filling”). Conceivably, loss of atrial contraction in case of atrial
fibrillation would thus have minor hemodynamic consequences. It is, however,
questionable whether this factor played a significant role since heart failure in
our study was probably less severe than in the above studies.
Another important issue also pertains to atrial function; it cannot be
excluded that recovery of atrial systolic function was still incomplete in
individual patients 6 weeks after cardioversion. It has been shown that this
process may take more time in case of longstanding atrial fibrillation.30 A final
possible cause for the limited effect of restoration of sinus rhythm on peak VO2
relates to the effect of sinus rhythm versus that of atrial fibrillation on the
heart rate response to exercise. Whereas heart rate at peak exercise was within
normal limits during atrial fibrillation, values during sinus rhythm were well
below normal (i.e. corrected for age and sex).31 Peak VO2, which by definition164
reflects performance at peak exercise, would presumably have been higher if
heart rate at peak exercise had been higher. As such, cardiac efficiency, expres-
sed as oxygen pulse (peak VO2 divided by heart rate at peak VO2),
8 might in
fact have been higher during sinus rhythm. Anyhow, the fact that drugs used
for rate control (particularly calcium-antagonists) were continued after cardi-
oversion presumably played a role in lowering peak heart rate. Also, chronotro-
pic incompetence as such was probably involved, chronotropic incompetence
being a recognized feature of patients with heart failure and sinus rhythm.
32
By contrast, from the present study as well as other studies 
12,25 it would appear
that chronotropic incompetence does play a less pronounced role in heart failure
patients with atrial fibrillation; despite the fact that sympathetic drive in the
present study was comparable during atrial fibrillation and sinus rhythm (jud-
ging from the plasma norepinephrine levels), the chronotropic response during
atrial fibrillation was clearly more marked than during sinus rhythm, including
peak heart rate. The explanation for this apparent difference should obviously
be sought in the differences between sinus rhythm and atrial fibrillation in
impulse formation and conduction, and the susceptibility of the related structu-
res to the effects of heart failure. In this connection, the fact that atrioven-
tricular node function (the atrioventricular node being the main determinant
of ventricular rate in atrial fibrillation) is affected more by beta-2 than beta-1
receptor stimulation,
33,34 and that beta-2 receptors are less susceptible to down-
regulation,
35 might be of relevance.
Since sample size was small the results should be considered with caution.
Thus, larger sample size might have rendered significant predictors of
arrhythmia outcome, which now merely showed a trend (for instance age,
exercise duration, and plasma norepinephrine). Also, the effect of restoration
of sinus rhythm on peak VO2 might thus have attained statistical significance,
though it is doubtful whether the observed increase is clinically significant.
The same holds true for several secondary measures of outcome, including left
atrial size and atrial natriuretic peptide. It cannot be excluded that follow-up
was too short for some potentially beneficial effects of restoration of sinus
rhythm to become apparent, for instance New York Heart Association functio-
nal class. On the other hand, longer follow-up would probably have resulted in
an even higher recurrence rate of atrial fibrillation, nullifying any beneficial
effect of cardioversion. In this connection, it should be realized that no165
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antiarrhythmics were given to prevent recurrence of atrial fibrillation. However,
it should be stressed that these agents may be harmful in the setting of heart
failure, both due to their negative inotropic and proarrhythmic effects,
36 though
a recent study suggests that amiodarone may be safe and efficacious.
37 In view
of the above limitations, this study should not be taken to suggest that cardiover-
sion should be withheld in all patients with heart failure and atrial fibrillation.
Nevertheless, our findings do indicate that indiscriminate cardioversion is not
warranted. Larger studies should be performed to identify which patients may
indeed benefit from cardioversion, both in terms of maintenance of sinus rhythm
and subsequent clinical improvement.
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ABSTRACT
Introduction After mitral valve (MV) surgery preoperative atrial fibrillation
(AF) often recurs while cardioversion therapy generally fails. Additional Cox-
maze surgery improves postoperative arrhythmia outcome but the extensive
character of such an approach limits general appliance. We investigated clinical
outcome of a simplified, less extensive Cox-maze procedure (“mini-maze”) as
adjunct to MV surgery.
Methods and Results Thirteen patients with MV disease and preoperative
AF were treated with combined surgery (Group 1). Nine control patients without
previous AF underwent isolated MV surgery (Group 2). We also compared
retrospectively to 23 patients with preoperative AF who had undergone isolated
MV surgery (Group 3). In group 1, mini-maze took an additional 46-minutes of
perfusion time. One 75-year old patient died of postoperative multiple organ
failure. Seven patients showed spontaneously converting (within 2-months)
postoperative AF. After 1-year, 82% were in sinus rhythm (SR). No sinus node
dysfunction was observed. In group 2, all patients were in SR after 1-year. In
group 3, only 53% were in SR after 1-year, despite serial cardioversion and
anti-arrhythmic drug therapy. Exercise tolerance and heart rate were
comparable for groups 1 and 2. Left-atrial function was present in all patients
but one in group 1 and in all patients in group 2 (after MV reconstruction).
Conclusion Adding a relatively simple mini-maze to MV surgery improves
arrhythmia outcome in patients with preoperative AF without introducing sinus
node dysfunction or persistent absence of left-atrial function. This type of
combined surgery is encouraging and deserves further attention.
INTRODUCTION
Atrial fibrillation (AF) is generally difficult to treat in terms of long-term main-
tenance of sinus rhythm (SR). AF is often associated with underlying cardio-
vascular disease such as hemodynamically significant mitral valve (MV) dis-
ease. Although MV surgery usually improves cardiac function,
1 it does not pre-
vent the recurrence of preoperative AF.
2 In addition, serial cardioversion therapy
for AF after valvar replacement is rather ineffective,
3 labeling the arrhythmia
as “medically refractory” and acceptance seems the only remaining option.172
Alternatively, after several surgical strategies were tested,4,5 the “maze” proce-
dure according to Cox became available for medically refractory AF and is now
the generally preferred surgical option.6-8 The results are satisfactory, but the
operation is quite elaborate. Several modifications of the operative technique
have led to success rates of 84% of patients remaining in SR (after at least 6-
months of follow-up) who underwent MV surgery combined with a maze proce-
dure.9
Many physicians, however, are reluctant to combine MV surgery with a
maze procedure, because of the extent of the operation. Simplifying the tech-
nique of the maze procedure could overcome this reluctance while maintain-
ing the advantage, i.e., SR throughout the atria with appropriate sinus node
function and atrial contractility. In an animal model, a very basic atrial ar-
rythmia operation consisting only in isolation of the pulmonary veins and re-
moval of the appendages proved to be highly effective in inhibiting re-induc-
tion of AF.10 Therefore, we aimed (1) to investigate the resulting rhythm in
patients with preoperative AF undergoing MV surgery combined with a less
extensive, simplified maze procedure (“mini-maze”) and to compare them with
patients in SR undergoing only MV surgery; and (2) to assess immediate and
long-term complications of this kind of combined surgery.
METHODS
Study patients Enrolled were patients with an indication for isolated mitral
valve surgery (1996 and onwards). The decision to intervene surgically was
made by the in-house cardiosurgical team; standard clinical and hemodynamic
criteria were applied to assess the indication for cardiac surgery. Advanced
age (> 75-year), significant co-morbidity (i.e., pulmonary disease), organic dis-
ease (limiting prognosis), instable heart failure (NYHA class IV), preoperative
signs of sinus node dysfunction, redo-surgery, or an increased risk for opera-
tive complications, i.e., overweight, were contraindications for study partici-
pation. Before cardiac surgery, the clinical characteristics of each patient (in-
cluding medication use and exercise tolerance according to the NYHA classifi-
cation) were assessed by one investigator (AET). Rhythm characteristics (e.g.,
presence, type, and duration of AF) were assessed using the patient’s history
and previous electrocardiograms. Echocardiographic data were obtained within173
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the 3-months prior to cardiac surgery.
Thirteen patients with preoperative AF were included (Group 1). These
patients had present persistent AF (n=8), or a previous episode of either
paroxysmal or persistent AF which was treated with pharmacological or elec-
trical cardioversion therapy (n=5). These 13 patients underwent the mini-maze
procedure (see section on “operative procedure”) concomitantly with the
primary MV surgery. Nine patients in SR underwent isolated valvar surgery
and served as controls (Group 2). Patients in this group were without any
previous episode of AF.  For retrospective comparison of long-term arrhythmia
outcome, 23 patients with preoperative AF and MV replacement without ar-
rhythmia surgery from before 1996 were used (Group 3).3 This “historic” group
underwent serial electrical cardioversion with serial anti-arrhythmic drug
(AAD) institution for postoperative persistent AF. Table I shows the character-
istics of the study patients (Groups 1 and 2) and historic patients (Group 3).
The investigation conforms with the principles outlined in the Declaration
of Helsinki, was approved by the Institutional Review Board, and written
informed consent was given by all patients.
Preoperative procedure All class I and III AAD were discontinued at least
5 half-lives prior to the moment of cardiac surgery. Continuation of rate control
medication with a calcium-entry blocker and/or digoxin was allowed until the
day before surgery, then it was discontinued. Oral anticoagulant therapy
(acenocoumarol) for the prophylaxis of thromboembolism secondary to AF was
discontinued 2-days before surgery. Beta-adrenergic blockers were reduced to
half the dosage the day before surgery, and thus continued.
Operative procedure Anesthesia was induced with midazolam, sufentanyl
and pancuronium bromide, and maintained thereafter with an infusion of
midazolam and sufentanyl, occasionally supplemented by isoflurane. All
patients received dexamethasone (1 mg/kg). Cardiopulmonary bypass was
performed at 28-30 °Celsius. Cold St Thomas cardioplegia was used to arrest
the heart. In case of AF, intra-thoracic epicardial electrical cardioversion was
attempted before institution of cardiopulmonary bypass. Three patients in
AF (23%)  could not be cardioverted immediately before surgery.
The mini-maze procedure was performed by one single experienced174
Figure 1. Artistic drawing of the minimal maze procedure or mini-maze, showing the critical
locations of the atrial incisions and cryo-ablating sites. The upper picture of the atria is in
anteroinferior view, asterisks indicating cryo-ablation on the AV-ridges. The lower picture of the
atria is in posterosuperior view, showing the circumferential isolation of the pulmonary veins.
Both pictures illustrate the removal of the atrial appendages.
surgeon (JGG) familiar with maze III surgery for “lone” AF. The mini-maze
resembles the Cox-maze III procedure,
11 but is without the incisions in the
inter-atrial septum and most of the incisions on the posterior side. Figure 1
shows the positions of the sutures and cryo-ablation used for the mini-maze
procedure. In short, the atrial appendages were removed, the pulmonary
veins were all isolated by a single circumferential suture line, one right-atrial
longitudinal incision was made which left the sinus node artery region
unaffected, and local cryo-ablation was applied to the coronary sinus and on
the positions where the incisions approached the tricuspid and MV annulus.
Taking into account that the left-atrial paraseptal incision for the MV inter-
vention was already made, the mini-maze took an additional 46-minutes of175
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cardiopulmonary bypass time or 33-minutes of aortic cross-clamp time on
average (compared to group 2). The procedure was considered successful when
SR was re-established. Concomitant MV surgery was performed according to
standard operative procedures, i.e., when technically feasible (guided by
echocardiography), the MV was reconstructed with the support of a Carpentier-
Edwards ring (n=9), otherwise a valvar prosthesis was inserted (n=4). All SR
patients (n=9) underwent isolated MV reconstruction. After completion of
surgery, temporary epicardial pacing leads were left behind at the right-atrial
free wall and right-ventricle to be used in case of postoperative bradycardia.
Postoperative procedure During recovery from surgery the patients were
treated according to in-hospital standard postoperative procedures including
pericardial and bilateral pleural drains, forced mechanical ventilation during
1-day, positive inotropics, diuretics, analgesics (NSAIDs and opiate-drugs), and
antibiotics (48-hours cefamandol in all patients). All patients started with (or
continued) low dose beta-adrenergic blocker at day 1 after surgery. No class I
or III AAD therapy was instituted. Postoperative AF was treated with rate-
control using verapamil (on top of adequate dose beta-adrenergic blocker) when
indicated. Oral anticoagulant therapy (e.g., acenocoumarol) was initiated at 1
or 2 days after surgery (depending on drain blood loss). Anticoagulation above
2.5 international-normalized-ratio (INR) was considered adequate. Oral
anticoagulant therapy was discontinued 3-months after surgery in patients
with a valvar reconstruction, but continued in patients who received a valvar
prosthesis. In patients who underwent the mini-maze, oral anticoagulant
therapy was only discontinued when a transmitral A-wave signal (indicative
for left-atrial contractility) was present on Doppler echocardiography.
Thereafter, they received aspirin. The mini-maze patients prophylactically
received low dose spironolactone (25 mg tid) from the first day for at least one
week because maze procedures are associated with immediate postoperative
fluid retention, related to temporary atrial natriuretic peptide depletion.
12
Persistent atrial arrhythmia recurrences during follow-up were treated
with electrical cardioversion and AAD (sotalol, amiodarone) therapy. Conditions
for acceptance of the arrhythmia consisted in failure of amiodarone, significant
co-morbidity limiting prognosis, or refusal to undergo (another) cardioversion.176
Postoperative measurements Follow-up intervals: During recovery from
surgery, patients were monitored daily for clinical condition and rhythm
(continuous telemetry) until hospital discharge. One month after surgery,
transthoracic echocardiography, ambulatory electrocardiography, and an
exercise tolerance test were performed. These cardiac function tests were
repeated (on the same day) after 3-months and 1-year. Thereafter, patients
were seen on a 6-months basis, and cardiac function tests were repeated only
when indicated. The median follow-up duration was 17-months (range 3-26
months).Transthoracic echocardiography: Atrial measurements were taken
at end-systole according to the inner edge - inner edge convention and averaged
from 3 cardiac cycles. The left-atrial anteroposterior dimension was obtained
from the parasternal long-axis view; left-atrial mediolateral and superoinferior
dimensions were measured from the apical 4-chamber view.
Left-ventricular diastolic and systolic dimensions were measured in the
parasternal long-axis view, in accordance with standard recommendations.
13
Doppler ultrasound was used to measure postoperative peak flow velocities
over the atrio-ventricular (AV) valves, e.g., E-wave (early ventricular filling
phase) and A-wave(late or atrial contribution to ventricular filling phase).
Exercise tolerance test: Symptom limited bicycle test, starting the first minute
at 50 Watts and increasing with 10 Watts every 30 seconds (modified Bruce
protocol). Ambulatory electrocardiography: 24-hours of electrocardiographic
registration was performed using a 3-channel Marquette Holter recorder (series
8500). Data analysis was done on a Marquette Laser Holter Systems analyzer
(series 8000 XP) with standard software (version 5.8; Marquette, Milwaukee,
WI).
Definitions Persistent AF: continuous presence of AF until the moment of
cardiac surgery, i.e., at least two consecutive electrocardiograms with AF more
than 24-hours apart, without intercurrent SR. Persistent AF does not
spontaneously convert to SR. but is considered cardiovertible.
14 Previously, this
type of AF was classified as chronic AF. Paroxysmal AF: AF typically occurring
in episodes of shorter duration than 24-hours (though paroxysms may
occasionally last longer) with intermittent SR. Paroxysmal AF either converts
spontaneously or can be terminated with an intravenously administered AAD.
14177
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Table 1. Characteristics of the study patients
Group 1 Group 2 Group 3
Mini-Maze Control Historic
Patient number (n) 13 9 23
Male / female 6 / 7 6 / 3 5 /18
Age (year) 57 ± 12 56 ± 13 57 ± 12
Cardiac surgery
Mitral valve reconstruction (n) 9 9 0*
Mitral valve prosthesis (n) 4 0 23*
Mini-maze procedure (n) 13 0* 0*
Cardiopulmonary bypass time (min.) 145 ± 28 99 ± 26* 140 ± 41
Aortic cross-clamp time (min.) 90 ± 23 57 ± 16* 78 ± 21*
Mitral valve disease (n)
Mitral regurgitation 12 9 8*
Mitral stenosis 1 0 15*
Etiology (n)
Degenerative heart disease 11 9 6*
Ischemic heart disease 1 0 5
Rheumatic heart disease 1 0 17*
Concomitant disease (n)
Hypertension 0 4* 1
LV dysfunction 1 0 NA
Rhythm characteristics
AF episode before surgery (n) 5 0* 7
Persistent AF before surgery (n) 8 0* 16
Duration of persistent AF (month)† 26 (0.5-86) - 3.5 (0.5-265)
Functional class for exercise tolerance (n)
NYHA II 3 7* 7
NYHA III 10 2* 13
NYHA IV 0 0 3
Echocardiographic data (mm)
LA anteroposterior diameter 49 ± 10 46 ± 6 54 ± 7
LA superoinferior diameter 72 ± 9 66 ± 7 74 ± 3
LA mediolateral diameter 51 ± 6 50 ± 6N A
LV end diastolic diameter 53 ± 8 58 ± 5 49 ± 3
LV end systolic diameter 36 ± 6 37 ± 6 31 ± 2
AF = atrial fibrillation, LA = left atrium, LV= left ventricle, NA = not available, NYHA = New
York Heart Association, SR = sinus rhythm. * = p-value < 0.05 compared to group 1. † =
median (range).
Statistical analysis All calculated p-values should be interpreted in the
perspective of the explorative character of the study. Unless stated otherwise,
mean values and standard deviations are reported. For the comparison between
groups, a Student’s t-test was used for normally distributed variables and a
Wilcoxon-Mann-Whitney test for non-normally distributed variables. In case
of categorical variables, a chi-square test with continuity correction or a178
Fisher’s exact test was used, when appropriate. To compare effects over time
for both study groups, and effects per time-point (1-, 3,- or 12-months after
surgery) between both study groups, ANOVA was applied. When heart rate
was the variable of interest, beta-adrenergic blocker-use was included in the
model, given its obvious negative chronotropic properties. Bonferroni correction
was performed to correct for multiple comparisons. The arrhythmia-free
survival curves were constructed using the Kaplan-Meier method; differences
between the curves were investigated with a log-rank test. A two-sided
probability level of < 0.05 was considered to indicate statistical significance.
The analysis was performed using SAS statistical software (SAS, version 6.12,
Cary, NC).
RESULTS
The 3 groups were comparable with respect to age and gender, but differ in
type of MV disease and, consequently, type of valvar intervention (Table 1).
The echocardiographic data were also comparable and indicate MV disease of
hemodynamic significance, given the enlarged left-atrial dimensions and
increased left-ventricular end-diastolic diameter. The control patients were in
a lower NYHA class for exercise tolerance.
Immediate postoperative outcome All mini-maze and control patients were
in SR while leaving the operating room. In the mini-maze group, sinus node
dysfunction was not encountered, although an accelerated AV nodal rhythm
(80-90 bpm) during the postoperative intensive care period was observed in 1
mini-maze patient, which reverted to SR the day after. Temporary cardiac pacing
for bradycardia (< 45 bpm) was necessary for 5-days in one female control
patient; she recovered uneventfully.
In the mini-maze group, in the first week after surgery, 7 patients developed
postoperative AF. Two patients relapsed to the arrhythmia on the first day,
another two on the third day, and the remaining three between day-5 and day-
7. Before hospital discharge, 3 of these patients spontaneously converted to
SR. The remaining 4 patients also converted spontaneously within 2-months
after discharge. In the control group, only one male patient suffered from
postoperative AF on the first postoperative day, but he spontaneously converted
within 24-hours.179
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Immediate postoperative complications A re-thoracotomy for postopera-
tive bleeding (< 24-hours) was necessary in 4 mini-maze patients. Impaired
hemostasis after discontinuation of oral anticoagulant therapy might have
played a role in bleeding from the sutures in 3 patients (preoperative INRs of
3.0, 2.3, and 1.6 respectively). After re-thoracotomy, one 74-year old female
developed multiple organ failure and died after 3 weeks, despite intensive
treatment. Contributing factors were a relatively old age, and co-morbidity
(diabetes, history of pulmonary tuberculosis). Additionally, one 54-year old male
developed urosepsis after re-thoracotomy and remained neurologically disabled
as a result from cerebral hypoperfusion. Remarkably, these latter two patients
remained in SR during the encountered complications. In the control group,
only one 38-year old female patient needed a re-thoracotomy for postoperative
bleeding. She had not received oral anticoagulant therapy before surgery.
Additionally, two mini-maze patients were on extended (> 24-hours)
mechanical ventilation. One patient developed mediastinitis, probably related
to overweight and diabetes. The other patient suffered from acute pulmonary
congestion 3-days after surgery; her preoperative left-ventricular function was
impaired after previous myocardial infarction. Temporary angiotensin-convert-
ing-enzyme (ACE) inhibitor discontinuation and fluid imbalance were held
responsible for the complication. She recovered promptly after diuretic therapy
and re-institution of ACE inhibitor therapy. Postoperative bleeding and other
complications were encountered more often in the mini-maze group as
compared to the control group (p < 0.05).
Long-term postoperative outcome After hospital discharge and spontane-
ously converted AF recurrence, 3 patients in the mini-maze group developed
new, persistent atrial arrhythmia recurrence at 3-, 10-, and 11-months of
follow-up. Preoperatively, these 3 patients were in persistent AF with a
duration of 86-, 62-, and 2-months respectively. In two patients the character
of the atrial arrhythmia was AF, in one patient it was an atypical atrial flutter
(positive deflections in leads II, III, aVF; atrial rate 236 bpm). Of these
patients, one died of esophageal malignancy without undergoing cardioversion
therapy. Although pericardial metastasis was not probable, the tumor might
have contributed to the AF recurrence. The two other patients, however, were
electrically cardioverted, but only one kept SR on AAD prophylaxis (sotalol).180
Figure 2. Kaplan-Meier plots, depicting the probability of survival free of permanent atrial fibril-
lation after mitral valve surgery. Group 1 are the patients who preoperatively suffered from atrial
fibrillation and who underwent a mini-maze during valvar surgery. Group 2 are the patients who
always were in sinus rhythm before valvar surgery (controls). Group 3 are the patients who preop-
eratively suffered from atrial fibrillation but who underwent isolated valvar surgery in the past
(historic controls).
Another patient with pre-existing AV-conduction delay (PQ > 240 msec), suf-
fered from recurrent AV-nodal tachycardia. Treatment with verapamil and low
dose beta-adrenergic blockers adequately suppressed this arrhythmia. After
follow-up, mini-maze was completely successful (no intercurrent AF) in 9 of
the initial 13 patients (69%); after cardioversion therapy with AAD, 10 of the
initial 13 patients (77%) were in SR. No sinus node dysfunction was observed,
thus no cardiac pacemaker was needed. All control patients kept long-term
SR. Figure 2 shows the results from the Kaplan-Meier analysis for atrial
arrhythmia outcome after cardioversion therapy in the mini-maze and control
patients (Groups 1 and 2); after 1-year, 82% and 100% of the patients were in
SR, respectively (p=0.218). For comparison, the plot of the historic patients
(Group 3) for arrhythmia outcome after cardioversion therapy with AAD is
depicted; after 1-year, only 53% of these patients were in SR (p=0.047181
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compared to Group 1).
The long-term results of MV intervention were satisfactory in all but two
control patients. After an initial (echocardiographic) good result, the repaired
MV showed significant regurgitation after 1-month of follow-up in both patients.
One 73-year old patient was completely asymptomatic and was not re-operated.
The other, symptomatic 63-year old patient received a MV prosthesis 3-months
after the initial operation; after that she refused further follow-up.
Four out of the 13 mini-maze patients had received a MV prosthesis and
therefore permanently used oral anticoagulation. One of the 9 patients with a
MV repair died of an immediate postoperative complication; of the remaining
8 patients 5 were off oral anticoagulation at the end of follow up. Anticoagulation
was continued in 2 patients for reason of AF persistence and in 1 patient because
of an absent A-wave over the MV. In the control group, at the end of follow up,
only the one female patient who eventually received a valvar prosthesis used
oral anticoagulation; the others neither used oral anticoagulation nor aspirin.
The clinical condition improved remarkably in almost all patients
(post-operative NYHA class I-II). The three patients surviving a serious
 post-operative complication (heart failure, mediastinitis, and urosepsis)
remained functionally impaired (postoperative NYHA class II-III). One, three,
and twelve months after surgery, exercise tolerance during the symptom
limited bicycle
Table 2. Exercise tolerance and heart rate at peak exercise  during the symptom
limited bicycle test
Month 1 Month 3 Month 12
Mini-Maze patients (Group 1)
Maximal load (Watts) 129±47* 138±58* 151±65*
Maximal HR (bpm) 118±28* 129±23* 135±30*
Beta-adrenergic blocker (n) 6 6 4
Control patients (Group 2)
Maximal load (Watts) 144±36 145±39 160±47
Maximal HR (bpm) 131±120 127±16 135±18
Beta-adrenergic blocker (n) 3 2 2
Bpm = beats per minute, HR = heart rate. * = p-value is not significant
compared to group 2, at the same time-point.182
test was comparable for mini-maze and control patients (p=NS; see table 2). In
both groups, a gradual improvement in exercise tolerance was observed over
time (p<0.001). During these tests, the maximally attained heart rate (during
SR) at 1-, 3-, and 12-months after surgery was also comparable (p=NS; see
table 2), and again, both groups showed a gradual improvement over time
(p=0.03). No chronotropic incompetence (maximal heart rate < 100 bpm or
heart rate increase < 20 bpm) was observed during follow-up.
Repeated ambulatory electrocardiography revealed no bradycardia, e.g.,
sick sinus syndrome, in any patient. Short episodes of AF were not detected
during SR, although asymptomatic, non-sustained supraventricular-
tachycardia (SVT) of < 25 beats was observed both in groups 1 and 2. In the
absence of apparent atrial flutter waves (either typical or atypical) it was
interpreted as short runs of atrial premature contractions. Table 3 shows the
incidence of these SVTs and the heart rates at 1-, 3-, and 12-months after
surgery. Over time, the minimal heart rate showed a significant decline
(p=0.007), but the average and maximal heart rates only exhibited a tendency
towards decrease. Between both groups, no difference in heart rates was
observed at any time-point (p=NS).
Table 3. Findings during 24-hours ambulatory electrocardiography
Month 1 Month 3 Month 12
Mini-Maze patients (Group 1)
SVT (n) 2 7 4
Maximal rate (bpm) 147±21 150±23 126±13
Maximal beats (n) 13±87 ± 48 ± 2
Minimal HR (bpm) 62±8* 67±7* 60±12*
Average HR (bpm) 79±9* 82±7* 78±13*
Maximal HR (bpm) 107±17* 119±24* 110±27*
Beta-adrenergic blocker (n) 6 6 4
Control patients (Group 2)
SVT (n) 2 1 2
Maximal rate (bpm) 155±15 108 119±13
Maximal beats (n) 27±258 ± 1
Minimal HR (bpm) 66±12 64±65 7 ± 5
Average HR (bpm) 90±15 83±97 7 ± 6
Maximal HR (bpm) 122±18 120±18 121±20
Beta-adrenergic blocker (n) 3 2 2
Bpm = beats per minute, HR = heart rate, SVT = supraventricular
tachycardia. * = p-value is not significant compared to group 2, at
the same time-point.183
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Table 4. Transthoracic echocardiographic Doppler peak flow velocities over the
mitral and tricuspid valve
Month 1 Month 3 Month 12
Mitral valve prosthesis
Mini-maze patients (Group 1; n=4)
E/A MV (m/sec) NA NA NA
E/A TV  (m/sec) 0.39/0.64 0.37/0.47 0.41/0.36
Mitral valve reconstruction
Mini-maze patients (Group 1; n=7)
E/A MV (m/sec) 1.50†/0.10† 1.14†/0.26† 1.41†/0.24†
E/A TV  (m/sec) 0.56*/0.56* 0.50*/0.46* 0.47*/0.50*
Control patients  (Group 2; n=9)
E/A MV (m/sec) 0.95/0.96 0.83/0.97 1.10/1.10
E/A TV (m/sec) 0.54/0.50 0.44/0.49 0.50/0.41
E/A = peak E-wave/peak A-wave, MV= mitral valve, NA = not
assessable (disturbed Doppler ultrasound signal), TV = tricuspid valve.
* = p-value is not significant compared to group 2, at the same time-point.
† = p-value < 0.05 compared to group 2, at the same time-point.
Repeated transthoracic echocardiography was performed during SR to
observe changes after surgery in Doppler peak flow velocities over the AV valves,
e.g., E-wave and A-wave. Data presentation is divided in patients who received
a MV prosthesis and patients who underwent MV reconstruction (Table 4)
since transmitral flow characteristics are seriously hampered by a valvar
prosthesis. For the following comparison, only the patients with a MV
reconstruction were used. In the mini-maze patients, the peak A-wave over
the MV remained considerably lower 1-, 3-, and 12-months after surgery as
compared to the control patients (p=0.013, p=0.003, and p=0.02 respectively).
Of note, the peak E-wave over the MV in the mini-maze group was higher at
any time-point (p=0.013, p=0.003, and p=0.02 respectively). The peak E-wave
and A-wave over the tricuspid valve remained constant over time in both groups
(p=NS). Eventually, 12-months after valvar reconstruction, the MV A-wave
was absent in 1 mini-maze patient. In another mini-maze patient, signal quality
was insufficient to reliably quantify. In the control patients, the MV
A-wave was present at all times.184
DISCUSSION
The study shows that additional mini-maze surgery is effective in terms of
restoring long-term SR in the setting of MV surgery in patients with
preoperative AF. No sinus node dysfunction was observed during follow-up.
Left-atrial function returned in all patients but one who underwent a MV
reconstruction. Immediate postoperative atrial arrhythmia recurrences after
the combined surgery are common, but terminate spontaneously within the
following weeks. The most serious complication of the combined surgery remains
postoperative surgical bleeding (in spite of center experience with maze surgery).
In our experience, great reluctance exists amongst the cardiologic and
cardiosurgical community to apply concomitant atrial arrhythmia surgery in
the setting of a MV intervention, although several studies have indicated the
validity of the concept.
9,15,16 The complete Cox-maze procedure is considered to
be very elaborate, increasing the risk for postoperative bleeding substantially.
At present, to avoid these problems, catheter guided ablation techniques of AF
during thoracic surgery (emulating the maze procedure) are being tested.
17 No
cutting (or only minor cutting) would be necessary, thus reducing the bleeding
risks. Whether this approach is just as effective as the complete maze procedure
remains to be proven. Simpler operative techniques (compared to maze surgery)
such as corridor or left-atrial isolating surgery of the atria are also effective,
4,5
but, in contrast to maze surgery, SR throughout the atria is usually not restored,
necessitating continuation of oral anticoagulation. It would be an improvement
to possess a technique with the advantages of complete maze surgery, while
reducing the disadvantages such as long procedure time.
The mechanisms behind the complete Cox-maze procedure are supposed
to be the critically applied incisions and bilateral atrial appendectomy. The
suture lines form conduction blocks, preventing atrial re-entry necessary for
AF, while the amount of atrial tissue between the sutures is insufficient for re-
entry to occur in there. The removal of the  appendages reduces the total amount
of atrial tissue, thus decreasing the number of wavelets “fitting” in the atria;
the critical, minimal number of wavelets mandatory for stable AF (> 3 in man)
cannot exist anymore. However, other factors contributing to the efficacy of
maze surgery may be present. There are some indications that a degree of
autonomic denervation of the atria occurs as a result of maze surgery.
18,19 Overall185
Appendix 8
reduction of autonomic tone to the atria might equalize pre-existent autonomic
heterogeneity and subsequently reduce susceptibility to AF. Indeed, in an animal
experiment, artificially induced autonomic damage of the atria reduced the
inducibility of AF.
20 More recently, the pulmonary veins region may play an
important role in the origin of “malignant” atrial premature beats, which initiate
AF.
21 The isolation of this region with atrial arrhythmia surgery might reduce
the occurrence of such potentially harmful atrial premature beats. The minimal
maze procedure (or mini-maze), as we have developed, might behold most of
the mentioned mechanisms (or advantages) of the complete Cox-maze
procedure, while being less elaborate; instead of an extra couple of hours, a
mere 46-minutes of extra perfusion time (on average) is needed to complete
mini-maze.
Our data indicate that a mini-maze combined with MV surgery would indeed
be sufficient to establish long-term SR in the majority of patients with MV
disease and preoperative AF. We have compared arrhythmia outcome of these
patients to patients without preoperative AF (thus no mini-maze), and to a
historic group of patients with preoperative AF who underwent isolated MV
surgery. Our results compare favorably, as well as to other studies on combined
surgery.
9,15 One might label the frequently occurring in-hospital postoperative
AF recurrences in many of the mini-maze patients as a failure of the mini-
maze procedure. However, transient postoperative AF occurs per se in many
patients undergoing cardiac surgery, especially after valvar surgery.
22
Remarkably, two of the three “late” AF recurrences occurred in patients with
long-standing (> 1-year) persistent AF. This suggests that these patients might
not have been properly selected. Indeed, it is known from previous studies
that a long duration of AF before surgery affects the outcome of atrial
arrhythmia surgery unfavorably.
5 Importantly, no sinus node dysfunction,
chronotropic incompetence, or necessity for a pacemaker was observed during
follow-up of mini-maze patients. Moreover, the sinus node function after mini-
maze is comparable to patients with preoperative SR who underwent isolated
valve surgery, assessed by ambulatory ECGs (during normal daily activity)
and bicycle exercise tests. In addition, exercise tolerance was comparable
between the study patients. In all, the advantages of mini-maze surgery seem
clear: improved probability for long-term maintenance of SR with normal sinus
node function.186
The main disadvantages of this type of combined surgery seem to be
postoperative bleeding and an impaired left-atrial function. Firstly, the
bleedings (and the other complications) occurred in spite of center experience
with Cox-maze surgery for “lone” AF. On the one hand, effects of “learning”
might still have been present for combined surgery. On the other hand, a relation
with oral anticoagulation use is not to be excluded; two of the four patients
with a bleeding still were within therapeutic range of anticoagulation while
undergoing surgery, although oral anticoagulation was stopped in advance. At
present, oral anticoagulation (acenocoumarol) is discontinued 5-days in advance
of combined surgery while patients receive antithrombotic therapy
(subcutaneous enoxiparine) in the mean time. Secondly, atrial contractile
function remains impaired after mini-maze (low MV peak A-wave), but the
nature and significance of such findings are under discussion.
23 Since the
appendages are removed and SR is present, thromboembolic risk is vastly
reduced, irrespective of MV peak A-wave value. However, no hard data are
available. In addition, transthoracic echocardiography was the only instrument
we used for investigation; no transesophageal measurements or magnetic
resonance imaging were routinely performed. Nevertheless, we did formulate
criteria for discontinuation of oral anticoagulation (presence of an A-wave over
the MV; see the section methods). Until more data become available on the
true significance of an absent A-wave over the MV after (mini-) maze, we remain
prudent with discontinuation of oral anticoagulation 3-months after a MV
reconstruction. Finally, it should be reminded that other factors than atrial
contractile function influence peak E-wave and A-wave values, e.g., ventricular
relaxation properties or MV orifice diameter.
Possible future directions The occurrence of AF might expedite the indication
for MV surgery combined with  atrial arrhythmia surgery, e.g., mini-maze. We
believe that the concept is valid, confirmed by the results of our study, and
deserves further attention. Indeed, randomized comparison to atrial arrhythmia
surgery (preferably mini-maze) or conventional treatment might further clarify
this issue. Still, the reluctance in many physicians even to consider combined
surgery is probably the biggest hurdle to first overcome.187
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Limitations of the study The main limitation of the study is the relatively
small number of patients that were investigated, making it hard to draw final
conclusions. Rheumatic heart disease was uncommon in our study patients, in
contrast to the historic patients. Thus, the effect of rheumatic heart disease
could not be singled out. The data suggest that a long duration of AF
inadvertently affects arrhythmia outcome. Whether this kind of patients are
to be excluded from combined surgery remains unclear. No prospective
comparison was made to conventional treatment for AF (rate control strategy
or serial cardioversion strategy), nor to complete Cox-maze surgery, nor to one
of the newer catheter ablational techniques. What would be the optimal strategy
to treat AF in the setting of MV disease cannot be answered from our study. It
has already been suggested that a large scale, multicenter clinical trial is needed
to draw more definite conclusions.
24,25
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ABSTRACT
Objective Maze surgery is a final solution for intractable atrial fibrillation
(AF), but an adverse effect on postoperative sinus node function has been
reported. Whether this applies specifically to maze surgery is unclear.
Methods We assessed postoperative rhythm status by means of repeated
exercise tolerance testing, ambulatory electrocardiography, and non-
invasive autonomic function testing between 1 to 12 months after surgery.
Thirteen patients without structural cardiac disease with medically refractory
AF underwent the maze III procedure, eleven patients with mitral valve disease
and preoperative AF underwent valvar surgery combined with a (simplified)
maze III procedure, and eight patients with mitral valve disease in sinus
rhythm underwent isolated valvar surgery. The control group consisted in eight
patients with sinus rhythm who underwent coronary artery bypass surgery
(CABG).
Results One month after surgery, the chronotropic response to exercise was
depressed, mean heart rate was high, and heart rate variability (HRV)
was low, especially after maze III, combined surgery, and isolated valvar surgery.
Twelve months after surgery, moderate improvements were observed. After
CABG, much less abnormalities were observed, and HRV parameters restored
to a large extent. Non-invasive testing of autonomic function indicated disturbed
vagal modulation of heart rate in all three groups with atrial incisions.
Conclusions Cardiac surgery per se seems to initially impair sinus node
function, but this partially recovers in the consecutive 12 months. Attenuation
of HRV and vagal modulation of sinus node function is not confined to maze
surgery, but applies to isolated mitral valve surgery as well. Atrial incision
therefore appears to be crucial and presumably produces autonomic
nervous damage followed by subsequent reinnervation.
INTRODUCTION
In the past decade, maze surgery (introduced by Cox) has become available as
a final option to treat “medically refractory” atrial fibrillation (AF).
1,2 The
procedure is effective in restoring sinus rhythm (SR) as well as atrial contractile
function. The initial maze technique was associated with sinus node192
dysfunction (high resting heart rate, depressed chronotropic response to
exercise) or occasionally even sick sinus syndrome necessitating an electronic
cardiac pacemaker.
2 Damage to the sinus node artery with maze incisions was
held responsible. To overcome these side effects, Cox’s group have proposed
modifications of the technique (maze III).
3 Most recent postoperative abnor-
malities in sinus node function are considered to be minor. Still, after maze III
surgery, sinus node function seems disturbed, showing delayed improvement
the year after surgery.
4,5 These studies, however, included patients concomi-
tantly undergoing other cardiac surgery. Thus, the influence of maze III sur-
gery could not be singled out.
We hypothesized that any cutting or manipulating of the atria during
 cardiac surgery induces a degree of autonomic nervous damage. Such damage
would in turn cause changes in autonomic modulation of sinus node function.
This implies that patients undergoing isolated mitral valve surgery might also
show postoperative disturbances in sinus node function comparably to maze
patients. Conversely, in patients undergoing isolated coronary artery bypass
surgery (CABG), sinus node function would be preserved. To investigate whether
effects on sinus node function are maze-specific, we prospectively investigated
rhythm status with non-invasive tools from 1 month until 12 months after
surgery in patients undergoing maze surgery without cardiac disease, patients
undergoing maze surgery with a concomitant mitral valve surgery, patients
undergoing isolated mitral valve surgery, and patients undergoing isolated
CABG.
METHODS
Study patients Patients were enrolled by using the in-house waiting list for
elective cardiac surgery (1996-1998). The decision to surgically intervene was
made by the in-house cardiosurgical team; standard clinical and hemodynamic
criteria were applied to assess the indication for cardiac surgery. Old age (>75
years), significant co-morbidity (i.e., pulmonary disease or diabetes), blatant
obesity, instable heart failure or angina pectoris, or redo-surgery were
contraindications for study participation. Preoperative signs of sinus node
dysfunction, AV-node dysfunction, or bradycardia during AF indicating AV-node
dysfunction, were also exclusion criteria. Before cardiac surgery, the clinical193
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characteristics of each patient (including medication use and exercise tolerance
according to the New York Heart Association classification) were assessed by
one investigator (AET). Rhythm characteristics (e.g., presence, type, and
duration of AF) were assessed using the patient’s history and previous
electrocardiograms. An echocardiogram was performed within 3 months prior
to the operation. The investigation complied with the principles outlined in
the Declaration of Helsinki, was approved by the Institutional Review Board,
and written informed consent was given by all patients.
Figure 1. Artistic drawing of the simplified maze procedure or mini-maze, showing the critical
locations of the atrial incisions and cryoablating sites. The upper picture of the atria is in
anteroinferior view, asterisks indicating cryoablation on the AV-ridges. The lower picture of the
atria is in posterosuperior view, showing the circumferential isolation of the pulmonary veins. Both
pictures illustrate the removal of the atrial appendages.194
Four different groups of patients were included in the study:
Group 1 Patients (n=14) with symptomatic, medically refractory AF (either
paroxysmal or persistent) who underwent isolated atrial arrhythmia surgery,
i.e., the Cox-maze III procedure.
3 Underlying cardiac disease and significant
non-cardiac disorders had to be absent, and patients had to be younger than
50 years.
Group 2 Patients (n=11) suffering from AF (either paroxysmal or persistent)
in the setting of mitral valve disease who underwent mitral valve surgery
combined with a maze procedure. Atrial arrhythmia surgery was considered
useful, since AF often recurs after valvar surgery
6 and cardioversion therapy
generally fails in such a condition.
7 The mitral valve was approached through
a standard left-atrial paraseptal incision. When technically feasible (guided
by echocardiographic data), the mitral valve was reconstructed with support
of a Carpentier Edwards ring (n=7), otherwise a valvar prosthesis (n=4) was
inserted. To limit the procedure, some of the original maze III incisions were
omitted (incisions in the interatrial septum and most of the incisions on the
posterior side).
3 Figure 1 shows an impression of the mini-maze procedure.
Group 3 Patients (n=8) in whom isolated mitral valve surgery was performed,
who never had had preoperative AF. The mitral valve was approached through
a standard left-atrial paraseptal incision and was reconstructed in all patients
with the support of a Carpentier Edwards ring.
Group 4 Patients (n=8) with coronary artery disease necessitating coronary
artery bypass surgery (CABG) served as controls (no atrial incisions or
manipulation). Re-vascularization was accomplished using arterial (n=8) and
venous (n=2) grafts. These patients had never suffered from AF preoperatively.
Preoperative procedure In the AF patients, all class I and III antiarrhyth-
mic drugs (AAD) were discontinued at least 5 half-lives prior to cardiac
surgery. Rate control medication with a calcium-entry blocker or digoxin was
continued until the day before surgery. In all patients, betablockers were
reduced to half the dosage the day before surgery.
Operative procedure Anesthesia was induced with midazolam, sufentanyl
and pancuronium bromide, and maintained thereafter with an infusion of
midazolam and sufentanyl, occasionally supplemented by isoflurane. All195
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patients received dexamethasone (1 mg/kg). Cardiopulmonary bypass was per-
formed at 28-30 °Celsius. Cold St Thomas cardioplegia was used to arrest the
heart. The valvar and atrial arrhythmia operations (groups 1, 2, and 3) were
performed by one experienced surgeon (JGG). After completion of surgery, tem-
porary epicardial pacing leads were left behind at the right atrial free wall and
right ventricle to be used for pacing of postoperative bradycardia if necessary.
Postoperative procedure During recovery from surgery the patients were
treated according to in-hospital standard postoperative procedures including
pericardial and bilateral pleural drains, forced mechanical ventilation during
1 day, positive inotropics, diuretics, analgesics, and antibiotics. All patients
either continued or started with low-dose betablocker on the first day after
surgery (intended to prevent immediate postoperative AF), discontinued again
at hospital discharge if feasible. Postoperative AF was treated with rate-con-
trol using verapamil (on top of full-dose betablocker) when indicated. The maze
III and mini-maze patients received prophylactically low-dose spironolactone
(tid 25 mg) from the first day for at least one week.
Persistent atrial arrhythmia recurrences during follow-up were treated
with electrical cardioversion and AAD (sotalol, amiodarone). Reasons for
acceptance of the arrhythmia consisted of failure of amiodarone or refusal to
undergo (another) cardioversion.
Postoperative measurements Follow-up intervals: During recovery from
surgery, patients were monitored daily for clinical condition and rhythm
(continuous telemetry for at least 48 hours in groups 3 and 4; for 7 days in
groups 1 and 2) until hospital discharge. One month after surgery, ambulatory
electrocardiography and exercise tolerance testing were performed. These tests
were repeated after 3 months and 12 months. Non-invasive autonomic
function testing was also performed 3 months and 12 months after surgery.
All tests were conducted during SR. Drugs, in particular betablockers
(if applicable; see table 1), were not discontinued in order to avoid withdrawal
or rebound phenomena.
Exercise tolerance testing: Symptom limited bicycle tests were performed,
starting the first minute at 50 Watts, and increasing with 10 Watts every
30 seconds (modified Bruce protocol). Heart rate at rest, at peak exercise196
(maximal attained workload), and after 3 minutes of recovery was measured.
Ambulatory electrocardiography: Twenty-four hours of electrocardiographic
registration was performed in accordance with standard recommendations.
8
Assessed were mean heart rate, SDNN (reflecting overall HRV and representing
vagal as well as sympathetic function), rMSSD (more specific for vagal function),
low frequency power (LF: 0.05-0.15 Hz), high frequency power(HF: 0.15-0.40
Hz), and total power (TP: 0.0033-0.40 Hz). HF reflects vagal function, whereas
LF is considered to represent combined vagal and sympathetic function.
Non-invasive autonomic function testing: Methods have been detailed
recently.
9 Tests were performed during the morning hours and in the presence
of SR. Blood pressure and heart rate were continuously (beat-to-beat) measured
with the Finapress system with the cuff around the middle finger of the right
hand.
10 During the tests, the patient was lying on a bed which could be tilted
to an 80° upright position. After stabilization of the signal, a baseline recording
of 10-minutes was made. Between each subsequent maneuver, a stabilization
period of 5-minutes was admitted. All data were digitalized and stored in
a personal computer for off-line analysis. Although most tests influence
vagal and sympathetic function simultaneously, the extent to which each part
of the autonomic nervous system is activated is variable.
11 Deep breathing
 is considered to test mainly vagal function, whereas isometric handgrip
is considered to test sympathetic function. The Valsalva maneuver, standing
up, and head-up tilting reflect combined function. Deep breathing: Using
a metronome, the patient was instructed to deeply inspire and expire 6 times
during 1 minute. The mean of all 6 breaths was taken to calculate the
ratio between in- and expiratory heart rate. Isometric handgrip: During 3
minutes a handgrip was held at 30% of the previously established maximum
force in the hand contralateral to the hand used for the Finapress. The
increase in diastolic blood pressure was determined. Valsalva maneuver:  The
patient was asked to blow into a mouthpiece connected to a mercury
blood pressure manometer and to maintain a pressure of 40 mm Hg for
15-seconds. All four phases of the maneuver were analyzed allowing
calculation of the Valsalva ratio as the ratio between the highest
heart rate during phase 2 and the lowest heart rate during phase 4.
Standing up: The patient was asked to stand up from the bed. The immediate
drop in systolic blood pressure was determined. Also, the 30/15197
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ratio was calculated as the ratio between the highest heart rate after standing
up (usually around the 30
th beat) and the lowest heart rate (usually around the
15
th beat). Head-up tilting: The bed on which the patient was positioned was
tilted to the 80° upright position. Tilting was continued for 30-minutes or
terminated earlier in case of symptoms (pre-syncope). A positive response was
defined as a sudden drop in systolic blood pressure >30 mm Hg (with or without
concomitant bradycardia) accompanied by symptoms. Asymptomatic
hypotension was scored separately.
Definitions Persistent AF: Continuous presence of AF until the moment of
cardiac surgery, i.e., at least two consecutive electrocardiograms with AF more
than 24-hours apart, without intercurrent SR. Persistent AF does not
spontaneously convert to SR, but is considered cardiovertible.
12 Previously, this
type of AF was classified as chronic AF. Paroxysmal AF: AF typically occurring
in episodes of shorter duration than 24-hours (though paroxysms may
occasionally last longer) with intermittent SR. Paroxysmal AF either converts
spontaneously or can be terminated with an intravenously administered AAD.
12
Chronotropic response to exercise: Difference between the heart rates at rest
and at peak exercise during exercise tolerance testing, reflecting the ability to
generate an appropriate sinus tachycardia. Sinus node dysfunction: Heart rate
<40 bpm, chronotropic response to exercise <100 bpm or an increase of <20bpm
(in the absence of negative inotropic drugs).
Statistical analysis Mean values and standard deviations are reported, unless
stated otherwise. For comparison of characteristics between groups, an F-test
was used for normally distributed variables and a Kruskal-Wallis test for non-
normally distributed variables. In case of categorical variables, a chi-square
test with continuity correction was used. To compare effects over time for all
groups, effects over time within group, and effects per time-point (1, 3, or 12
months after surgery) between groups, a 3-way ANOVA (e.g., group, time-point,
and betablocker-use) was applied. Betablocker-use was included in the model,
given its obvious negative chronotropic properties and effects on HRV.
13 When
present, interaction effects were also included in the model. Non-normally
distributed variables were logarithmically transformed before being entered
in the model (or were subjected to a non-parametric model). Bonferroni198
Table 1. Characteristics of the study patients
Group1 Group 2 Group 3 Group 4
maze III MVS+ MVS CABG
mini-maze
Patients (n) 14 11 8 8
Male / female (n)† 14 / 0 5 / 6 6 / 2 6 / 2
Age (year)† 48 ± 7 56 ± 13 55 ± 14 64 ± 6
Length (cm) 185 ± 8 177 ± 12 175 ± 10 174 ± 9
Weight (kg)† 96 ± 17 80 ± 18 72 ± 12 82 ± 11
Cardiac surgery†
Arterial re-vascularization (n) 0 0 0 8
Full maze III surgery (n) 14 0 0 0
Mini maze III surgery (n) 0 11 0 0
Mitral valve reconstruction (n) 0 7 8 0
Mitral valve prosthesis (n) 0 4 0 0
Cardiopulmonary bypass time (min.)  147 ± 26‡ 146 ± 30‡ 99 ± 26 82 ± 18
Aortic cross-clamp time (min.) 73 ± 24‡ 89 ± 24‡ 57 ± 16 49 ± 21
Mitral valve disease (n)†
Mitral regurgitation 0 10 8 0
Mitral stenosis 0 1 0 0
Etiology (n)†
Degenerative heart disease 0 9 8 0
Ischemic heart disease 0 1 0 8
Rheumatic heart disease 0 1 0 0
Concomitant disease (n)†
Hypertension 1 0 3 3
Rhythm characteristics†
Paroxysmal AF (n) 8 4 0 0
Persistent AF (n) 6 7 0 0
Duration of persistent AF (months)*   17 (8-20) 8 (0.5-86) - -
Functional class for exercise tolerance (n)†
NYHA I 12 0 0 0
NYHA II 2 2 7 3
NYHA III 0 9 1 5
NYHA IV 0 0 0 0
Echocardiographic data (mm)†
LA anteroposterior diameter 41 ± 6 48 ± 10 45 ± 5 41 ± 3
LA superoinferior diameter 62 ± 7 73 ± 9 65 ± 8 64 ± 3
LA mediolateral diameter 42 ± 6 49 ± 6 50 ± 6N A
LV end diastolic diameter 51 ± 4 53 ± 6 58 ± 5 49 ± 8
LV end systolic diameter 35 ± 6 36 ± 5 38 ± 6 35 ± 7
Postoperative medication (n)†
Betablocker 6 6 2 6
AF = atrial fibrillation, LA = left atrium, LV= left ventricle, MVS = mitral valve surgery, NA
= not available, NYHA = New York Heart Association, SR = sinus rhythm. * = median (range).
† = p <0.05 between groups. ‡ = p <0.05 compared to CABG group.199
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correction was performed to correct for multiple comparisons. A two-sided
probability level of <0.05 was considered to indicate statistical significance.
The analysis was performed using SAS statistical software (SAS, version 6.12,
Cary, NC).
RESULTS
Study patients The characteristics of the patients are presented in Table 1.
Inherent to the design of the study, patients differed in several clinical
characteristics, but it should be emphasized that the clinical condition was
stable and ventricular function was preserved in all patients. Cardiopulmonary
bypass time and aortic cross-clamp time was longer in maze III and mini-maze
patients.
General outcome Immediately after surgery, a total of 5 re-thoracotomies
were needed for postoperative bleeding in the groups 1, 2, and 3. Thereafter,
these patients recovered uneventfully. Forced mechanical ventilation was
extended over 24-hours in 3 patients; they mobilized within the usual 10-day
period. Slowly resolving pericardial effusion was observed in 3 patients in group
1, but did not pose a clinical problem. Cardiac surgery was successful in all
patients and clinical condition improved markedly in the consecutive months.
Arrhythmia outcome All patients were in SR at the time of leaving the
operating room. During postoperative stay on the intensive care ward, one
patient in group 1 and one patient in group 2 showed temporary accelerated
AV-nodal rhythm (80-90 bpm), which soon reverted to SR (after intravenous
inotropic support was discontinued). During the subsequent in-hospital
recovery, two maze III patients relapsed into AF; one converted spontaneously
to SR before hospital discharge, the other was electrically cardioverted within
the next month. Five patients in group 2 showed a recurrence of AF, which
spontaneously converted to SR before hospital discharge in one case and within
the next month in the remaining four patients. In group 3, one patient exhibited
transient AF on the first postoperative day; he converted spontaneously within
24 hours. In group 4, transient AF occurred on the first postoperative day
in one patient while another patient encountered postoperative AF on the200
seventh day. The latter was probably related to hemodynamic challenge while
suffered from gastric bleeding; he was cardioverted electrically within the next
days. Of note, with postoperative telemetry and daily rhythm observation no
significant bradycardia (< 40 bpm) was observed in any of the patients. No
antiarrhythmic prophylaxis with class I or III AAD was instituted.
After hospital discharge, all patients kept SR, except for 2 patients in group
2; one patient was cardioverted successfully and kept SR with sotalol, the other
was not cardioverted due co-morbidity (newly discovered esophageal
malignancy).
Figure 2. Chronotropic response to exercise 1 month, 3 months, and 12 months after surgery.
Depicted are heart rate (mean ± standard error of the mean) after 2-minutes of rest ( • ), at peak
exercise (   ), and after 3 minutes of recovery (   ). Below the point in time, the corresponding
attained workload (mean ± standard deviation) is given. CABG = coronary artery bypass surgery,
MVS = mitral valve surgery, W = Watts. * = p-value <0.05 for chronotropic response, compared to
month 1 within group.201
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Table 2. Heart rate variability analysis of 24-hour ambulatory electrocardiography
recordings
Variable Group 1 Group 2 Group 3 Group 4
(Normal value‡) Maze III MVS+ MVS CABG
mini-maze
n=14 n=11 n=8 n=8
Mean heart rate (bpm) Month 1 84±13 78±79 4 ± 13 79±3
(73±8) Month 3 80±13 82±88 4 ± 97 8 ± 7
Month 12 73±11† 76±12 78±6† 72±9
SDNN (ms) Month 1 61±24 85±12 69±10 61±10
(151±35) Month 3 87±37 52±25 80±16 85±17
Month 12 93±26† 86±22 89±26 109±23
rMSSD (ms) Month 1 15±12 22±10 15±82 4 ± 16
(32±1) Month 3 16±91 7 ± 91 3 ± 52 4 ± 12
Month 12 20±8*† 23±20* 17±7* 33±15
Low frequency power (ms) Month 1 4.0±3.6* 6.7±4.7 3.2±1.6* 12.0±3.0
(25.5±7.0) Month 3 5.3±2.4* 5.0±3.5* 5.7±3.9* 12.4±3.7
Month 12 9.9±5.4† 11.0±11.0 8.9±4.4† 16.9±5.7
High frequency power (ms) Month 1 4.0±3.4 6.7±3.7 3.5±1.6 6.3±2.5
(12.5±5.1) Month 3 4.4±2.0 5.0±2.4 3.4±1.5* 7.3±3.0
Month 12 6.1±2.5*† 8.5±7.8 4.9±1.2* 10.4±3.6
Total power (ms) Month 1 8.5±6.3* 12.6±6.7* 8.2±2.9* 20.6±2.5
(38.4±10.2) Month 3 10.6±3.4* 10.5±5.0* 10.7±4.9* 21.9±4.1
Month 12 17.1±7.6*† 19.3±15.1* 14.6±6.3*† 29.1±4.6
CABG = coronary artery bypass surgery, MVS = mitral valve surgery. * = p-value <0.05 com-
pared to CABG group at the same time-point. † = p-value <0.05 compared to month 1 within
group. ‡ = normal values are given for an age and gender matched population without struc-
tural heart disease.
Sinus node function during exercise tolerance testing The chronotropic
response to exercise 1 month, 3 months, and 12 months after surgery is depicted
in Figure 2. The initial measurements reveal a blunted response in all groups.
Over time, the chronotropic response to exercise gradually increased in groups
1 and 2. When comparing to group 4, however, the changes over time did not
reach statistical significance. In addition, differences between groups at a
certain phase (rest, peak exercise, or recovery) were absent at any point in
time (1 month, 3 months, or 12 months after surgery). One month after surgery,
four patients in groups 1 and 2 had a severely depressed chronotropic response
to exercise (sinus node dysfunction). After 3 months, two patients had recovered,202
Table 3. Non-invasive autonomic function testing.
Variable Group 1 Group 2 Group 3 Group 4
(Normal value) Maze III MVS+ MVS CABG
mini-maze
n=14 n=11 n=8 n=8
Deep breathing Month 3  4±3* 3±3* 4±3* 16±7
(HR variation >15 bpm) Month 12  5±4* 7±68 ± 61 2 ± 8
Isometric handgrip Month 3 23±62 4 ± 82 2 ± 11 25±9
(DBP increase >15 mm Hg) Month 12 19±72 1 ± 72 6 ± 11 27±14
Valsalva maneuver Month 3 1.13±0.06 1.20±0.15 1.20±0.10 1.29±0.14
(Ratio phase 2/4 >1.20) Month 12 1.18±0.09 1.13±0.09 1.21±0.17 1.20±0.13
Standing up - SBP drop Month 3 8±10 11±14 32±32 16±35
(SBP drop <20 mm Hg) Month 12 5±10 -3±25 12±15 5±15
Standing up - 30/15 ratio Month 3 1.13±0.07 1.12±0.11 1.05±0.04 1.13±0.05
(30/15 ratio >1.04) Month 12 1.19±0.14* 1.05±0.03 1.16±0.12 1.13±0.05
Head-up tilting Month 3 0  / 1- 0  / 1- 1+ / 1- 0  / 2-
(BP drop <30 mm Hg†) Month 12 0  / 1- 1+ / 1- 0  / 3- 1+ / 0
CABG = coronary artery bypass surgery, DBP = diastolic blood pressure, HR = heart rate, MVS
= mitral valve surgery, SBP = systolic blood pressure. * = p-value <0.05 compared to CABG
group at the same time-point. † = a “+” sign indicates a positive test with symptoms; a “-” sign
indicates a positive test without symptoms.
 and after 12 months, all patients were able to produce sufficient chronotropic
response to exercise.
Sinus node function during ambulatory electrocardiography The results
of the HRV analysis are shown in Table 2. One month postoperatively, mean
heart rate was high, but only groups 1 and 3 showed a significant decline over
time.  The other time domain parameters were initially depressed. Twelve
months postoperatively, SDNN and rMSSD had gradually improved in group
1. Still, SDNN remained subnormal in all groups, and rMSSD remained low in
groups 1, 2, and 3 when comparing to group 4.  The frequency domain
parameters were also initially depressed. Over time, TP and LF made a relative
recovery in both groups 1 and 3. TP remained lower at all times in groups 1, 2,
and 3 when comparing to group 4 whereas LF had equalized between groups
after 12 months. In contrast, HF had only made a relatively recovery203
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after 12 months in group 1 and was still depressed in groups 1 and 3 when
comparing to group 4. Summarizing the results: HRV abnormalities were most
pronounced for the maze III patients. During ambulatory electrocardiography,
no symptomatic bradycardia necessitating an artificial pacemaker was observed
in any patient.
Sinus node function during non-invasive autonomic function testing
The results of the five different tests are given in Table 3. Most autonomic
responses were preserved. The response to deep breathing, however, was
initially disturbed in groups 1, 2, and 3. After 12 months, groups 2 and 3 had
made a relative recovery in their response, in contrast to the maze III patients.
The head-up tilting test revealed a few abnormal responses, but this was not
different between groups.
DISCUSSION
The key findings of the study are that not only the maze III patients, but all
who have undergone atrial surgery exhibit postoperative disturbances in sinus
node function. Initially, various tests reflecting modulation of heart rate are
depressed, and merely moderate improvements are observed over time,
especially on vagal scales of testing. Conversely, after CABG, considerable less
abnormalities in sinus node function are present. We conclude that the essential
feature of these findings is atrial cutting.
Various explanations can be offered; atrial cutting may produce vascular
trauma, tissue edema, or neural trauma. With “state of the art” techniques in
atrial arrhythmia surgery, incisions close to the sinus node were avoided,
preserving arterial blood supply to the sinus node. Indeed, no sick sinus
syndrome was observed in general or, more specific, in any maze III and mini-
maze patient. Consequently, the previously high incidence of sick sinus
syndrome reported after the original maze procedure
2 was not observed in our
study. In addition, permanent damage to sinus node vascularization would be
incompatible with our results; no reversal of sinus node dysfunction is to be
expected in such a condition.
The initially disturbed sinus node function, however, gradually improved
in the consecutive 12 months. Transient postoperative edema might have had204
an influence on these disturbances, but atrial edema as a result of surgery is
considered to be short lasting. Any resulting sinus node dysfunction should
have been largely restored after a couple of weeks, and this is incompatible
with the extended time course of improvement as we observed. An alternative
explanation for the slow improvement in sinus node function after cardiac
surgery might be an adverse effect on sinus node function of cardioplegia.
Indeed, maze III and mini-maze patients were subjected to the longest durations
of cardioplegia, but patients undergoing isolated mitral valve surgery also
exhibited disturbances in postoperative sinus node modulation while their
cardioplegia duration was in the same magnitude as for CABG patients.
However, specific data on cardioplegia in relation to long-term postoperative
effects on sinus node function are lacking. To what extent other non-specific
mechanisms (such as dissolving postoperative pain or effects of generalized
anesthesia) contributed to the observations can not be answered from our study.
Nevertheless, the time course of improvement in sinus node dysfunction
after maze III, mini-maze, and isolated mitral valve surgery would be consistent
with delayed autonomic nervous recovery as observed after orthotopic heart
transplantation.
9 Underlying is late functional and histological reinnervation
after initial cardiac denervation.
14 Although complete cardiac or sinus node
denervation was not performed in our study, a comparison can still be made.
The anatomy of atrial autonomic innervation is rather complex; vagal and
sympathetic fibers have extensive interactions on the atrial level,
15 and the
projections of the nerve fibers are overlapping in all regions of the atria,
including the sinus node area.
16 It is thus conceivable that single or few atrial
incisions do not produce complete sinus node denervation, but only attenuate
autonomic modulation of heart rate. Previously, the maze procedure was held
specifically responsible for attenuated heart rate variability after surgery.
4,5
Although maze surgery involves cutting trough several areas with a high-
density of autonomic fibers (superior vena cava, pulmonary veins), the left-
atrial paraseptal incision (to approach the mitral valve) dissects such a region
as well.
16,17 Conceivably, even a single atrial incision at a critical location may
produce disturbances in sinus node function which in turn improve slowly,
consistent with late reinnervation as observed after heart transplantation.205
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Limitations of the study The main limitation of the study is the small sample
size. A larger number of patients might have proven that chronotropic responses
differ between groups, while now only trends are observed. Preoperative rhythm
status, measured with invasive or non-invasive tools, is lacking. We wish to
emphasize that AF and clinical status (such as exercise related angina pectoris
or dyspnea) posed the impossibility to do so in the majority of patients. Still,
the observed postoperative time-dependent changes are evident. Whether HRV
can be applied to investigate disturbances in sinus node function is debatable.
In the usual sense, HRV is used to assess autonomic function assuming normal
intrinsic sinus node function. The observed improvements over time, however,
suggest preservation of intrinsic sinus node function. Furthermore, extensive
non-invasive autonomic function testing did not indicate generalized autonomic
dysfunction in our patients.
Clinical relevance Full and minimal maze III surgery appear to be effective
in terms of restoration of sinus rhythm and safe with respect to the absence of
true sick sinus syndrome. Abnormal HRV patterns after atrial surgery do not
have to reflect left ventricular dysfunction (or heart failure), but might be related
to the operation per se. In any patient undergoing cardiac surgery, improvement
of sinus node function is to be expected in the consecutive 12 months.
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Summary and conclusions
Summary and conclusions
Atrial fibrillation is a considerable problem both from an epidemiological and
a clinical point of view. The arrhythmia carries substantial morbidity and also
increased mortality. Unfortunately, no definite answer in terms of permanent
restoration of sinus rhythm is available. Conventional arrhythmia treatment
(antiarrhythmic drugs and cardioversion) is in the long run rather ineffective
for most patients. More aggressive, surgical treatment is acceptable only in
highly symptomatic patients or in patients already undergoing cardiac surgery.
In addition, other unconventional (non-pharmacological) therapy such as the
atrial defibrillator seems not suited as a general approach. Perhaps it is not
surprising that the generally poor results have led to the opinion of many
physicians “to digitalize and forget” since all effort to restore sinus rhythm is
frustrated. Consequently, “rhythm-control” therapy is withheld from many
elderly patients.
The management of the arrhythmia may be inadequate because we simply
do not sufficiently understand the involved pathophysiological mechanisms.
Many patients develop the arrhythmia in the absence of underlying disease
and it is unclear what line of pathophysiological events has led to the
arrhythmia. Other patients distinctly develop atrial fibrillation in the setting
of underlying disease challenging the atria. Evidently, adequate treatment of
underlying disease might reduce the arrhythmia in these cases but should
start early to avoid arrhythmogenic structural alterations. Still, it has become
increasingly clear that atrial fibrillation may reinforce its own
electrophysiological basis especially at the very beginning of the disease (“atrial
fibrillation begets atrial fibrillation”). Moreover, this important process is just
a part of remodeling of the atria in response to atrial tachycardia. Many other
determinants promoting atrial remodeling have been identified, including
increased levels of neurohormones, ion channel alterations, subcellular changes,
cellular dedifferentiation, and finally, apoptosis and necrosis.
Understanding why these changes occur, their time course, and their impact
on the reinforcement of atrial fibrillation will hopefully direct interventions
aimed at preventing and treating atrial remodeling. Clearly, the ultimate goal
is to effectively restore and maintain sinus rhythm. This thesis addressed both
fundamental and clinical issues of human atrial fibrillation in an attempt to208
improve our insight in the intractability of the arrhythmia.
Until now, most data on atrial electrical remodeling come from animal
experiments, partly fast atrial pacing models mimicking atrial fibrillation,
partly from models using artificially induced atrial fibrillation. Data on the
time course of atrial electrical remodeling in spontaneous, naturally occurring
atrial fibrillation were lacking. In appendix 1, atrial remodeling in man was
investigated with a focus on electrophysiology. Patients undergoing elective
cardiac surgery with either persistent atrial fibrillation, paroxysmal atrial
fibrillation, or sinus rhythm were compared for atrial refractoriness during
the actual operation. The effective atrial refractory period was shortened in
preoperative persistent atrial fibrillation. In patients with paroxysmal atrial
fibrillation, the shortening of refractoriness was inversely proportional to the
preoperative duration of sinus rhythm. This shortening of the atrial refractory
period is presumably the cause rather than the consequence of the arrhythmia
since all patients had paroxysmal atrial fibrillation of too short duration to
provoke substantial electrical remodeling. By contrast, a short atrial refractory
period during surgery was not predictive for the occurrence of postoperative
atrial fibrillation. Furthermore, mitral valve regurgitation seemed to prolong
refractoriness. Presumably, chronic atrial stretch induces this relative increase
in refractoriness.
The cardiovascular system has many regulatory mechanisms trying to maintain
stable hemodynamics. A pivotal role is fulfilled by cardiovascular
neurohormones that are produced by several systems, including the natriuretic
peptide system, the renin-angiotensin system, and the adrenal gland system.
These systems come in to action when hemodynamics are compromised, for
example in the presence of heart failure. On the level of the heart, receptors
are stimulated by these neurohormones, influencing myocyte function (such
as contractility and electrophysiology) and morphology (for example cellular
dedifferentiation, fibrosis, apoptosis, and necrosis). Appendix 2 dealt with
mRNA expression of the natriuretic peptide system in the right atrial appendage
in relation to atrial fibrillation. In patients with paroxysmal atrial fibrillation,
no changes were present as compared to patients with sinus rhythm. Patients
with persistent atrial fibrillation, however, showed distinct alterations in mRNA209
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content, irrespective of valve disease. This implies that atrial fibrillation is an
independent stimulus for the expression of mRNA involved in the
neurohormonal status of the atria. In appendix 3, we demonstrated in patients
with advanced heart failure that atrial fibrillation was associated with higher
levels of plasma endothelin and atrial natriuretic peptide, as compared to those
in sinus rhythm. It could be argued that endothelin release (vasoconstrictive
compound) is triggered by an increase in atrial natriuretic peptide level
(vasodilating properties), but this is speculative. Since excessive neurohormonal
activation in general is associated with a worse hemodynamic situation and
clinical outcome, these results warrant further study on the impact of atrial
fibrillation on (atrial and ventricular) myocyte function and molecular
adaptations on the one hand, and patient morbidity and survival on the other.
Further to the above, autonomic activation affects quality of life. Appendix 4
addressed quality of life in relation to autonomic nervous state in paroxysmal
atrial fibrillation. It was shown that patients with paroxysmal atrial fibrillation
had a significant impairment of quality of life, even in the absence of structural
heart disease. In addition, depressed autonomic function was strongly
associated with impaired quality of life. The results implicate that in addition
to the impact on atrial fibrillation itself, the autonomic nervous system also
determines the patients’ well being.
In appendix 5, the common intersection of atrial fibrillation and heart failure
was reviewed. On the one hand, atrial fibrillation occurs in the setting of
preexistent heart failure. On the other hand, atrial fibrillation may promote
heart failure. Both mechanisms may be present in the same patient and it is
sometimes not clear which came first. In any case, striving for adequate rate-
control during the arrhythmia is of utmost importance. Additionally, appropriate
treatment of heart failure is very important, in particular when cardioversion
therapy is considered. In drug refractory cases, AV-node ablation with
permanent rate-responsive ventricular pacing may be considered. At present,
it is unsettled whether the latter treatment should be offered in general.
Nevertheless, cardioversion therapy is still considered a first line measure and
we explored its usefulness. In appendix 6, the outcome of serial electrical
cardioversion therapy with a focus on heart failure was described for a large
cohort of patients with persistent atrial fibrillation. Serial electrical210
cardioversion combined with serial antiarrhythmic drug therapy was rather
unsuccessful in terms of preventing heart failure and maintenance of sinus
rhythm. In addition, these failures occurred more often in patients with higher
NYHA classes. Although this may seem rather obvious, and in line with the
clinical experience of many physicians, it does not prove that rate-control
therapy is just as good. A randomized comparison is needed to draw more
definite conclusions. Therefore, the results of this study provide the rationale
for the “RACE” study. This Dutch study entails a randomized comparison of
serial cardioversion therapy versus rate-control therapy. The primary endpoints
comprise morbidity (including heart failure, thromboembolism, and bleeding)
and quality of life. Appendix 7 continued with the feasibility of cardioversion
therapy, investigated in a small group of selected patients with heart failure
and persistent atrial fibrillation. As expected, the results were rather
disappointing in terms of maintenance of sinus rhythm. However, treatment
before cardioversion with ACE-inhibition may increase the immediate likelihood
of successful cardioversion. The study does not warrant indiscriminate electrical
cardioversion of every heart failure patient. Acceptance of the arrhythmia,
amiodarone as initial antiarrhythmic drug, or alternative treatment should
also be considered.
A final option in the treatment of (medically refractory) atrial fibrillation is
atrial arrhythmia surgery. Many are reluctant to take this step, but patients
with atrial fibrillation undergoing cardiac surgery for another reason are logical
candidates. In appendix 8, we investigated patients with mitral valve disease
and preoperative atrial fibrillation who underwent mitral valve surgery
combined with a simplified Cox-maze procedure or “mini-maze”. The latter is
not as extensive as the original procedure and consequently takes less time. A
comparison was made between the aforementioned patients and patients in
sinus rhythm as well as a historic group of patients with preoperative atrial
fibrillation, both undergoing isolated mitral valve surgery. The results one year
after surgery were encouraging, mini-maze patients showing comparable sinus
rhythm, sinus node function, and exercise tolerance as compared to those with
preoperative sinus rhythm. In addition, left atrial function returned in the
majority of mini-maze patients. In spite of these favourable findings, atrial
arrhythmia surgery is often associated with postoperative disturbances in sinus211
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node function. Appendix 9 dealt with the characteristics of rhythm after atrial
arrhythmia surgery. Patients with preoperative atrial fibrillation undergoing
maze surgery exclusively or combined (with a mitral valve intervention) were
compared with patients in sinus rhythm either undergoing coronary artery
bypass surgery or mitral valve surgery. Using an integrated approach,
postoperative rhythm was explored with exercise tests, 24-hour ambulatory
electrocardiography (including heart rate variability analysis), and non-invasive
autonomic function testing. Cardiac surgery seemed to initially depress sinus
node function, but improvement occurred in the consecutive 12 months. There
was a marked attenuation of heart rate variability and vagal modulation of
sinus node function which was not confined to maze surgery since it also applied
to isolated mitral valvular surgery. These side effects were less pronounced or
absent after coronary artery bypass surgery. We speculate that cutting the
atria induces a degree of autonomic destruction, which improves but does not
normalize within the year following surgery. Subsequently, it might be
postulated that the above mentioned autonomic alteration contributes to the
efficacy of maze surgery.
Clinical implications and future directions
This clinically oriented and mainly descriptive thesis on human atrial
fibrillation illustrates several consequences of the arrhythmia that in turn
correlate with difficulties in rhythm-control management. Although it is
demonstrated that distinct changes on electrophysiological and neurohormonal
levels occur, their exact pathophysiological role remains to be clarified.
Therefore, future research should focus on changes on a cellular level, including
(stretch activated) ion channel expression, cellular calcium handling, cellular
neurohormonal status in terms of neurohormone production, receptor density,
growth regulation and interaction between myocytes and non-myocytes, the
time course of cellular adaptation and dedifferentiation, and the time course
until the occurrence of irreversible cellular damage. In addition, clinical studies
on how to prevent, reverse or attenuate these processes with pharmacotherapy
(for instance with calcium antagonists or angiotensin II receptor blockers) or
with more aggressive rhythm-control (for example TEE-guided cardioversion
as soon as atrial fibrillation occurs or recurs) will be necessary to test the concept
that reversion of atrial remodeling may improve sinus rhythm maintenance.212
Hopefully, these efforts will turn atrial fibrillation into a less intractable
arrhythmia. However, measuring quality of life in these clinical studies is
mandatory to assess the impact on the patient. It is not unlikely that new,
invasive, and even aggressive rhythm-control strategies will not improve quality
of life. The same perhaps applies to atrial arrhythmia surgery, which is effective,
but seems not very suitable for most patients since it concerns a major operation.
Therefore, comparing different treatments (rate-control, conventional rhythm-
control, unconventional rhythm-control, and surgical rhythm-control) with a
focus on quality of life is urgently needed.
At present, many questions remain unresolved, but the elements
contributing to the pathophysiology of the arrhythmia are becoming increasingly
evident. As a result, a more effective treatment of atrial fibrillation can be
expected in the next decade.213
Samenvatting en conclusies
Nederlandse samenvatting en conclusies
Boezemfibrilleren is zowel vanuit epidemiologisch als klinisch standpunt een
aanzienlijk probleem. De ritmestoornis draagt een duidelijke morbiditeit maar
ook verhoogde mortaliteit met zich mee. Helaas is er geen genezing in de zin
van permanent herstel van sinusritme beschikbaar. Conventionele behandeling
van de ritmestoornis (met antiaritmica en cardioversie) is op de lange termijn
bij de meeste patiënten niet erg effectief. Meer agressieve, chirurgische
behandeling wordt alleen toegepast bij patiënten met veel klachten of bij
patiënten die toch al hartchirurgie moeten ondergaan. Ook andere, niet-
conventionele (lees: geen farmacologische) therapie zoals de atriale defibrillator
lijkt niet erg geschikt voor een algemene benadering. Misschien is het niet
verbazingwekkend dat door deze matige resultaten veel artsen de mening
hebben van “digitaliseren en vergeten” omdat alle moeite om sinusritme te
herstellen niet wordt beloond. Als een gevolg hiervan wordt cardioversie
therapie aan veel, met name oudere patiënten onthouden.
Onze behandeling van de ritmestoornis kan echter inadequaat zijn omdat
we de betrokken pathofysiologische mechanismen onvoldoende begrijpen. Veel
patiënten ontwikkelen de ritmestoornis in afwezigheid van een onderliggende
(hart)ziekte en dan is het onduidelijk welke cascade van gebeurtenissen tot de
ritmestoornis heeft geleid. Andere patiënten ontwikkelen de ritmestoornis wel
degelijk tegen de achtergrond van een onderliggende hartziekte die de boezems
belast. Uiteraard zou adequate behandeling van onderliggend lijden het
optreden van de ritmestoornis kunnen verminderen, maar moet dan wel tijdig
beginnen om structurele veranderingen die de ritmestoornis kunnen bevorderen
te voorkomen. Inmiddels is het duidelijk geworden dat de ritmestoornis zijn
eigen electrofysiologische basis reeds bij aanvang versterkt (“boezemfibrilleren
bevordert boezemfibrilleren”). Daarbij komt dat dit belangrijke proces maar
een onderdeel is van de zogenaamde remodelering van de boezems veroorzaakt
door de ritmestoornis zelf. Vele andere factoren zijn geïdentificeerd die tijdens
boezemfibrilleren remodelering van de boezems teweegbrengen, zoals verhoogde
neurohormoonspiegels, ion kanaal aanpassingen, subcellulaire veranderingen,
cellulaire dedifferentiatie, en uiteindelijk apoptose en necrose.
Het begrijpen waarom deze veranderingen optreden, het tijdsverloop en
hun invloed op het voortbestaan van de ritmestoornis zal hopelijk richting214
kunnen geven aan interventies bedoeld om remodelering van de boezems te
voorkomen en te behandelen. Uiteraard is het uiteindelijke doel om sinusritme
effectief te kunnen herstellen en behouden. Dit proefschrift behandelde zowel
fundamentele als klinische vraagstukken van boezemfibrilleren in een poging
om ons inzicht in deze hardnekkige ritmestoornis te verbeteren.
Tot nu toe komen de meeste gegevens over electrische remodelering van
dierenonderzoek, deels met modellen die snelle boezempacing gebruiken, deels
met modellen met kunstmatig geïnduceerd boezemfibrilleren. Gegevens over
het verloop van die electrische remodelering van de boezems bij spontaan
ontstaan boezemfibrilleren ontbraken echter. In appendix 1 werd electrische
boezemremodelering onderzocht in de mens. Patiënten met persisterend
(chronisch) boezemfibrilleren, paroxysmaal (aanvalsgewijs) boezemfibrilleren
en sinusritme die electieve chirurgie aan hun hart moesten ondergaan, werden
tijdens de feitelijke operatie vergeleken op atriale refractaire tijden (als maatstaf
van electrofysiologische eigenschappen). Het bleek dat de effectieve atriale
refractaire periode was verkort bij preoperatief persisterend boezemfibrilleren.
Bij patiënten met paroxysmaal boezemfibrilleren verhield de verkorting van
de refractaire periode zich omgekeerd proportioneel tot de tijdsduur van
preoperatief sinusritme. Waarschijnlijk is dit eerder de oorzaak dan het gevolg
van boezemfibrilleren omdat bij deze patiënten de paroxysmen te kort duurden
om substantiële remodelering te kunnen uitlokken. In tegenstelling hiermee
was een korte refractaire periode tijdens chirurgie niet voorspellend voor het
optreden van postoperatief boezemfibrilleren. Daarnaast leek een lekkende
mitraalklep de refractaire periode juist te verlengen. Het lijkt aannemelijk
dat chronische boezemrek deze relatieve verlenging veroorzaakt.
Het cardiovasculaire systeem behelst vele regelmechanismen die proberen een
stabiele hemodynamische omgeving te handhaven. Een hoofdrol wordt hierin
vervuld door cardiovasculair actieve neurohormonen die worden aangemaakt
in de desbetreffende systemen zoals het natriuretisch peptide systeem, het
renine-angiotensine systeem en de bijnieren. Deze systemen komen in actie
wanneer de hemodynamiek wordt belast, bijvoorbeeld bij hartfalen. Op het
nivo van het hart stimuleren de genoemde neurohormonen receptoren, die
vervolgens myocytenfunctie (waaronder contractiliteit en electrofysiologie) en215
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morfologie (zoals cellulaire dedifferentiatie, fibrose, apoptose, necrose)
beïnvloeden.  Appendix 2 handelde over mRNA expressie van het natriuretisch
peptide systeem in het rechter hartoor in relatie tot de ritmestoornis. Bij
patiënten met paroxysmaal boezemfibrilleren werden geen genetische
veranderingen aangetroffen in vergelijking met patiënten in sinusritme.
Patiënten met persisterend boezemfibrilleren lieten daarentegen wèl
veranderingen gezien, onafhankelijk van kleplijden. Dit betekent dat
boezemfibrilleren een onafhankelijke prikkel is voor de expressie van mRNA
betrokken bij de neurohormonale toestand van de boezems. In appendix 3
lieten we zien dat bij patiënten met gevorderd hartfalen het boezemfibrilleren
was geassocieerd met een hogere plasmaspiegel van endotheline en atriaal
natriuretisch peptide, vergeleken met diegenen in sinusritme. Men zou kunnen
zeggen dat endotheline afgifte (een vaatvernauwende stof) wordt uitgelokt door
een stijging van het atriaal natriuretisch peptide (vaatverwijdende stof), maar
dit is speculatief. Omdat in zijn algemeenheid een excessieve neurohormonale
activering is geassocieerd met een slechtere hemodynamiek en klinische
uitkomst, vragen deze resultaten om verder onderzoek naar de invloed van
boezemfibrilleren op myocytenfunctie en moleculaire aanpassing enerzijds, en
morbiditeit en mortaliteit anderzijds. In aanvulling hierop beïnvloedt autonome
activatie de kwaliteit van leven. Appendix 4 ging over de kwaliteit van leven
in relatie tot de toestand van het autonoom zenuwstelsel bij paroxysmaal
boezemfibrilleren. Er werd een duidelijke aantasting van de kwaliteit van leven
aangetoond bij patiënten met paroxysmaal boezemfibrilleren, zelfs als er geen
onderliggende hartziekte aanwezig was. Daarbij kwam dat een verminderde
autonome functie sterk was geassocieerd met een aangetaste kwaliteit van
leven. Dit impliceert dat naast een invloed op het boezemfibrilleren zelf, het
autonoom zenuwstelsel ook het welbevinden van de patiënt bepaalt.
In appendix 5 werd het bekende snijpunt van boezemfibrilleren en hartfalen
besproken. Enerzijds komt boezemfibrilleren voor tegen de achtergrond van
reeds aanwezig hartfalen. Anderzijds kan boezemfibrilleren hartfalen
teweegbrengen. Beide mechanismen kunnen in dezelfde patiënt voor komen
en het is soms onduidelijk wat er het eerste was. In elk geval is het nastreven
van adequate “rate-control” (beheersing van de hartfrequentie) tijdens de
ritmestoornis van het grootste belang. Daarnaast is correcte behandeling van216
hartfalen heel belangrijk, zeker als men cardioversie overweegt. Bij hardnekkige
gevallen zou AV-knoop ablatie en pacing kunnen worden overwogen. Tot op
heden is het onduidelijk of dit laatste vaker aan patiënten moet worden
aangeboden. Hoe dan ook, cardioversie is nog steeds een gangbare behandeling
en we onderzochten het nut daarvan. In appendix 6 werd de uitkomst van
seriële cardioversie therapie in een grote groep met persisterend
boezemfibrilleren beschreven, met de nadruk op hartfalen. Seriële cardioversie
therapie gecombineerd met seriële antiarrhythmica was tamelijk succesloos
om hartfalen te voorkomen en om sinusritme te behouden. Daarnaast kwam
dit falen vaker voor bij patiënten met een hogere NYHA klasse. Alhoewel dit
allemaal logisch lijkt, en aansluit bij de ervaring van velen, bewijst het niet
dat men net zo goed rate-control therapie kan geven. Om een meer definitieve
conclusie te trekken is gerandomiseerd onderzoek nodig. De resultaten van
deze studie vormen dan ook de ratio achter de “RACE” studie. Dit Nederlands
onderzoek omvat een gerandomiseerde vergelijking tussen seriële cardioversie
therapie en rate-control therapie. De primaire eindpunten omvatten kwesties
als morbiditeit (zoals hartfalen, thromboembolie, en bloeding) en kwaliteit van
leven. Appendix 7 ging verder met de haalbaarheid van cardioversie therapie,
nu onderzocht in een kleine groep van geselecteerde patiënten met hartfalen
en persisterend boezemfibrilleren. Zoals te verwachten waren de resultaten
nogal teleurstellend met betrekking tot het behoud van sinusritme. Behandeling
van hartfalen met een ACE-remmer vooraf aan cardioversie leek echter wel de
slagingskans te verhogen. De studie staat niet in voor het zonder meer
cardioverteren van elke patiënt met hartfalen. Het accepteren van de
ritmestoornis, amiodarone als initieel antiarrhythmicum of een alternatieve
behandeling dient ook te worden overwogen.
Een laatste mogelijkheid om (medicamenteus onbehandelbaar)
boezemfibrilleren te behandelen is ritme-chirurgie van de boezems. Velen zijn
terughoudend om deze stap te nemen, maar patiënten die toch al aan hun hart
moeten worden geopereerd om een andere reden zijn logische kandidaten. In
appendix 8 onderzochten we patiënten met mitraalklep lijden en preoperatief
boezemfibrilleren die mitraalklep chirurgie gecombineerd met een
vereenvoudigde Cox-maze procedure oftewel een “mini-maze” ondergingen.
Deze laatste is niet zo uitgebreid als de originele procedure en duurt dus korter.217
Samenvatting en conclusies
Een vergelijking werd gemaakt tussen enerzijds de genoemde patiënten en
anderzijds patiënten in sinusritme en een historische groep van patiënten met
preoperatief boezemfibrilleren, die beiden alleen mitraalklep chirurgie
ondergingen. Een jaar na operatie waren de resultaten bemoedigend en de
mini-maze patiënten hadden sinusritme, een goede sinusknoop functie en hun
inspanningstolerantie was vergelijkbaar met de patiënten met preoperatief
sinusritme. Daarnaast kwam bij de meeste mini-maze patiënten de linker
boezem contractie terug. Ondanks deze gunstige bevindingen wordt ritme-
chirurgie toch geassocieerd met postoperatieve verstoringen in sinusknoop
functie. Appendix 9 handelde over de eigenschappen van het hartritme na
ritme-chirurgie van de boezems. Patiënten met preoperatief boezemfibrilleren
die exclusief of gecombineerd (met mitraalklep interventie) maze chirurgie
ondergingen werden vergeleken met patiënten in sinusritme die een coronaire
bypass operatie of mitraalklep chirurgie ondergingen. Als integrale benadering
werd het postoperatieve hartritme onderzocht met inspanningstesten, 24-uurs
Holter onderzoek (met hartritme variabiliteit analyse) en non-invasieve
autonome functietests. Hartchirurgie leek initieel de sinusknoop functie te
verminderen, maar in de volgende 12 maanden trad er verbetering op. Er was
een uitgesproken afname van hartritme variabiliteit en vagale modulering van
de sinusknoop functie die niet beperkt bleef tot maze chirurgie. Dit was ook
van toepassing op geïsoleerde mitraalklep chirurgie. Deze neveneffecten waren
minder uitgesproken of afwezig na coronaire bypass chirurgie. Wij nemen aan
dat het snijden in de boezems een zekere autonome schade geeft, die het jaar
na de operatie verbetert maar niet normaliseert. Er zou gepostuleerd kunnen
worden dat een dergelijke autonome verandering bijdraagt aan de effectiviteit
van de maze operatie.
Klinische implicaties en toekomst verwachting
Dit klinisch georiënteerd en voornamelijk beschrijvend proefschrift laat
verscheidene gevolgen zien van de ritmestoornis die op hun beurt weer de
behandeling bemoeilijken. Alhoewel het is aangetoond dat duidelijk
veranderingen op electrofysiologisch en neurohormonaal gebied plaatshebben,
dient hun exacte pathofysiologische rol verder te worden opgehelderd.
Toekomstig onderzoek dient zich daarom te richten op veranderingen op
cellulair nivo, inclusief (rek geactiveerde) ion kanaal expressie, cellulair calcium218
metabolisme, de neurohormonale toestand (met name productie) van de cel,
receptor expressie, groei regulatie en de interactie tussen myocyten en non-
myocyten, het tijdsverloop van cellulaire adaptatie en dedifferentiatie, en het
tijdsverloop tot er onherstelbare celschade optreedt. Daarnaast zullen klinische
studies naar de preventie, omkering en afzwakking van deze processen met
farmacotherapie (zoals calcium antagonisten en angotensine II receptor
blokkers) of met nog agressiever ritme-controle (TEE-geleide cardioversie zodra
boezemfibrilleren ontstaat of terugkeert) noodzakelijk zijn om het idee te testen
dat terugremodelering van de boezems het lange termijn behoud van sinusritme
bevordert. Hopelijk kan dit alles boezemfibrilleren minder onhandelbaar
maken. Echter, het meten van de kwaliteit van leven is in zulke klinische
studies vereist om de invloed op de patiënt in te schatten. Het is niet
onaannemelijk dat nieuwe, invasieve en zelfs agressieve ritme-controle
therapieën de kwaliteit van leven niet zullen bevorderen. Hetzelfde is misschien
van toepassing op ritme-chirurgie van de boezems, welke wel effectief maar
niet heel geschikt is voor de meeste patiënten omdat het een grote operatie
betreft. Het vergelijken van verschillende behandelingen (rate-control,
conventionele ritme-controle, onconventionele ritme-controle, en chirurgische
ritme-controle) met aandacht voor kwaliteit van leven is dus dringend gewenst.
Tot op heden blijven er veel vragen bestaan, maar de elementen die
bijdragen aan de pathofysiologie van de ritmestoornis worden langzamerhand
duidelijk. Dientengevolge kan een meer effectieve behandeling van
boezemfibrilleren worden verwacht binnen het volgende decennium.219
Dankwoord
Het is een lange reis geweest met kuilen in het wegdek, enkele fascinerende
vergezichten en de gebruikelijke motorpech. Gelukkig konden de bijrijders goed
kaartlezen en werd ook de olie tijdig ververst zodat de eindbestemming is
bereikt. Kortom, ik had het niet alleen kunnen doen en veel mensen hebben
bijgedragen aan de totstandkoming van dit proefschrift. Zonder iemand tekort
te willen doen, wil ik graag een aantal van hen persoonlijk bedanken.
Op de eerste plaats wil ik Prof. Dr. H.J.G.M. Crijns bedanken voor zijn
inzet als promotor. Geachte professor, beste Harry, jouw niet aflatende
betrokkenheid bij het verrichte klinische onderzoek waardeer ik enorm. Zonder
jouw stimulerende invloed maar vooral intellectuele gedachtengoed was het
niet geworden wat het nu is: een proefschrift waar ik trots op ben. Naast een
energiek onderzoeker ben je ook een betrokken clinicus en ik hoop daarom nog
veel van je te mogen leren tijdens mijn opleiding tot cardioloog.
Mijn tweede promotor, Prof. Dr. W.H. van Gilst, wil ik vooral bedanken
voor het mogelijk maken van de samenwerking tussen “kliniek en
laboratorium”; in het kader van de META-studie heeft menig hartoor gedompeld
in de vloeibare stikstof de weg gevonden naar de afdeling klinische farmacologie.
Geachte professor, beste Wiek, ik wil je bedanken voor het realiseren van deze
co-produktie en ik hoop dat hiermee de genetische grondslag van
cardiovasculaire aandoeningen verder kan worden opgehelderd.
Vervolgens wil ik het woord richten tot Prof. Dr. K.I. Lie, die mij in de
nadagen van zijn Groningse periode de gelegenheid heeft geboden om promotie
onderzoek naar boezemfibrilleren te gaan doen. Geachte professor, ik wil U
nadrukkelijk bedanken voor het vertrouwen dat U destijds in mij gesteld heeft.
De leden van de beoordelingscommissie, Prof. Dr. T. Ebels, Prof. Dr.
R.N.W. Hauer, en Prof. Dr. L.J.L.M.  Jordaens, wil ik bedanken voor hun
bereidwilligheid om het proefschrift te bekritiseren en om te opponeren tijdens
de verdediging. U allen respecteer ik als collega-onderzoekers en ben daarom
verheugd dat U mijn proefschrift wilt becommentariëren.
Mijn beide referenten, Dr. I.C. van Gelder en Dr. M.P. van den Berg,
kan ik niet genoeg bedanken voor hun inzet tijdens de verschillende fasen van
het gedane onderzoek. Beste Isabelle, gaandeweg hebben we de afgelopen jaren
veel lief en leed gedeeld. Vooral de META-studie staat hiervoor symbool. Dit220
intensieve project heeft ons veel goeds en inzicht gebracht maar heeft ook de
begrenzingen van klinisch onderzoek duidelijk gemaakt. Het toont aan dat je
karakter moet bezitten om iets tot een goed einde te brengen. Het project is
mede dank zij jou gelukt en ik wil je bedanken voor je motivering en
verantwoordelijkheidsgevoel. Verder heb je mij geïntroduceerd in de moleculaire
biologie van boezemfibrilleren; ik ben je voor dit alles zeer dankbaar. De
chronologie wil dat ik het eerste met mijn andere referent van doen kreeg.
Beste Maarten, ik ben niet vergeten hoe wij samen mijn komst naar het AZG
hebben voorbereid en jij de aanzet tot een promotie onderzoek naar
boezemfibrilleren hebt gegeven. Het “quality of life” artikel vind ik een mooie
illustratie van de uitkomst. Een boezemfibrilleren-studie met een ACE-remmer
hebben we helaas moeten uitstellen, maar misschien dat het tijdperk van de
moleculaire biologie dit in een nieuw perspectief kan plaatsen. Alhoewel wij de
laatste jaren slechts in beperkte mate op de “werkvloer” hebben samengewerkt
heb jij gedurende het schrijven van de verschillende manuscripten wel degelijk
een belangrijke invloed gehad; ik ben je daar zeer erkentelijk voor.
Ook wil ik Dr. D.J. van Veldhuisen bedanken voor onze substudie van de
PRIME II-studie. Beste Dirk Jan, zoals je weet hebben deze gegevens tot mijn
eerste internationale artikel geleid; ik wil je daarvoor bedanken. Het bewijst
dat met goed onderzoek meer dan één vraag beantwoord kan worden.
Mijn ene paranimf Robert Tieleman wil ik bedanken voor zijn collegialiteit
en de vriendschap die wij in de afgelopen jaren hebben opgebouwd. Beste Robert,
ik mis onze gesprekken op kamer 12 (later The Greenhouse) en de META-
ochtenden op het operatie centrum. Jouw enthousiasme voor de electrofysiologie
van boezemfibrilleren is aanstekelijk, maar onze conversaties over “het gewone
leven” zijn ook niet onbelangrijk voor me geweest. Verder denk ik nog steeds
met veel plezier terug aan ons (ook in wetenschappelijke zin) geslaagde congres
in Orlando; wat was die convertible cool ...
Mijn andere paranimf Robert Tuinenburg kent mij niet zozeer als
wetenschapper maar vooral als broer en vriend. Ik zie ons als laatbloeiers, met
een voorliefde voor “groovy beats” en doorzettingsvermogen tot de derde orde:
broer, ik ben blij dat je me tijdens de promotie bij wilt staan want het is een
belangrijk moment voor me. Ik hoop dat jouw ambities in de rechterlijke macht
ook vervuld zullen worden.
Zoals gezegd, de META-studie heeft de afgelopen jaren in grote mate de221
toonzetting bepaald. Het acroniem staat voor “MEchanisms of atrial
TAchycardiomyopathy” die in dit veelomvattende, door De Nederlands
Hartstichting gesponsorde protocol werden onderzocht. Op eerste plaats wil
ik de voorzitter, Dr. V. Manger Cats, bedanken voor de financiële
ondersteuning waardoor het voor mij mogelijk werd om het onderzoek te kunnen
verrichten. Daarnaast zijn veel mensen binnen het Thorax Centrum
behulpzaam geweest. De inzet van thoraxchirurgen Prof. Dr. Tjark Ebels,
Prof. Dr. Piet Boonstra, Dr. Jan Grandjean, Roland Laurens en Massimo
Mariani die aan het project meewerkten wil ik onderstrepen. Met name Jan
Grandjean heeft een hoofdrol gehad bij het ontwikkelen en uitvoeren van de
maze procedures. Beste Jan, als vaardig chirurg en sociaal ingesteld mens heb
ik jouw bijdrage als zeer leerzaam en plezierig ervaren; ik wens je veel succes
toe als hoogleraar in Pisa. Ook is de coördinerende rol van Marja de Bruin
van het secretariaat thoraxchirurgie van groot belang geweest om iedereen
telkens weer op de operatiekamer bij elkaar te krijgen. De samenwerking met
anesthesiologen Rolf Huet en Joost van der Maaten heb ik als plezierig
ervaren, en het ging er tijdens de OK-metingen behalve interdisciplinair ook
zeker gedisciplineerd aan toe. Vooral Els Pieper, Erwin Göbel, Jan Brouwer,
Stan van den Broek en Yong Tan hebben zich als medewerkers van de
echokamer flexibel opgesteld als we weer eens protocollaire metingen op
“onmogelijke” tijdstippen en plaatsen moesten doen. Zo heeft Dick Nagelkerke
van de pacemaker kamer “de kar” meer dan eens welwillend uitgeleend ten
behoeve van onze OK-metingen. Kortom, iedereen in de kliniek die de META-
studie een warm hart heeft toegedragen wil ik oprecht bedanken.
De afdeling klinische farmacologie van de RUG wil ik bedanken voor de
voortreffelijke samenwerking tussen kliniek en laboratorium. Prof. Dr. Wiek
van Gilst en Dr. Robert Henning hebben zich hier niet tevergeefs voor
ingespannen. Ik hoop dat mijn “collega-AIO” en moleculair bioloog Bianca
Brundel met behulp van de verzamelde hartoren de kanaalexpressie en het
intracellulair calcium metabolisme tijdens boezemfibrilleren verder kan
ophelderen.
Het Trial Coordinatie Centrum-extern heeft een belangrijke rol gespeeld
bij de statistische verwerking van de data, verricht door Pieter Jan de Kam
en Corine Volkers. Beste Pieter Jan, ik wil je bedanken voor je hulp en
kameraadschap. Verder wens ik je veel succes toe in je nieuwe baan. Het TCC-222
intern (tegenwoordig Cardio Research AZG) inclusief modieus personeel is
niet weg te denken als het gaat om de logistieke ondersteuning van de
verschillende projecten. Vele poli afspraken en emmertjes met vloeibare stikstof
zijn door jullie verzorgd, waarvoor mijn uitdrukkelijke dank.
Verbonden aan de cardiologie staf en altijd even behulpzaam zijn Gretha
Beuker en Olga Klompstra, onze charmante secretaresses. Beste Gretha, je
hebt me enorm geholpen met “de laatste loodjes” door de thesis op tijd naar de
beoordelingscommissie te krijgen; je bent altijd even goed gehumeurd en
accuraat, en dat waardeer ik enorm. Beste Olga, onze vriendschap begon ooit
met het plannen en verrichten van de cardioversies op de hartbewaking, maar
in de loop der jaren was er altijd wel even tijd om bij te kletsen; ik wil je
bedanken voor een luisterend oor.
Werken als arts (en promovendus) in een academisch ziekenhuis is haast
onmogelijk zonder een computer met functionerende programmatuur. Jan
Ruys van de computer ondersteuning Thorax Centrum kan daar van
meepraten. Beste Jan, mijn vasthoudendheid aan “obsoleet” Word Perfect 5.1
en Reference Manager 7.0 heeft jou verbaasd. Desondanks ben je me
behulpzaam gebleven en daar ben ik je dankbaar voor.
De bloem der cardiologie bloeit (hoe kan het ook anders) in de serre van het
oude poortgebouw van het AZG, toepasselijk genaamd The Greenhouse. Ook
ik heb hier mijn dagen als research-arts cardiologie gesleten. Soms lijkt het er
meer op een studentenhuis met veel koffie en gezelligheid, maar de wetenschap
kan er ongestoord tot bloei komen door vrije uitwisseling van gedachten en
ervaringen. Binnen de groep heerst een grote mate van verbondenheid die
zich buiten de ziekenhuismuren voortzet in het Feithhuis of de sportschool;
beste Greenhousers, ik zal jullie missen. Een speciale rol was weggelegd voor
Robert Tieleman, Bas Schoonderwoerd, en Trudeke van Noord, de
overige leden van de “ritmesectie van het research-corps”. Beste Bas, een
gezamenlijk buitenlands congres hebben we nog niet gehad, maar toerritjes
met de classic cars en trainen bij “Construction” zijn zeer geslaagd gebleken.
Beste Trudeke, je hebt je PC weer voor jezelf alleen. Ik hoop dat jouw klinische
studies naar boezemfibrilleren ook hun vruchten zullen afwerpen. Verder zijn
de afgelopen jaren meerdere studenten bij de ritmesectie betrokken geweest;
vooral Yuri Blaauw en Rutger Hassink wil ik bedanken voor hun inzet.
De vormgeving van het proefschrift is op professionele wijze door Peter223
van der Sijde verzorgd; mijn dank en waardering voor de prettige
samenwerking. Mijn taalgebruik van het Engels is gecorrigeerd door Yvonne
Larrabee, waarvoor mijn dank. Verder wil ik Dr. Tjip van der Werf bedanken
voor zijn hulp met de digitale camera.
Lieve familie, geduldig hebben jullie het wel en wee van de afgelopen
jaren doorstaan. Steeds opnieuw hebben jullie me gemotiveerd om mijn ambitie
te vervullen. Lieve moeder, ik wil je bedanken voor alle steun die ik heb mogen
ontvangen om een wetenschappelijke opleiding te kunnen afronden. Verder
ben ik erg blij met jouw mooie keramiek; ik hoop dat de toekomst jou nog lang
artistieke inspiratie mag brengen. Lieve zussen en broer, elk van ons heeft een
academische titel in de wacht weten te slepen en jullie weten dus als geen
ander wat hard studeren en onderzoek doen inhoudt; ik hoop dat we naast een
drukke carrière ook blijven genieten van het leven, want een moderne cardioloog
kan veel, maar een gebroken hart kan hij niet lijmen.225
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